trametinib profile

ID Source	ID
PubMed CID	11707110
CHEMBL ID	2103875
CHEBI ID	75998
SCHEMBL ID	170938
MeSH ID	M0575714

Synonym
HY-10999
A25168
n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide
gsk 1120212
871700-17-3
EX-5957
D10175
trametinib (usan)
trametinib (gsk1120212)
gsk-1120212
n-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)acetamide
trametinib [usan:inn]
n-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl}phenyl)acetamide
unii-33e86k87qn
trametinib ,
mekinist
jtp-74057
acetamide, n-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)-
jtp 74057
jtp74057
33e86k87qn ,
tmt-212
CHEMBL2103875
chebi:75998 ,
tmt212
gsk212
FT-0688438
GSK1120212 ,
BCPP000218
gsk1120212,jtp-74057, gsk212
NCGC00263180-01
trametinib [mi]
trametinib [vandf]
trametinib [usan]
trametinib [who-dd]
trametinib [inn]
CS-0060
AKOS015850628
S2673
trametinibum
n-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl}phenyl)acetamide
n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide
gtpl6495
BRD-K12343256-001-01-4
DB08911
acetamide, n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]-
AM90271
SCHEMBL170938
n-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide
LIRYPHYGHXZJBZ-UHFFFAOYSA-N
n-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl)phenyl)acetamide
n-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl)phenyl)acetamide
AC-25891
n-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe nyl]acetamide
J-523325
EX-A022
mfcd17215075
sr-01000941589
SR-01000941589-1
HMS3656J11
NCGC00263180-07
SW218089-2
BCP02307
gsk1120212 (trametinib) ,
AS-19382
Q7833138
SB16553
HMS3295I05
CCG-264976
NCGC00263180-14
n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl}ethanimidic acid
DTXSID901007381
qom ,
nsc758246
nsc-758246
nsc800956
nsc-800956
bdbm50531540
EN300-25299821
n-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-1h,2h,3h,4h,6h,7h-pyrido[4,3-d]pyrimidin-1-yl}phenyl)acetamide
mek inhibitor gsk1120212
l01xe25
n-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide
SY067882

Excerpt	Reference	Relevance
"Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). "	( Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. Bedard, PL; Chen, EX; Chen, HX; Hansen, AR; Hotte, SJ; Ivy, SP; Kelly, K; Lockhart, AC; Razak, AR; Renouf, DJ; Sahebjam, S; Singh, A; Siu, LL; Spreafico, A; Stayner, LA; Subbiah, V; Vaishampayan, UN; Voon, PJ; Wang, L, 2022)	2.42
"Trametinib is a MEK inhibitor with intracranial activity indicated for BRAF-mutant metastatic malignancies. "	( Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Arnett, A; Bazan, J; Beyer, S; Blakaj, D; Chakravarti, A; Elder, JB; Fabian, D; Giglio, P; Grecula, J; Haglund, K; Kendra, K; Liebner, D; Palmer, JD; Prasad, RN; Puduvalli, V; Raval, R; Tan, Y; Wei, L; Welliver, M; Williams, T; Wuthrick, E; Yildiz, VO, 2022)	2.5
"Trametinib is an MEK1 inhibitor for treating EML4-ALK-positive, EGFR-activated, and KRAS-mutant lung cancers."	( Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib. Guo, X; Han, W; Huang, T; Li, C; Yang, H; Zhu, J, 2020)	1.5
"Trametinib is a MEK1/2 inhibitor and exerts anticancer activity against a variety of cancers. "	( Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells. Cao, P; Ding, D; Li, B; Li, S; Lin, L; Xiao, X, 2020)	3.44
"Trametinib appears to be an effective treatment for patients with recurrent/progressive pLGG. "	( Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. Bandopadhayay, P; Chi, SN; Choi, J; Chordas, C; Clymer, J; Filbin, M; Manoharan, N; Scully, J; Ullrich, NJ; Yeo, KK; Zimmerman, MA, 2020)	3.44
"Trametinib is a specific mitogen-activated protein kinase inhibitor, approved for the treatment of metastatic melanoma."	( Combined treatment with auranofin and trametinib induces synergistic apoptosis in breast cancer cells. An, HG; Baek, HS; Chun, YJ; Joo, MK; Kwon, TU; Kwon, YJ; Shin, S; Ye, DJ, 2021)	1.61
"Trametinib is an effective therapy for advanced PNF and refractory PLGG in patients with NF-1 and is well tolerated in children. "	( Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma. Cheng, S; Duncan, WJ; Dunham, C; Gardiner, J; Ghag, A; Hounjet, CD; Hukin, J; Ludemann, JP; Rassekh, SR; Rehmus, W; Ronsley, R; Sargent, MA; Wensley, D, 2021)	3.51
"Trametinib is a potent, highly selective, allosteric non-competitive inhibitor of MEK1/MEK2."	( Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. Creasy, CL; Felitsky, DJ; Fukutomi, A; Furuse, J; Gorman, S; Ikeda, M; Ioka, T; Kasuga, A; Kobayashi, M; Morizane, C; Okusaka, T; Takahashi, H; Todaka, A; Zhang, F, 2018)	1.51
"Trametinib appears to be a suitable option for refractory pediatric low-grade glioma and warrants further investigations in case of progression."	( Trametinib for progressive pediatric low-grade gliomas. Crevier, L; Ellezam, B; Farmer, JP; Jabado, N; Kondyli, M; Larouche, V; Legault, G; Perreault, S; Pouliot, L; Saint-Martin, C; Sinnett, D; Weil, A, 2018)	3.37
"Trametinib is an orally bioavailable mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor with antineoplastic activity. "	( Trametinib: first global approval. McCormack, PL; Wright, CJ, 2013)	3.28
"Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity."	( Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Bauman, J; Fang, L; Henriquez, F; Ho, M; Leonowens, C; Morrison, RA; Orford, K; Ouellet, D; Pendry, C; Young, GC, 2014)	1.37
"Trametinib is a novel oral MEK inhibitor with clinical activity in BRAF(V600) mutant metastatic melanoma alone and in combination with dabrafenib. "	( Trametinib in the treatment of melanoma. Johnson, DB; Sosman, JA; Thota, R, 2015)	3.3
"Trametinib is an inhibitor of MEK1/MEK2 activation and kinase activity. "	( A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Fujisaka, Y; Furuse, J; Kasuga, A; Kitamura, H; Kurata, T; Matsushita, H; Mukaiyama, A; Nagashima, F; Nakagawa, K; Naruge, D; Nishimura, Y; Nishina, S; Okamoto, W; Shimizu, T; Takasu, A, 2015)	2.17
"Trametinib (Mekinist®) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) approved in the United States as a single agent and in combination with dabrafenib (Tafinlar®) for treatment of patients with unresectable or metastatic melanoma with a positive BRAF V600E/V600K mutation for which a pediatric oral solution formulation is being developed. "	( Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Allred, A; Bendell, J; Burris, H; Cox, DS; Gordon, MS; Infante, JR; Jones, S; Orford, K; Zhou, Y, 2015)	2.09
"Trametinib is a reversible, selective inhibitor of the mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and 2 (MEK2). "	( Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Bauman, JW; Beeram, M; Cox, DS; Hamid, M; Papadopoulos, KP; Patel, BR; Patnaik, A; Rasco, D; Scheuber, A; Schramek, D; Sharma, S; Tolcher, A; Werner, TL; Zhou, Y, 2016)	2.12
"Trametinib is a selective, orally administered MEK1/MEK2 inhibitor."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	1.32

Excerpt	Reference	Relevance
"Trametinib has a strong anti-proliferative effect on established GB cell lines, stem cell-like cells and their differentiated progeny and while it does not enhance anti-proliferative and cell death-inducing properties of the standard treatment, i.e."	( The limitations of targeting MEK signalling in Glioblastoma therapy. Debatin, KM; Hadzalic, A; Halatsch, ME; Karpel-Massler, G; Payer, C; Schuster, A; Selvasaravanan, KD; Siegelin, MD; Strobel, H; Westhoff, MA; Wiederspohn, N, 2020)	1.28

Excerpt	Reference	Relevance
"Trametinib will allow us to target directly and specifically the MAPK/ERK pathway. "	( A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. Bouffet, É; Cantin, É; Caru, M; Décarie, JC; Ellezam, B; Erker, C; Hawkin, C; Hukin, J; Jabado, N; Lafay-Cousin, L; Larouche, V; Legault, G; Lippé, S; Métras, MÉ; Perreault, S; Routhier, MÈ; Sultan, S; Tabori, U; Théoret, Y, 2019)	2.29

Excerpt	Reference	Relevance
"Trametinib pretreatment also attenuated the MEK-ERK-Egr-1 pathway in lung tissues."	( Trametinib alleviates lipopolysaccharide-induced acute lung injury by inhibiting the MEK-ERK-Egr-1 pathway. Chen, S; Ding, X; Le, S; Wu, C; Wu, J; Xia, J; Xu, H; Ye, P; Zhang, H; Zhao, J; Zou, Y, 2020)	2.72
"Trametinib treatment of a PDX from a responder patient resulted in evolution of resistance with increased Yap1 expression and activity."	( Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. Adkins, DR; Barnell, EK; Campbell, KM; Dunn, GP; Egloff, AM; Giri, T; Griffith, M; Griffith, OL; Mudianto, T; Ozgenc, I; Riley, R; Skidmore, ZL; Uppaluri, R; Webb, J; Zolkind, P, 2021)	1.7
"Trametinib treatment led to up-regulation of major histocompatibility complex (MHC-I) and programmed cell death ligand 1 (PD-L-1) (programmed cell death ligand 1) on tumor cells in vitro."	( Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Diggs, LP; Green, BL; Greten, TF; Heinrich, B; Ma, C; McCallen, JD; McVey, JC; Ruf, B; Tandon, M; Wabitsch, S; Zhang, Q, 2021)	1.63
"Trametinib treatment reduced the COX-2 level in Apc(Δ716) tumors in vivo and in primary culture of intestinal fibroblasts in vitro."	( Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2. Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Taketo, MM, 2015)	1.41
"Treatment with trametinib and ganitumab resulted in synergistic cellular growth inhibition in all cell lines tested and inhibition of tumor growth in four of six models of RAS-mutant RMS. "	( The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models. Awasthi, P; Barr, FG; Butcher, D; Chen, JQ; Chen, L; Difilippantonio, S; Edmondson, EF; Figg, WD; Frye, WJE; Hall, MD; Hebron, KE; Isanogle, KA; James, A; Kedei, N; Khan, J; Kim, A; Kortum, RL; Lei, H; Liewehr, DJ; Luo, X; Peer, CJ; Perkins, OL; Robey, RW; Robinson, CM; Roth, JS; Sealover, NE; Shankarappa, P; Shern, JF; Smith, R; Stauffer, S; Sun, W; Vaseva, AV; Wan, X; Yohe, ME, 2023)	1.59
"Treatment with trametinib resulted in a substantial decrease in blood flow to the AVM, with a >75% reduction in arterial inflow after 6 months of trametinib therapy."	( Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy. Cooke, D; Edwards, EA; Frieden, IJ; Fullerton, HJ; Phelps, AS; Shimano, KA; Zapala, MA, 2020)	0.9
"Cotreatment with trametinib (a MEK inhibitor) and osimertinib resensitized the cells to osimertinib."	( Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Arai, S; Fukuda, K; Nanjo, S; Naoki, K; Nishiyama, A; Otani, S; Takeuchi, S; Tanimoto, A; Yano, S, 2021)	2.39
"Treatment with trametinib in KRas mutant cells increased phospho-ERα S167 and increased expression of estrogen-regulated genes."	( Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Celestino, J; Kwan, SY; Lu, KH; Onstad, M; Ring, KL; Schmandt, R; Yates, MS; Zhang, Q, 2017)	0.79
"Treatment by trametinib, a MEK kinase inhibitor, led to a significant reduction in microglia- and macrophage-derived tumor necrosis factor alpha (TNFα) secretion in response to oHSV treatment and increased survival of glioma-bearing mice."	( Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. Banasavadi-Siddegowda, Y; Bystry, D; Geng, F; Guo, D; Hong, B; Jaime-Ramirez, AC; Kaur, B; Lee, TJ; Liu, J; Nair, M; Otani, Y; Park, F; Phelphs, M; Quadri, H; Swanner, J; Yoo, JY, 2019)	1.15
"Treatment with trametinib plus dabrafenib was estimated to cost an additional CHF199 647 (Swiss francs) on average and yield a gain of 0·52 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of CHF385 603 per QALY. "	( A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. Ademi, Z; Braun, R; Dummer, R; Kolb, C; Matter-Walstra, K; Pestalozzi, BC; Schwenkglenks, M, 2015)	1.05
"Treatment with trametinib, compared with chemotherapy, significantly reduced the risk of death and risk of disease progression in patients with BRAF V600E/K mutation-positive advanced melanoma or MM."	( Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR, 2016)	0.99

Excerpt	Reference	Relevance
" Adverse events were defined with common toxicity criteria, and tumour response was measured by Response Evaluation Criteria In Solid Tumors."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	0.6
" Dose-limiting toxic effects included rash (n=2), diarrhoea (n=1), and central serous retinopathy (n=2)."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	0.6
" In the Phase III study testing dabrafenib, 53% of patients reported grade 2 or higher adverse events (AEs)."	( Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. Blank, C; Rutkowski, P, 2014)	0.4
" Patients' adverse events were recorded in a specific database."	( Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Anforth, R; Carlos, G; Clements, A; Fernandez-Peñas, P; Kefford, R, 2015)	0.42
"Patients continued to develop cutaneous adverse events after 52 weeks of continuous therapy."	( Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Anforth, R; Carlos, G; Clements, A; Fernandez-Peñas, P; Kefford, R, 2015)	0.42
"BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events."	( Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Algazi, A; Chong, K; Choudhry, A; Daud, A; Johnston, K; Meier, M; Ortiz-Urda, S; Osella-Abate, S; Posch, C; Quaglino, P; Rappersberger, K; Sanlorenzo, M; Vujic, I, 2014)	0.4
" Patient characteristics, and the occurrence and severity of cutaneous adverse events, are described."	( Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Algazi, A; Chong, K; Choudhry, A; Daud, A; Johnston, K; Meier, M; Ortiz-Urda, S; Osella-Abate, S; Posch, C; Quaglino, P; Rappersberger, K; Sanlorenzo, M; Vujic, I, 2014)	0.4
"The development of cutaneous adverse events was significantly less frequent (P = ."	( Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Algazi, A; Chong, K; Choudhry, A; Daud, A; Johnston, K; Meier, M; Ortiz-Urda, S; Osella-Abate, S; Posch, C; Quaglino, P; Rappersberger, K; Sanlorenzo, M; Vujic, I, 2014)	0.4
"Combination regimen with BRAFi and MEKi shows fewer cutaneous adverse events and longer cutaneous adverse event-free interval compared with BRAFi monotherapy."	( Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Algazi, A; Chong, K; Choudhry, A; Daud, A; Johnston, K; Meier, M; Ortiz-Urda, S; Osella-Abate, S; Posch, C; Quaglino, P; Rappersberger, K; Sanlorenzo, M; Vujic, I, 2014)	0.4
"The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well reported."	( Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Anforth, R; Carlino, MS; Carlos, G; Chou, S; Clements, A; Fernandez-Peñas, P; Menzies, AM, 2015)	0.42
"To compare the cutaneous toxic effects of BRAF inhibitor monotherapy and CombiDT therapy in a large cohort of patients."	( Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Anforth, R; Carlino, MS; Carlos, G; Chou, S; Clements, A; Fernandez-Peñas, P; Menzies, AM, 2015)	0.42
"Multiple cutaneous adverse effects between BRAF inhibitor monotherapy and CombiDT therapy were identified and compared in a cohort of patients who underwent the same dermatologic assessment."	( Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Anforth, R; Carlino, MS; Carlos, G; Chou, S; Clements, A; Fernandez-Peñas, P; Menzies, AM, 2015)	0.42
"The most common cutaneous adverse effects seen in patients receiving the single-agent BRAF inhibitor dabrafenib or vemurafenib included Grover disease (51 patients [42."	( Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Anforth, R; Carlino, MS; Carlos, G; Chou, S; Clements, A; Fernandez-Peñas, P; Menzies, AM, 2015)	0.42
"This study confirms that the prevalence of cutaneous toxic effects differs among vemurafenib, dabrafenib, and CombiDT therapies."	( Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. Anforth, R; Carlino, MS; Carlos, G; Chou, S; Clements, A; Fernandez-Peñas, P; Menzies, AM, 2015)	0.42
" Cutaneous adverse events have been reported, but hair and nail data have been rarely detailed."	( Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Dika, E; Fanti, PA; Melotti, B; Patrizi, A; Piraccini, BM; Ribero, S; Sperandi, F; Starace, M, 2016)	0.43
" Although they have shown promising results, they also have caused multiple adverse events (AEs), particularly immune-related AEs (irAEs)."	( Novel melanoma therapies and their side effects. González, N; Ratner, D, 2016)	0.43
"All patients presented with at least 1 adverse skin reaction."	( Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib. Lacroix, JP; Wang, B, )	0.36
"Selective BRAF inhibitor dabrafenib and MEK inhibitor trametinib are associated with multiple skin adverse effects."	( Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib. Lacroix, JP; Wang, B, )	0.6
" Our algorithm, based on partial least squares-discriminant analysis (PLS-DA) and cross-validation by bootstrapping, discriminated to variable degrees spectra from patient suffering and not suffering cutaneous adverse events."	( A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. Azan, A; Bakker Schut, TC; Besse, B; Boutros, C; Caspers, PJ; Eggermont, AM; Kamsu Kom, N; Koljenović, S; Lanoy, E; Mateus, C; Mir, LM; Noordhoek Hegt, V; Paci, A; Planchard, D; Puppels, GJ; Robert, C; Routier, E; Roy, S; Seck, A; Texier, M; Tomasic, G, 2017)	0.46
" The combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown its superiority to single agent therapy and is characterized by a tolerable spectrum of adverse events which shows a decrease in incidence over time on treatment."	( The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. Kanaki, T; Knispel, S; Livingstone, E; Schadendorf, D; Ugurel, S; Zimmer, L, 2018)	0.98
" Phase 1 was primarily intended to assess safety and tolerability as assessed by adverse events (AE), and the primary end-point in phase 2 was to assess confirmed overall response rate (ORR)."	( Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma. Fujiwara, Y; Kiyohara, Y; Kondo, S; Mukaiyama, A; Namikawa, K; Takahashi, A; Tsutsumida, A; Yamazaki, N; Yoshikawa, S; Zhang, F, 2018)	0.72
" Data suggest that immune-related adverse events (irAEs) are associated with clinical benefit in patients treated with immunotherapy and that response to BRAF/MEK therapy may have an underlying immune mechanism."	( Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Asher, N; Baruch, EN; Ben-Betzalel, G; Boursi, B; Markel, G; Schachter, J; Shapira-Frommer, R; Steinberg-Silman, Y, 2018)	0.48
" In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea."	( Severe gastrointestinal toxicity of MEK inhibitors. Allayous, C; Allez, M; Ballon, A; Baroudjian, B; Bertheau, P; Delyon, J; Eftekhari, P; Lebbé, C; Lourenço, N; Mourad, N; Pagès, C, 2019)	0.51
" In addition, dabrafenib-trametinib has a favorable effect on Grades 3 and 4 adverse events."	( Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis. Castañeda-Cardona, C; Castrillón, J; Garzón-Orjuela, N; González-Bravo, D; Herrera, D; Lasalvia, P; Prieto-Pinto, L; Rosselli, D, 2020)	1.14
" We retrieved evidence on treatment-related grade III/IV adverse events, progression-free survival (PFS) and overall survival (OS)."	( A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM, 2019)	0.51
" Adverse events occurred in 88% of cases; 16% were grade 3 or worse."	( Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma. Nakano, E; Namikawa, K; Takahashi, A; Yamazaki, N, 2020)	0.81
"Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy."	( Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma. Aiba, S; Amagai, R; Fujimura, T; Furudate, S; Hashimoto, A; Kambayashi, Y; Muto, Y; Ohuchi, K; Okuma, T, 2021)	1.04
" Outcomes of interest included recurrence-free survival (RFS)/disease-free survival (DFS), distant metastasis-free survival (DMFS), all-cause grade 3/4 adverse events (AEs), discontinuations, and discontinuations due to AEs."	( Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. Amadi, A; Chan, K; Kotapati, S; Middleton, MR; Moshyk, A; Toor, K, 2021)	0.62
" Treatment-related adverse events occurred in all patients (100%); most (89%) were grade 1-2."	( Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. Amaria, RN; Davies, MA; Flaherty, KT; Johnson, DB; Nebhan, CA; Sosman, JA; Sullivan, RJ, 2021)	0.93
"Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood."	( Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021)	0.62
" We utilized the cross-sectional FDA's Adverse Events Reporting System (FAERS) and longitudinal Truven Health Analytics/IBM MarketScan database from 2011 to 2018."	( Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021)	0.62
"4%) were cardiovascular adverse events (mortality rate 19%)."	( Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021)	0.62
" Target drug-associated AKI signals were detected by reporting odds ratio (ROR) derived from report data in the Food and Drug Administration Adverse Events Reporting System database."	( BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. Hotta, Y; Kataoka, T; Kimura, K; Mori, N; Sanagawa, A; Tohkin, M; Tomita, N, 2021)	0.62
" COMBI-APlus evaluated whether an adapted pyrexia management algorithm reduces high-grade pyrexia and pyrexia-related adverse outcomes."	( Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. Atkinson, V; Banerjee, H; Del Vecchio, M; Demidov, L; Dutriaux, C; Gogas, H; Grob, JJ; Gupta, A; Lau, M; Menzies, AM; Miranda, F; Robert, C; Ryll, B, 2022)	0.92
" The most common adverse events were consistent with those in COMBI-AD, and 14."	( Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. Atkinson, V; Banerjee, H; Del Vecchio, M; Demidov, L; Dutriaux, C; Gogas, H; Grob, JJ; Gupta, A; Lau, M; Menzies, AM; Miranda, F; Robert, C; Ryll, B, 2022)	0.92
" There were no differences in adverse events (AEs) rate or grade between the groups."	( Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). Aguado, C; Cabrera Suárez, MÁ; Castellón Rubio, VE; España, S; García-Castaño, A; González-Barrallo, I; Majem, M; Martínez-Fernández, A; Medina, J; Mujika, K; Osterloh, L; Palacio, I, 2022)	1

Excerpt	Reference	Relevance
" In xenografted tumor models, GSK1120212 orally dosed once daily had a long circulating half-life and sustained suppression of p-ERK1/2 for more than 24 hours; GSK1120212 also reduced tumor Ki67, increased p27(Kip1/CDKN1B), and caused tumor growth inhibition in multiple tumor models."	( GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Annan, R; Bleam, MR; Erskine, S; Fisher, KE; Gilmartin, AG; Groy, A; Kulkarni, SG; Laquerre, SG; Minthorn, EA; Moss, KG; Rominger, CM; Sutton, D; Yang, J; Zappacosta, F, 2011)	0.37
" The study was in three parts: dose escalation to define the maximum tolerated dose; identification of the recommended phase 2 dose; and assessment of pharmacodynamic changes."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	0.6
" The effective half-life of trametinib was about 4 days."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	0.9
" The design of this 2 treatment, 2 period crossover, incomplete wash-out study was influenced by the subject population, long half-life and PK variability; 24 subjects were randomized to a single, oral 2 mg trametinib dose administered in a fed/fasted state, followed by 7 days of serial PK sampling."	( Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer. Bauman, J; Cox, DS; Fang, L; LoRusso, P; Orford, K; Ouellet, D; Papadopoulos, K; Patnaik, A; Pendry, C; Tolcher, A, 2013)	0.81
" and oral pharmacokinetic parameters, simultaneously."	( Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Bauman, J; Fang, L; Henriquez, F; Ho, M; Leonowens, C; Morrison, RA; Orford, K; Ouellet, D; Pendry, C; Young, GC, 2014)	0.65
"Trametinib concentrations obtained in three clinical studies were included in the population pharmacokinetic analysis."	( Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Chiu, J; Cox, D; Crist, W; DeMarini, DJ; Gardner, O; Kassir, N; Leonowens, C; Mouksassi, MS; Ouellet, D; Patel, K, 2016)	2.13
" Pharmacokinetic profiling of dabrafenib was undertaken, and its metabolites were similar pre- and post-dialysis and comparable to those in patients with normal renal function."	( Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Boddy, AV; Carlino, MS; Harris, D; Kefford, RF; Lee, V; Liu, X; Park, JJ, 2017)	0.46
" Pharmacokinetic analysis may provide an explanation for the pyrexia."	( Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Boddy, AV; Duong, JK; Gonzalez, M; Kim, HY; Lee, J; Lim, SY; Long, GV; Menzies, AM; Rizos, H, 2019)	0.74
" This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametinib in patients with advanced solid tumors who had various degrees of hepatic dysfunction (HD)."	( Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. Bedard, PL; Chen, EX; Chen, HX; Hansen, AR; Hotte, SJ; Ivy, SP; Kelly, K; Lockhart, AC; Razak, AR; Renouf, DJ; Sahebjam, S; Singh, A; Siu, LL; Spreafico, A; Stayner, LA; Subbiah, V; Vaishampayan, UN; Voon, PJ; Wang, L, 2022)	1.19

Excerpt	Reference	Relevance
"This phase 1b study determined the safety, tolerability, and recommended phase 2 dose (RP2D) and schedule of trametinib in combination with gemcitabine."	( A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW, 2013)	0.93
" During expansion, trametinib 2mg was combined with gemcitabine."	( A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW, 2013)	1.04
"Administration of trametinib at its full monotherapy dose of 2mg daily in combination with standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 every 28 days) was feasible."	( A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW, 2013)	1.05
" Taken together, our findings offer preclinical proof of concept for dabrafenib as a specific and highly efficacious BRAF inhibitor and provide evidence for its potential clinical benefits when used in combination with a MEK inhibitor."	( Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. Arnone, MR; Bleam, MR; Erhardt, JA; Fedorowicz, KE; Hughes-Earle, A; Kane-Carson, LS; King, AJ; Laquerre, SG; Moss, KG; Qi, H; Rheault, TR; Sinnamon, RH; Smitheman, KN; Uehling, DE; Yang, J, 2013)	0.62
" Dabrafenib did not have an impact on T lymphocytes or moDCs, whereas trametinib alone or in combination with dabrafenib suppressed T-lymphocyte proliferation, cytokine production, and antigen-specific expansion."	( MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Andrews, M; Cebon, JS; Chen, W; Dimopoulos, N; Knights, A; Louahed, J; Pasam, A; Puaux, AL; Vella, LJ; Woods, K, 2014)	0.64
"This phase Ib trial investigated the safety, tolerability, and recommended phase II dose and schedule of the MEK inhibitor trametinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus."	( A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, J; Patnaik, A; Rasco, D; Tolcher, AW, 2015)	0.89
" PK assessment did not suggest drug-drug interactions between these two agents."	( A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, J; Patnaik, A; Rasco, D; Tolcher, AW, 2015)	0.68
"This study was unable to identify a recommended phase II dose and schedule of trametinib in combination with everolimus that provided an acceptable tolerability and adequate drug exposure."	( A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, J; Patnaik, A; Rasco, D; Tolcher, AW, 2015)	0.91
"Trametinib can safely be given with weekly paclitaxel at the full monotherapy dose."	( PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Ciria, C; Collins, L; Corrie, P; Coupe, N; Gore, M; Gupta, A; Hategan, M; Larkin, J; Love, S; Middleton, MR; Suter, S; Wise, A, 2015)	2.12
" In order to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of single-agent trametinib (part 1) and trametinib in combination with gemcitabine (part 2), we undertook the first clinical study of this combination in Japanese patients with cancer and herein report our results."	( A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Fujisaka, Y; Furuse, J; Kasuga, A; Kitamura, H; Kurata, T; Matsushita, H; Mukaiyama, A; Nagashima, F; Nakagawa, K; Naruge, D; Nishimura, Y; Nishina, S; Okamoto, W; Shimizu, T; Takasu, A, 2015)	0.94
"0 mg once daily) in combination with gemcitabine (1000 mg/m(2))."	( A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Fujisaka, Y; Furuse, J; Kasuga, A; Kitamura, H; Kurata, T; Matsushita, H; Mukaiyama, A; Nagashima, F; Nakagawa, K; Naruge, D; Nishimura, Y; Nishina, S; Okamoto, W; Shimizu, T; Takasu, A, 2015)	0.73
" We found that cetuximab, in combination with chemotherapy, fostered ICD in CRC cells, which we measured via the endoplasmic reticulum (ER) stress response and an increase in phagocytosis by dendritic cells."	( The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG, 2016)	0.43
" These data suggest that MBZ, a well-tolerated off-patent approved drug, should be considered as a therapeutic option in combination with trametinib, for patients with NRASQ61mut or other non-V600E BRAF mutant melanomas."	( The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Abdussamad, M; Atkins, MB; Byers, SW; Calvert, V; Chen, YS; Dakshanamurthy, S; Fang, HB; Gaur, A; Petricoin, EF; Rosenthal, DS; Simbulan-Rosenthal, CM; Zapas, J; Zhou, H, 2017)	0.9
" In the present study, we show that gemcitabine (GEM) in combination with TRA was more effective than TRA alone."	( MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Bouvet, M; Clary, B; Delong, JC; Hoffman, RM; Hwang, HK; Igarashi, K; Kawaguchi, K; Kiyuna, T; Lwin, TM; Miyake, K; Miyake, M; Murakami, T; Singh, SR; Unno, M, 2018)	0.84
"In this study we evaluated the multitargeted Janus kinase/TANK-binding kinase 1 (TBK1) inhibitor momelotinib combined with the mitogen/extracellular signal-related kinase (MEK)1/MEK2 inhibitor trametinib in patients with platinum-treated, refractory, metastatic, KRAS-mutated NSCLC."	( Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. Barbie, DA; Humeniuk, R; Kawashima, J; Kelly, K; Koczywas, M; Kong, S; Spira, A, 2018)	0.93
"We sought to determine safety and efficacy of the AKT inhibitor, GSK2141795, combined with the MEK inhibitor, trametinib, in endometrial cancer."	( Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Aghajanian, C; Birrer, MJ; Coleman, RL; Fracasso, PM; Ju, Z; Lee, S; Martin, LP; Mathews, CA; Mills, GB; Modesitt, SC; Moore, KN; Schilder, RJ; Sill, MW; Waggoner, S; Westin, SN, 2019)	1
"Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested."	( Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Becerra, C; D'Amelio, AM; Ellis, C; Gauvin, J; Gonzalez, R; Heist, RS; Ibrahim, N; Kalyana-Sundaram, S; Kleha, JF; Kurzrock, R; Leonowens, C; Means-Powell, J; Tan, AR; Tolcher, AW; Valero, V; Wang, C; Werner, TL; Yan, L, 2020)	1.04
" This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n = 26), or durvalumab and trametinib given concomitantly (cohort B, n = 20) or sequentially (cohort C, n = 22) for patients with BRAF-wild type melanoma."	( PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Algazi, A; Ascierto, PA; Butler, MO; Campbell, KM; Chandra, S; Delafont, B; Gordon, M; Hernandez-Aya, L; Lawrence, D; Lutzky, J; Marshall, S; Miller, WH; Mueller, N; Ribas, A; Robert, C, 2020)	0.74
" We evaluated the anticancer potential of metformin in combination with trametinib plus paclitaxel, against four melanoma cell lines."	( Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells. Lee, Y; Park, D, 2021)	1.12
" The combination with anti-PD-1 results in optimal treatment efficacy for iCCA."	( Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Diggs, LP; Green, BL; Greten, TF; Heinrich, B; Ma, C; McCallen, JD; McVey, JC; Ruf, B; Tandon, M; Wabitsch, S; Zhang, Q, 2021)	0.91
" In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL)."	( Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report. Hu, BF; Shen, SH; Wang, GL; Wang, J, 2021)	1.2
"The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy."	( Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report. Hu, BF; Shen, SH; Wang, GL; Wang, J, 2021)	0.96
"We conducted a phase I study to evaluate the maximum tolerated dose (MTD), safety, and efficacy of trametinib in combination with TAS-102 in patients with chemotherapy-refractory KRAS-mutant, wild-type PIK3CA/PTEN metastatic colorectal cancer (mCRC)."	( A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C, 2022)	1.23
"Trametinib in combination with TAS-102 demonstrated a manageable safety profile."	( A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C, 2022)	2.46
" The selective BRAF inhibitor, dabrafenib, in combination with the MEK1/2 inhibitor, trametinib, has been approved in select BRAF V600-mutant solid tumors."	( Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Choi, J; Dunkel, IJ; Geoerger, B; Hargrave, D; Osterloh, L; Roughton, M; Russo, M; Whitlock, JA, 2023)	1.4
" This may be due to suboptimal drug dosing given drug-drug interactions."	( A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Blum Murphy, M; Fu, S; Gao, M; Karp, DD; Kawedia, JD; Kee, BK; Lim, J; Meric-Bernstam, F; Morris, VK; Pant, S; Piha-Paul, SA; Subbiah, V; Tran, HT; Tseng, C; Tsimberidou, AM; Yap, TA, 2023)	1.13
" Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promising efficacy in preclinical studies."	( A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma. Bai, C; Cheng, Y; Ge, Y; Li, X; Tang, H; Wang, Y; You, T, 2023)	2.12

Excerpt	Reference	Relevance
"Trametinib is an orally bioavailable mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor with antineoplastic activity."	( Trametinib: first global approval. McCormack, PL; Wright, CJ, 2013)	3.28
"The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2 mg oral dose of trametinib."	( Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Bauman, J; Fang, L; Henriquez, F; Ho, M; Leonowens, C; Morrison, RA; Orford, K; Ouellet, D; Pendry, C; Young, GC, 2014)	0.85
"The least-squares mean (90% confidence interval) absolute bioavailability of trametinib (2 mg tablet) was 72."	( Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Bauman, J; Fang, L; Henriquez, F; Ho, M; Leonowens, C; Morrison, RA; Orford, K; Ouellet, D; Pendry, C; Young, GC, 2014)	0.88
"Trametinib absolute bioavailability was moderate to high, whereas first pass metabolism was low."	( Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Bauman, J; Fang, L; Henriquez, F; Ho, M; Leonowens, C; Morrison, RA; Orford, K; Ouellet, D; Pendry, C; Young, GC, 2014)	2.09
" This open-label, two-period, two-treatment, randomized, crossover study assessed the relative bioavailability of the trametinib pediatric oral solution compared to the tablet formulation after a single-dose administration to adult patients with solid tumors."	( Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Allred, A; Bendell, J; Burris, H; Cox, DS; Gordon, MS; Infante, JR; Jones, S; Orford, K; Zhou, Y, 2015)	0.85
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" In this open-label, phase 1, single-dose, randomized, 2-treatment, 2-period crossover study in healthy volunteers, bioavailability of a single 2-mg tablet of trametinib containing 9% DMSO (test formulation), corresponding to the lowest DMSO content in the tablet after storage at 25°C for 36 months, was evaluated vs bioavailability of a 2-mg tablet containing 11% DMSO (reference formulation)."	( Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature. Chiparus, O; Choudhury, S; Ilankumaran, P; Kim, C; Lau, M; Tan, EY; Ziltener, C, 2022)	1.17
"In this randomized, open-label, 2-part, 2 × 2 crossover, phase 1 study, the effect of a low-fat low-calorie (LFLC) meal on the relative bioavailability of a trametinib 2-mg tablet or dabrafenib 150-mg capsule was evaluated in healthy participants."	( Evaluation of a Low-Fat Low-Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open-Label, 2-Part Study in Healthy Participants. Iyer, GR; Pazdirkova, M; Singh, N; Tan, EY; Taylor, AJ, 2023)	1.34

Excerpt	Relevance	Reference
" In xenografted tumor models, GSK1120212 orally dosed once daily had a long circulating half-life and sustained suppression of p-ERK1/2 for more than 24 hours; GSK1120212 also reduced tumor Ki67, increased p27(Kip1/CDKN1B), and caused tumor growth inhibition in multiple tumor models."	( GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Annan, R; Bleam, MR; Erskine, S; Fisher, KE; Gilmartin, AG; Groy, A; Kulkarni, SG; Laquerre, SG; Minthorn, EA; Moss, KG; Rominger, CM; Sutton, D; Yang, J; Zappacosta, F, 2011)	0.37
" Intermittent and continuous dosing regimens were analysed."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	0.6
" Furthermore, mean concentrations in plasma were greater than the preclinical target concentration throughout the dosing interval."	( Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Becerra, C; Bendell, JC; Burris, HA; Cox, DS; DeMarini, DJ; Eckhardt, G; Falchook, GS; Fecher, LA; Flaherty, K; Gordon, MS; Hart, L; Infante, JR; Kurzrock, R; Le, NT; Messersmith, WA; Morris, SR; Nallapareddy, S; Peddareddigari, VG; Xu, Y, 2012)	0.6
"5mg) was escalated in a 3+3 design with standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)."	( A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW, 2013)	0.71
"Administration of trametinib at its full monotherapy dose of 2mg daily in combination with standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 every 28 days) was feasible."	( A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW, 2013)	1.05
" The continued MAPK signaling-based resistance identified in these patients suggests that alternative dosing of current agents, more potent RAF/MEK inhibitors, and/or inhibition of the downstream kinase ERK may be needed for durable control of BRAF-mutant melanoma."	( MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Anderka, K; Carter, SL; Cibulskis, K; Cooper, ZA; Farlow, DN; Fisher, S; Flaherty, KT; Frederick, DT; Friedrich, DC; Gabriel, SB; Garraway, LA; Getz, G; Goetz, EM; Hodis, E; Johannessen, CM; Kryukov, G; Lawrence, DP; McKenna, A; Perrin, D; Rosenberg, M; Sullivan, RJ; Taylor-Weiner, A; Treacy, DJ; Van Allen, EM; Wagle, N; Wargo, JA, 2014)	0.4
" These eruptions seem to be reduced when dosed in combination with dabrafenib."	( Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Anforth, R; Clements, A; Fernandez-Peñas, P; Kefford, R; Liu, M; Long, GV; Nguyen, B; Uribe, P, 2014)	0.64
" Patients were assigned to one of 10 different cohorts, involving either daily dosing with both agents or daily dosing with trametinib and intermittent everolimus dosing."	( A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, J; Patnaik, A; Rasco, D; Tolcher, AW, 2015)	0.89
" Intermittent dosing schedule [1."	( Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Aktan, G; Allred, AJ; Becerra, CR; Cornfeld, M; Ferron-Brady, G; Gauvin, J; Ibrahim, N; Motwani, M; Orford, K; Papadopoulos, KP; Patnaik, A; Rasco, DW; Tolcher, AW, 2015)	0.69
"Continuous daily dosing of trametinib/afuresertib combination was poorly tolerated."	( Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Aktan, G; Allred, AJ; Becerra, CR; Cornfeld, M; Ferron-Brady, G; Gauvin, J; Ibrahim, N; Motwani, M; Orford, K; Papadopoulos, KP; Patnaik, A; Rasco, DW; Tolcher, AW, 2015)	0.99
" The recommended dosage of trametinib monotherapy is 2 mg orally once daily until disease progression or unacceptable toxicity occurs."	( Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. Chung, C; Reilly, S, 2015)	2.16
" Tumours showed a reduced growth in response to the MEK inhibitors, but halting the selumetinib dosing resulted in tumour relapse."	( Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airway-tumour-stroma lung cancer model. Boda, B; CaulFuty, M; Constant, S; Huang, S; Mas, C; Wiszniewski, L, 2015)	0.68
"No dosage adjustments are required with any of the covariates tested."	( Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Chiu, J; Cox, D; Crist, W; DeMarini, DJ; Gardner, O; Kassir, N; Leonowens, C; Mouksassi, MS; Ouellet, D; Patel, K, 2016)	0.68
" In 16 patients the first plasma sample was obtained before the first dosing of dabrafenib/trametinib."	( Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Bott, A; Buyl, R; Chevolet, I; Jacobs, B; Jansen, Y; Maertens, G; Meersseman, G; Neyns, B; Schreuer, M; Seremet, T; Van Den Herrewegen, S; Wilgenhof, S, 2016)	0.65
"Eligible patients with solid tumours received placebo on day 1, once-daily trametinib 2-mg doses on days 2-14, and a single trametinib 3-mg dose on day 15 to achieve supratherapeutic dosing for QTc measurement."	( Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Bauman, JW; Beeram, M; Cox, DS; Hamid, M; Papadopoulos, KP; Patel, BR; Patnaik, A; Rasco, D; Scheuber, A; Schramek, D; Sharma, S; Tolcher, A; Werner, TL; Zhou, Y, 2016)	0.91
" Results 57 patients were enrolled onto the continuous dosing cohort and 12 patients onto an intermittent BID dosing cohort."	( A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Bedard, PL; Bendell, J; Burris, HA; Cartee, L; Cornfeld, M; Del Conte, G; Fasolo, A; Greenwood, R; Grilley-Olson, JE; Infante, JR; Lee, CB; Razak, AR; Sessa, C; Singh, R; Stayner, LA; Wu, Y, 2016)	0.68
" The same dosing regimen of topical BRAF inhibitor does not increase the incidence of cutaneous squamous cell carcinomas in mice."	( Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Atefi, M; Azhdam, A; Cochran, AJ; Comin-Anduix, B; de-Faria, FM; Escuin-Ordinas, H; Herschman, HR; Huang, RR; Hugo, W; Jiao, J; Komenan, SM; Krystofinski, P; Li, S; Lo, RS; McBride, WH; Modlin, RL; Pellegrini, M; Realegeno, S; Ribas, A; Segura, T; Sun, L; Xie, MW, 2016)	0.43
"A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer."	( Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF Eton, O; Lee, SL; Pudusseri, A; White, PS, 2017)	0.94
" They also noted improved tolerance of treatment upon transitioning to the intermittent dosing schedule."	( Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF Eton, O; Lee, SL; Pudusseri, A; White, PS, 2017)	0.73
" In addition, the pulsatile dosing schedule alone shows superior anti-tumor effects and delays the emergence of drug resistance."	( Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Akbay, EA; Boiarsky, J; Brea, EJ; Choi, H; Deng, J; Dong, L; Houghton, S; Li, S; Merghoub, T; Redmond, D; Silk, T; Smith, PD; Wolchok, JD; Wong, KK; Zhong, H, 2019)	0.51
" Among 126 enrolled patients, 63 received continuous oral daily dosing of trametinib and uprosertib, 29 received various alternative dosing schedules, and 34 were enrolled into expansion cohorts."	( Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Becerra, C; D'Amelio, AM; Ellis, C; Gauvin, J; Gonzalez, R; Heist, RS; Ibrahim, N; Kalyana-Sundaram, S; Kleha, JF; Kurzrock, R; Leonowens, C; Means-Powell, J; Tan, AR; Tolcher, AW; Valero, V; Wang, C; Werner, TL; Yan, L, 2020)	1
"Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested."	( Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Becerra, C; D'Amelio, AM; Ellis, C; Gauvin, J; Gonzalez, R; Heist, RS; Ibrahim, N; Kalyana-Sundaram, S; Kleha, JF; Kurzrock, R; Leonowens, C; Means-Powell, J; Tan, AR; Tolcher, AW; Valero, V; Wang, C; Werner, TL; Yan, L, 2020)	1.04
"Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity."	( Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Beijnen, JH; Bernards, R; Huijberts, SCFA; Huitema, ADR; Marchetti, S; Monkhorst, K; Opdam, FL; Pulleman, S; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM, 2020)	1.2
"Patients received intermittent or concurrent dosing of pembrolizumab plus trametinib."	( KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. Ascierto, PA; Butler, MO; Carlino, MS; Croydon, E; Del Vecchio, M; Diede, SJ; Ferrucci, PF; Gasal, E; Ghori, R; Hamid, O; Joshua, AM; Maio, M; McWhirter, E; Miller, WH; Ribas, A; Zielinski, RR, 2022)	1.24
"MTDs for concurrent and intermittent dosing of pembrolizumab with trametinib were identified."	( KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. Ascierto, PA; Butler, MO; Carlino, MS; Croydon, E; Del Vecchio, M; Diede, SJ; Ferrucci, PF; Gasal, E; Ghori, R; Hamid, O; Joshua, AM; Maio, M; McWhirter, E; Miller, WH; Ribas, A; Zielinski, RR, 2022)	1.24
" Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance."	( Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Arance, A; Basterretxea, L; Bellido, L; Berciano-Guerrero, MA; Berrocal, A; Campos, B; Cerezuela, P; de la Cruz, L; Diaz Beveridge, R; Drozdowskyj, A; Espinosa, E; Gonzalez-Cao, M; Lopez-Martin, JA; Mayo de Las Casas, C; Molina, MA; Montagut, C; Muñoz-Couselo, E; Ochenduszko, S; Oramas, J; Puertolas, T; Rodriguez, D; Villanueva, MJ, 2021)	0.62
" A monitoring protocol was established to standardize medication dosing and monitoring of outcome measures."	( Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome. Annam, A; Chatfield, KC; Hill, LR; Kulungowski, AM; McCallen, LM; Nakano, TA; Rankin, AW, 2022)	2.16
" This may be due to suboptimal drug dosing given drug-drug interactions."	( A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Blum Murphy, M; Fu, S; Gao, M; Karp, DD; Kawedia, JD; Kee, BK; Lim, J; Meric-Bernstam, F; Morris, VK; Pant, S; Piha-Paul, SA; Subbiah, V; Tran, HT; Tseng, C; Tsimberidou, AM; Yap, TA, 2023)	1.13

Role	Description
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of mitogen-activated protein kinase (EC 2.7.11.24).
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
anticoronaviral agent	Any antiviral agent which inhibits the activity of coronaviruses.
geroprotector	Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyridopyrimidine	Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
organoiodine compound	An organoiodine compound is a compound containing at least one carbon-iodine bond.
acetamides	Compounds with the general formula RNHC(=O)CH3.
ring assembly	Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
cyclopropanes	Cyclopropane and its derivatives formed by substitution.
aromatic amine	An amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	11.7704	0.0030	8.7949	48.0869	AID1347053
EWS/FLI fusion protein	Homo sapiens (human)	Potency	13.1922	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	11.7704	0.0030	8.7949	48.0869	AID1347053
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	1.5849	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0043	0.0002	0.4653	9.7000	AID1633264; AID1697076; AID1875924; AID1876027; AID1876276
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0011	0.0002	0.6813	9.7000	AID1633263; AID1697076; AID1875923; AID1876026; AID1876276
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bone morphogenetic protein receptor type-1B	Homo sapiens (human)	Kd	30.0000	0.0009	1.1413	3.7000	AID1424922
Membrane-associated progesterone receptor component 1	Homo sapiens (human)	Kd	30.0000	0.2040	0.2040	0.2040	AID1425109
Cell division cycle 7-related protein kinase	Homo sapiens (human)	Kd	30.0000	0.5110	0.5110	0.5110	AID1424936
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	Kd	30.0000	0.0008	1.5144	9.0000	AID1425121
ATP-dependent RNA helicase DDX3X	Homo sapiens (human)	Kd	30.0000	0.4350	0.4350	0.4350	AID1424975
Pyridoxal kinase	Homo sapiens (human)	Kd	30.0000	0.2860	5.0765	16.4040	AID1425106
Citron Rho-interacting kinase	Homo sapiens (human)	Kd	30.0000	0.0330	3.0646	48.8760	AID1424954
Serine/threonine-protein kinase Chk1	Homo sapiens (human)	Kd	30.0000	0.0028	1.4744	8.7000	AID1424953
Aurora kinase A	Homo sapiens (human)	Kd	30.0000	0.0001	0.7342	9.3000	AID1424917
Cyclin-G-associated kinase	Homo sapiens (human)	Kd	30.0000	0.0003	0.9086	28.6510	AID1425009
Ephrin type-B receptor 6	Homo sapiens (human)	Kd	30.0000	0.0000	1.0768	9.0000	AID1424995
Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)	Kd	30.0000	0.0260	1.3140	2.6020	AID1424896
Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)	Kd	30.0000	0.0020	1.6212	11.4330	AID1425155
Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)	Kd	30.0000	0.0940	1.3910	3.5070	AID1424926
Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0170	0.3610	0.7050	AID1425097
Tyrosine-protein kinase JAK2	Homo sapiens (human)	Kd	30.0000	0.0000	0.8851	7.0000	AID1425031
Eukaryotic translation initiation factor 5B	Homo sapiens (human)	Kd	30.0000	0.2320	0.2320	0.2320	AID1424986
Rho-associated protein kinase 2	Homo sapiens (human)	Kd	30.0000	0.0002	2.7105	56.0660	AID1425158
Serine/threonine-protein kinase ULK1	Homo sapiens (human)	Kd	30.0000	0.0008	1.8410	23.2730	AID1425208
Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)	Kd	30.0000	0.0057	2.0095	12.2010	AID1424997
Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)	Kd	30.0000	0.0170	1.9737	29.9570	AID1425162
U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)	Kd	30.0000	1.3820	1.3820	1.3820	AID1425174
Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)	Kd	30.0000	0.0120	1.6396	7.2000	AID1425161
Serine/threonine-protein kinase 16	Homo sapiens (human)	Kd	30.0000	0.0017	1.2483	9.9690	AID1425179
Cyclin-dependent kinase-like 5	Homo sapiens (human)	Kd	30.0000	0.0017	1.4788	7.3000	AID1424951
Serine/threonine-protein kinase 10	Homo sapiens (human)	Kd	30.0000	0.0000	2.9234	57.4530	AID1425177
Serine/threonine-protein kinase D3	Homo sapiens (human)	Kd	30.0000	0.0089	2.2738	23.3410	AID1425137
Structural maintenance of chromosomes protein 2	Homo sapiens (human)	Kd	30.0000	0.2090	0.6575	1.1060	AID1425173
Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)	Kd	30.0000	0.1700	1.5781	8.0000	AID1425050
Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)	Kd	30.0000	0.0082	2.3645	62.7720	AID1425054
Serine/threonine-protein kinase LATS1	Homo sapiens (human)	Kd	30.0000	0.0140	1.8393	10.7330	AID1425033
Serine/threonine-protein kinase PAK 4	Homo sapiens (human)	Kd	30.0000	0.0027	2.5694	30.3710	AID1425100
Tyrosine-protein kinase ABL1	Homo sapiens (human)	Kd	30.0000	0.0000	1.0411	13.4530	AID1424890
Epidermal growth factor receptor	Homo sapiens (human)	Kd	30.0000	0.0001	1.3514	20.8270	AID1424983
High affinity nerve growth factor receptor	Homo sapiens (human)	Kd	30.0000	0.0020	1.3484	9.2000	AID1425094
Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)	Kd	30.0000	0.1840	0.1840	0.1840	AID1425011
ADP/ATP translocase 2	Homo sapiens (human)	Kd	30.0000	0.4510	0.4510	0.4510	AID1425169
Protein kinase C beta type	Homo sapiens (human)	Kd	30.0000	0.0013	2.7081	26.3240	AID1425130
Insulin receptor	Homo sapiens (human)	Kd	30.0000	0.0017	1.0823	7.9060	AID1425026
Tyrosine-protein kinase Lck	Homo sapiens (human)	Kd	30.0000	0.0002	1.1174	24.2210	AID1425034
Tyrosine-protein kinase Fyn	Homo sapiens (human)	Kd	30.0000	0.0008	1.4238	8.4000	AID1425008
Cyclin-dependent kinase 1	Homo sapiens (human)	Kd	30.0000	0.2880	1.4952	3.0490	AID1424937
Glycogen phosphorylase, liver form	Homo sapiens (human)	Kd	30.0000	2.1210	2.1210	2.1210	AID1425146
Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)	Kd	30.0000	0.0048	1.0986	7.4000	AID1425003
Adenine phosphoribosyltransferase	Homo sapiens (human)	Kd	30.0000	0.0290	0.0290	0.0290	AID1424914
Tyrosine-protein kinase Yes	Homo sapiens (human)	Kd	30.0000	0.0003	1.3708	17.1520	AID1425212
Tyrosine-protein kinase Lyn	Homo sapiens (human)	Kd	30.0000	0.0006	1.0485	5.7000	AID1425037
Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)	Kd	30.0000	0.0007	0.8642	27.5420	AID1425154
Insulin-like growth factor 1 receptor	Homo sapiens (human)	Kd	30.0000	0.0010	1.9211	19.2170	AID1425022
ATP-dependent translocase ABCB1	Homo sapiens (human)	EC50 (µMol)	0.2470	0.0160	0.6786	3.1000	AID1623456
Signal recognition particle receptor subunit alpha	Homo sapiens (human)	Kd	30.0000	0.0080	0.0080	0.0080	AID1425176
Cytochrome c1, heme protein, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.2020	0.2020	0.2020	AID1424969
Hepatocyte growth factor receptor	Homo sapiens (human)	Kd	30.0000	0.0002	1.6297	8.5000	AID1425076
Tyrosine-protein kinase HCK	Homo sapiens (human)	Kd	30.0000	0.0003	2.0343	15.9930	AID1425017
Platelet-derived growth factor receptor beta	Homo sapiens (human)	Kd	30.0000	0.0001	1.0050	11.1070	AID1425104
Tyrosine-protein kinase Fgr	Homo sapiens (human)	Kd	30.0000	0.0005	1.0721	7.8000	AID1425005
Serine/threonine-protein kinase A-Raf	Homo sapiens (human)	Kd	30.0000	0.0470	9.6832	33.6550	AID1424915
Glycogen phosphorylase, brain form	Homo sapiens (human)	Kd	30.0000	3.5690	3.5690	3.5690	AID1425145
Breakpoint cluster region protein	Homo sapiens (human)	Kd	30.0000	0.0030	1.2196	17.3640	AID1424919
Serine/threonine-protein kinase pim-1	Homo sapiens (human)	Kd	30.0000	0.0010	1.1393	19.3160	AID1425111
Fibroblast growth factor receptor 1	Homo sapiens (human)	Kd	30.0000	0.0003	1.5581	6.2000	AID1425004
DNA topoisomerase 2-alpha	Homo sapiens (human)	Kd	30.0000	0.0640	0.2750	0.4860	AID1425202
Cyclin-dependent kinase 4	Homo sapiens (human)	Kd	30.0000	0.0033	1.6050	8.6000	AID1424946
ADP/ATP translocase 3	Homo sapiens (human)	Kd	30.0000	0.0060	0.2505	0.4950	AID1425170
Proto-oncogene tyrosine-protein kinase Src	Homo sapiens (human)	Kd	30.0000	0.0002	1.5077	9.6000	AID1425175
cAMP-dependent protein kinase type II-alpha regulatory subunit	Homo sapiens (human)	Kd	30.0000	0.0520	1.7535	3.4550	AID1425128
Serine/threonine-protein kinase B-raf	Homo sapiens (human)	Kd	30.0000	0.0002	1.6258	26.0180	AID1424924
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	Homo sapiens (human)	Kd	30.0000	0.0001	2.0569	9.5000	AID1425110
Ribosyldihydronicotinamide dehydrogenase [quinone]	Homo sapiens (human)	Kd	30.0000	0.0040	6.7556	88.9030	AID1425093
Tyrosine-protein kinase Fer	Homo sapiens (human)	Kd	30.0000	0.0014	1.3604	8.8000	AID1425002
Protein kinase C alpha type	Homo sapiens (human)	Kd	30.0000	0.0003	1.7922	21.3520	AID1425129
cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)	Kd	30.0000	0.0039	2.9479	23.2450	AID1425123
General transcription and DNA repair factor IIH helicase subunit XPD	Homo sapiens (human)	Kd	30.0000	0.0020	1.6906	12.0220	AID1424996
Casein kinase II subunit alpha'	Homo sapiens (human)	Kd	30.0000	0.0010	2.5309	28.8720	AID1424968
Ras-related protein Rab-6A	Homo sapiens (human)	Kd	30.0000	0.0330	0.0330	0.0330	AID1425150
Ephrin type-A receptor 1	Homo sapiens (human)	Kd	30.0000	0.0041	1.8000	9.8000	AID1424987
Multifunctional protein ADE2	Homo sapiens (human)	Kd	30.0000	5.4810	5.4810	5.4810	AID1425098
cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)	Kd	30.0000	0.0020	8.5577	49.2780	AID1425125
cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)	Kd	30.0000	0.0130	0.7408	4.1000	AID1425124
Ferrochelatase, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.2430	6.4343	67.9140	AID1425001
Ribosomal protein S6 kinase beta-1	Homo sapiens (human)	Kd	30.0000	0.0013	1.1805	4.8000	AID1425164
Tyrosine-protein kinase JAK1	Homo sapiens (human)	Kd	30.0000	0.0016	1.2166	7.8000	AID1425030
Cyclin-dependent kinase 2	Homo sapiens (human)	Kd	30.0000	0.0070	1.5179	10.4870	AID1424944
Beta-adrenergic receptor kinase 1	Homo sapiens (human)	Kd	30.0000	0.1700	5.5791	22.4940	AID1424908
Probable ATP-dependent RNA helicase DDX6	Homo sapiens (human)	Kd	30.0000	4.1030	4.1030	4.1030	AID1424977
Mitogen-activated protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.4300	5.2743	9.8000	AID1425061
MAP/microtubule affinity-regulating kinase 3	Homo sapiens (human)	Kd	30.0000	0.0030	3.9689	58.2400	AID1425069
Deoxycytidine kinase	Homo sapiens (human)	Kd	30.0000	0.0120	1.0875	2.1630	AID1424970
Mitogen-activated protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0001	2.7441	7.3000	AID1425056
Ephrin type-A receptor 2	Homo sapiens (human)	Kd	30.0000	0.0009	1.0752	8.1980	AID1424988
Ephrin type-B receptor 2	Homo sapiens (human)	Kd	30.0000	0.0004	3.1536	53.1980	AID1424992
Non-receptor tyrosine-protein kinase TYK2	Homo sapiens (human)	Kd	30.0000	0.0009	1.5575	8.7000	AID1425207
UMP-CMP kinase	Homo sapiens (human)	Kd	30.0000	0.0030	0.0045	0.0060	AID1424959
Phosphatidylethanolamine-binding protein 1	Homo sapiens (human)	Kd	30.0000	0.0030	0.0030	0.0030	AID1425107
Wee1-like protein kinase	Homo sapiens (human)	Kd	30.0000	0.0014	3.5389	65.1580	AID1425210
Heme oxygenase 2	Homo sapiens (human)	Kd	30.0000	0.1190	0.1190	0.1190	AID1425018
DnaJ homolog subfamily A member 1	Homo sapiens (human)	Kd	30.0000	0.9620	0.9620	0.9620	AID1424980
RAC-alpha serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0006	1.0621	4.4000	AID1424910
RAC-beta serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0021	1.6196	8.7000	AID1424911
Dual specificity protein kinase TTK	Homo sapiens (human)	Kd	30.0000	0.0065	1.6269	8.5000	AID1425205
DNA replication licensing factor MCM4	Homo sapiens (human)	Kd	30.0000	0.6290	0.6290	0.6290	AID1425072
Myosin-10	Homo sapiens (human)	Kd	30.0000	0.2290	0.4935	0.7580	AID1425079
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	Kd	0.0090	0.0039	1.6429	9.6000	AID1425039
Receptor-type tyrosine-protein kinase FLT3	Homo sapiens (human)	Kd	30.0000	0.0002	0.9559	9.9000	AID1425006
Bone morphogenetic protein receptor type-1A	Homo sapiens (human)	Kd	30.0000	0.0600	1.5010	7.0000	AID1424921
Activin receptor type-1B	Homo sapiens (human)	Kd	30.0000	0.0040	1.5110	15.2580	AID1424901
TGF-beta receptor type-1	Homo sapiens (human)	Kd	30.0000	0.0050	2.2785	9.6000	AID1425196
Serine/threonine-protein kinase receptor R3	Homo sapiens (human)	Kd	30.0000	0.0029	1.9936	9.5000	AID1424903
TGF-beta receptor type-2	Homo sapiens (human)	Kd	30.0000	0.0800	1.8351	6.9000	AID1425197
Electron transfer flavoprotein subunit beta	Homo sapiens (human)	Kd	30.0000	0.0120	0.0120	0.0120	AID1424999
Tyrosine-protein kinase CSK	Homo sapiens (human)	Kd	30.0000	0.0010	3.4578	39.5530	AID1424960
Glycine--tRNA ligase	Homo sapiens (human)	Kd	30.0000	0.0400	0.0400	0.0400	AID1425010
Protein kinase C iota type	Homo sapiens (human)	Kd	30.0000	0.0260	9.3316	51.0180	AID1425133
Exosome RNA helicase MTR4	Homo sapiens (human)	Kd	30.0000	2.6070	2.6070	2.6070	AID1425168
Tyrosine-protein kinase Tec	Homo sapiens (human)	Kd	30.0000	0.0010	1.0095	8.7000	AID1425193
Tyrosine-protein kinase ABL2	Homo sapiens (human)	Kd	30.0000	0.0002	1.1249	14.9240	AID1424891
Tyrosine-protein kinase FRK	Homo sapiens (human)	Kd	30.0000	0.0003	1.2424	10.8370	AID1425007
G protein-coupled receptor kinase 6	Homo sapiens (human)	Kd	30.0000	1.1890	1.4020	1.6150	AID1425012
Tyrosine-protein kinase SYK	Homo sapiens (human)	Kd	30.0000	0.0070	2.0052	9.2260	AID1425188
26S proteasome regulatory subunit 6B	Homo sapiens (human)	Kd	30.0000	0.0050	0.0050	0.0050	AID1425141
Mitogen-activated protein kinase 8	Homo sapiens (human)	Kd	30.0000	0.0110	2.0965	26.0590	AID1425063
Mitogen-activated protein kinase 9	Homo sapiens (human)	Kd	30.0000	0.0020	1.4596	8.1000	AID1425064
Dual specificity mitogen-activated protein kinase kinase 4	Homo sapiens (human)	Kd	30.0000	0.0038	1.6264	9.9000	AID1425041
Dual specificity mitogen-activated protein kinase kinase 3	Homo sapiens (human)	Kd	30.0000	0.0050	2.0462	6.6000	AID1425040
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha	Homo sapiens (human)	Kd	30.0000	0.2080	3.6125	7.0170	AID1425113
Casein kinase I isoform alpha	Homo sapiens (human)	Kd	30.0000	0.0010	2.5756	19.3520	AID1424961
Casein kinase I isoform delta	Homo sapiens (human)	Kd	30.0000	0.0150	2.2270	18.3960	AID1424962
MAP kinase-activated protein kinase 2	Homo sapiens (human)	Kd	30.0000	0.0003	2.0274	14.7420	AID1425065
Elongation factor Tu, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.4640	0.4640	0.4640	AID1425206
Choline-phosphate cytidylyltransferase A	Homo sapiens (human)	Kd	30.0000	0.0410	0.0410	0.0410	AID1425103
Cysteine--tRNA ligase, cytoplasmic	Homo sapiens (human)	Kd	30.0000	0.0120	0.3320	0.6520	AID1424932
Casein kinase I isoform epsilon	Homo sapiens (human)	Kd	30.0000	0.0130	1.4086	12.4090	AID1424963
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial	Homo sapiens (human)	Kd	30.0000	1.6890	1.6890	1.6890	AID1424894
Dual specificity protein kinase CLK1	Homo sapiens (human)	Kd	30.0000	0.0020	1.8791	29.8810	AID1424955
Dual specificity protein kinase CLK2	Homo sapiens (human)	Kd	30.0000	0.0070	1.1384	6.5000	AID1424956
Dual specificity protein kinase CLK3	Homo sapiens (human)	Kd	30.0000	0.0100	2.4499	9.0000	AID1424957
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	Kd	30.0000	0.0060	2.4754	22.5430	AID1425013
Glycogen synthase kinase-3 beta	Homo sapiens (human)	Kd	30.0000	0.0070	1.0057	6.1680	AID1425014
Cyclin-dependent kinase 7	Homo sapiens (human)	Kd	30.0000	0.0025	1.6783	7.7000	AID1424949
Cyclin-dependent kinase 9	Homo sapiens (human)	Kd	30.0000	0.0010	1.6166	9.9010	AID1424950
Ras-related protein Rab-27A	Homo sapiens (human)	Kd	30.0000	4.4930	4.4930	4.4930	AID1425149
Interleukin-1 receptor-associated kinase 1	Homo sapiens (human)	Kd	30.0000	0.0061	1.5252	8.5000	AID1425027
Ribosomal protein S6 kinase alpha-3	Homo sapiens (human)	Kd	30.0000	0.0170	2.8896	37.6050	AID1425160
Serine/threonine-protein kinase Nek2	Homo sapiens (human)	Kd	30.0000	0.1100	1.5649	6.5000	AID1425086
Serine/threonine-protein kinase Nek3	Homo sapiens (human)	Kd	30.0000	0.1700	5.9368	38.0880	AID1425087
Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)	Kd	30.0000	0.0034	2.3943	6.5000	AID1425043
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	Kd	30.0000	0.0001	0.5711	5.0000	AID1425120
LIM domain kinase 1	Homo sapiens (human)	Kd	30.0000	0.0260	1.7840	21.0890	AID1425035
LIM domain kinase 2	Homo sapiens (human)	Kd	30.0000	0.0570	4.9717	52.0560	AID1425036
Mitogen-activated protein kinase 10	Homo sapiens (human)	Kd	30.0000	0.0010	1.6354	5.9000	AID1425057
Tyrosine--tRNA ligase, cytoplasmic	Homo sapiens (human)	Kd	30.0000	3.3160	3.3160	3.3160	AID1425211
5'-AMP-activated protein kinase subunit gamma-1	Homo sapiens (human)	Kd	30.0000	0.0060	1.4681	10.2120	AID1425126
Ephrin type-B receptor 3	Homo sapiens (human)	Kd	30.0000	0.0069	2.1713	6.4100	AID1424993
Ephrin type-A receptor 5	Homo sapiens (human)	Kd	30.0000	0.0002	1.2100	5.9000	AID1424990
Ephrin type-B receptor 4	Homo sapiens (human)	Kd	30.0000	0.0003	2.1678	26.3990	AID1424994
Ephrin type-A receptor 4	Homo sapiens (human)	Kd	30.0000	0.0012	3.1525	43.9420	AID1424989
Adenylate kinase 2, mitochondrial	Homo sapiens (human)	Kd	30.0000	1.0360	1.0360	1.0360	AID1424909
Adenosine kinase	Homo sapiens (human)	Kd	30.0000	0.0130	1.8368	3.4930	AID1424907
Ras-related protein Rab-10	Homo sapiens (human)	Kd	30.0000	1.3480	1.3480	1.3480	AID1425148
Actin-related protein 3	Homo sapiens (human)	Kd	30.0000	0.0360	2.7735	5.5110	AID1424899
Actin-related protein 2	Homo sapiens (human)	Kd	30.0000	0.0040	0.0040	0.0040	AID1424898
GTP-binding nuclear protein Ran	Homo sapiens (human)	Kd	30.0000	0.7590	0.7590	0.7590	AID1425153
Casein kinase I isoform gamma-2	Homo sapiens (human)	Kd	30.0000	0.0460	1.4506	6.6000	AID1424965
Cyclin-dependent kinase 3	Homo sapiens (human)	Kd	30.0000	0.0080	3.0602	63.6140	AID1424945
Cyclin-dependent kinase 6	Homo sapiens (human)	Kd	30.0000	0.0320	1.2007	3.3560	AID1424948
Cyclin-dependent-like kinase 5	Homo sapiens (human)	Kd	30.0000	0.0430	1.3757	8.3000	AID1424947
Cyclin-dependent kinase 16	Homo sapiens (human)	Kd	30.0000	0.0011	1.5855	10.0000	AID1424941
Cyclin-dependent kinase 17	Homo sapiens (human)	Kd	30.0000	0.0010	0.8233	5.6000	AID1424942
ATP-dependent 6-phosphofructokinase, platelet type	Homo sapiens (human)	Kd	30.0000	0.9830	0.9830	0.9830	AID1425108
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	Kd	0.0620	0.0002	1.1386	8.7730	AID1425038
DNA topoisomerase 2-beta	Homo sapiens (human)	Kd	30.0000	0.1480	1.2270	2.5970	AID1425203
Protein kinase C theta type	Homo sapiens (human)	Kd	30.0000	0.0007	1.6140	7.2000	AID1425134
Activin receptor type-1	Homo sapiens (human)	Kd	30.0000	0.0040	1.4853	16.1210	AID1424900
Macrophage-stimulating protein receptor	Homo sapiens (human)	Kd	30.0000	0.0030	2.0718	8.4000	AID1425078
Focal adhesion kinase 1	Homo sapiens (human)	Kd	30.0000	0.0005	1.2255	13.0390	AID1425142
Protein kinase C delta type	Homo sapiens (human)	Kd	30.0000	0.0002	1.1261	9.2060	AID1425131
Tyrosine-protein kinase BTK	Homo sapiens (human)	Kd	30.0000	0.0006	1.5299	10.1530	AID1424925
Cyclin-dependent kinase 18	Homo sapiens (human)	Kd	30.0000	0.0140	1.4941	8.4000	AID1424943
Activated CDC42 kinase 1	Homo sapiens (human)	Kd	30.0000	0.0020	1.7138	9.6000	AID1425201
Epithelial discoidin domain-containing receptor 1	Homo sapiens (human)	Kd	30.0000	0.0002	1.6314	71.4840	AID1424972
Mitogen-activated protein kinase kinase kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0031	1.4681	14.0430	AID1425052
Serine/threonine-protein kinase 4	Homo sapiens (human)	Kd	30.0000	0.0002	1.7120	25.9020	AID1425185
5'-AMP-activated protein kinase catalytic subunit alpha-1	Homo sapiens (human)	Kd	30.0000	0.0037	1.8913	15.3890	AID1425122
Dual specificity mitogen-activated protein kinase kinase 5	Homo sapiens (human)	Kd	30.0000	0.0002	2.6590	65.6770	AID1425042
Mitogen-activated protein kinase 7	Homo sapiens (human)	Kd	30.0000	0.0420	2.0073	9.9000	AID1425062
Serine/threonine-protein kinase PAK 2	Homo sapiens (human)	Kd	30.0000	0.0031	2.3045	6.0000	AID1425099
Serine/threonine-protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.0002	1.8602	17.5260	AID1425182
Mitogen-activated protein kinase kinase kinase 1	Homo sapiens (human)	Kd	30.0000	0.0970	2.5995	12.4730	AID1425044
Integrin-linked protein kinase	Homo sapiens (human)	Kd	30.0000	0.0200	0.4603	1.3290	AID1425024
Rho-associated protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0003	1.7555	13.4620	AID1425157
Non-receptor tyrosine-protein kinase TNK1	Homo sapiens (human)	Kd	30.0000	0.0018	1.0064	11.2690	AID1425200
Calcium/calmodulin-dependent protein kinase type II subunit gamma	Homo sapiens (human)	Kd	30.0000	0.0005	1.0209	7.8000	AID1424929
Calcium/calmodulin-dependent protein kinase type II subunit delta	Homo sapiens (human)	Kd	30.0000	0.0003	1.5044	20.3010	AID1424928
Dual specificity tyrosine-phosphorylation-regulated kinase 1A	Homo sapiens (human)	Kd	30.0000	0.0001	2.1016	40.2910	AID1424981
Activin receptor type-2B	Homo sapiens (human)	Kd	30.0000	0.0076	2.7328	9.9000	AID1424902
Bone morphogenetic protein receptor type-2	Homo sapiens (human)	Kd	30.0000	0.0190	2.5917	14.3770	AID1424923
Protein-tyrosine kinase 6	Homo sapiens (human)	Kd	30.0000	0.0043	1.7430	9.0000	AID1425144
cGMP-dependent protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0016	0.7072	3.8000	AID1425138
Cyclin-dependent kinase 13	Homo sapiens (human)	Kd	30.0000	0.0009	1.2571	4.5180	AID1424940
Inhibitor of nuclear factor kappa-B kinase subunit epsilon	Homo sapiens (human)	Kd	30.0000	0.0051	1.1093	8.3000	AID1425023
Protein-tyrosine kinase 2-beta	Homo sapiens (human)	Kd	30.0000	0.0011	1.9450	30.4140	AID1425143
Maternal embryonic leucine zipper kinase	Homo sapiens (human)	Kd	30.0000	0.0049	2.2835	29.9330	AID1425074
Structural maintenance of chromosomes protein 1A	Homo sapiens (human)	Kd	30.0000	0.3650	0.3650	0.3650	AID1425172
Chromodomain-helicase-DNA-binding protein 4	Homo sapiens (human)	Kd	30.0000	0.0030	0.0030	0.0030	AID1424952
Peroxisomal acyl-coenzyme A oxidase 1	Homo sapiens (human)	Kd	30.0000	0.0140	0.1425	0.2710	AID1424895
Cyclin-dependent kinase 10	Homo sapiens (human)	Kd	30.0000	0.0090	0.0090	0.0090	AID1424938
Ephrin type-A receptor 7	Homo sapiens (human)	Kd	30.0000	0.0025	1.4445	6.5000	AID1424991
Delta(24)-sterol reductase	Homo sapiens (human)	Kd	30.0000	0.4320	0.4320	0.4320	AID1424978
Ribosomal protein S6 kinase alpha-1	Homo sapiens (human)	Kd	30.0000	0.0280	2.5286	22.7260	AID1425159
Dual specificity testis-specific protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0330	1.7568	5.6000	AID1425194
Myosin light chain kinase, smooth muscle	Homo sapiens (human)	Kd	30.0000	0.0030	1.2088	7.9000	AID1425081
Mitogen-activated protein kinase 11	Homo sapiens (human)	Kd	30.0000	0.0001	0.4610	3.7430	AID1425058
Serine/threonine-protein kinase STK11	Homo sapiens (human)	Kd	30.0000	0.0030	0.9949	5.9000	AID1425178
Serine/threonine-protein kinase N1	Homo sapiens (human)	Kd	30.0000	0.0013	3.1729	49.8130	AID1425117
Serine/threonine-protein kinase N2	Homo sapiens (human)	Kd	30.0000	0.0018	1.7527	9.9000	AID1425118
Mitogen-activated protein kinase 14	Homo sapiens (human)	Kd	30.0000	0.0000	0.5036	8.5000	AID1425059
Calcium/calmodulin-dependent protein kinase type IV	Homo sapiens (human)	Kd	30.0000	0.0300	1.9215	5.4600	AID1424930
Mitogen-activated protein kinase kinase kinase 11	Homo sapiens (human)	Kd	30.0000	0.0110	1.5639	17.9840	AID1425045
MAP kinase-activated protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.0020	0.0170	0.0260	AID1425066
Discoidin domain-containing receptor 2	Homo sapiens (human)	Kd	30.0000	0.0030	1.9888	42.2800	AID1424973
AP2-associated protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0012	1.3707	13.7110	AID1424889
Myosin light chain kinase 3	Homo sapiens (human)	Kd	30.0000	0.0020	1.6184	10.4240	AID1425082
Uncharacterized aarF domain-containing protein kinase 5	Homo sapiens (human)	Kd	30.0000	0.2020	0.4990	0.7960	AID1424906
Putative heat shock protein HSP 90-beta 2	Homo sapiens (human)	Kd	30.0000	2.5660	2.5660	2.5660	AID1425019
Rab-like protein 3	Homo sapiens (human)	Kd	30.0000	4.8300	4.8300	4.8300	AID1425151
Serine/threonine-protein kinase MRCK alpha	Homo sapiens (human)	Kd	30.0000	0.0570	4.5547	14.0200	AID1424933
Serine/threonine-protein kinase MRCK gamma	Homo sapiens (human)	Kd	30.0000	0.0370	1.9625	9.5000	AID1424935
Acyl-CoA dehydrogenase family member 10	Homo sapiens (human)	Kd	30.0000	0.0780	1.6997	3.9570	AID1424892
Serine/threonine-protein kinase N3	Homo sapiens (human)	Kd	30.0000	0.0990	0.7365	1.3740	AID1425119
Serine/threonine-protein kinase ULK3	Homo sapiens (human)	Kd	30.0000	0.0012	1.3350	9.9000	AID1425209
Uncharacterized protein FLJ45252	Homo sapiens (human)	Kd	30.0000	0.0030	1.2292	9.3110	AID1425147
Acyl-CoA dehydrogenase family member 11	Homo sapiens (human)	Kd	30.0000	1.9160	3.0730	4.1470	AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2	Homo sapiens (human)	Kd	30.0000	0.1160	0.7604	1.5000	AID1424998
Serine/threonine-protein kinase MARK2	Homo sapiens (human)	Kd	30.0000	0.0001	1.8425	11.1030	AID1425068
ATP-dependent RNA helicase DHX30	Homo sapiens (human)	Kd	30.0000	0.0060	0.0060	0.0060	AID1424979
Serine/threonine-protein kinase TAO1	Homo sapiens (human)	Kd	30.0000	0.0004	2.1612	18.7570	AID1425189
STE20-related kinase adapter protein alpha	Homo sapiens (human)	Kd	30.0000	0.3160	1.7208	3.6720	AID1425186
AarF domain-containing protein kinase 1	Homo sapiens (human)	Kd	30.0000	0.0230	3.1137	22.7470	AID1424904
Mitogen-activated protein kinase kinase kinase kinase 3	Homo sapiens (human)	Kd	30.0000	0.0051	1.6413	15.4350	AID1425053
MAP kinase-activated protein kinase 5	Homo sapiens (human)	Kd	30.0000	0.0080	1.1241	3.1180	AID1425067
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B	Homo sapiens (human)	Kd	30.0000	0.0030	0.0030	0.0030	AID1425015
Misshapen-like kinase 1	Homo sapiens (human)	Kd	30.0000	0.0010	1.1425	8.9000	AID1425077
Atypical kinase COQ8A, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0940	5.1673	65.3020	AID1424905
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	Homo sapiens (human)	Kd	30.0000	0.0030	2.7522	8.8000	AID1425115
Mitogen-activated protein kinase 15	Homo sapiens (human)	Kd	30.0000	0.0049	0.6880	4.5000	AID1425060
Serine/threonine-protein kinase Nek9	Homo sapiens (human)	Kd	30.0000	0.0160	2.7428	19.6170	AID1425089
ATP-dependent RNA helicase DDX1	Homo sapiens (human)	Kd	30.0000	0.0860	0.0860	0.0860	AID1424974
Mitogen-activated protein kinase kinase kinase kinase 1	Homo sapiens (human)	Kd	30.0000	0.0010	0.9378	5.5000	AID1425051
Aurora kinase B	Homo sapiens (human)	Kd	30.0000	0.0020	1.0614	22.8520	AID1424918
MAP/microtubule affinity-regulating kinase 4	Homo sapiens (human)	Kd	30.0000	0.0054	1.1029	4.9000	AID1425070
Serine/threonine-protein kinase Nek1	Homo sapiens (human)	Kd	30.0000	0.1700	2.4294	8.3000	AID1425085
PAS domain-containing serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	1.0670	1.0670	1.0670	AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0000	3.2331	52.8470	AID1424931
EKC/KEOPS complex subunit TP53RK	Homo sapiens (human)	Kd	30.0000	0.3110	1.9519	3.8400	AID1425204
Dual specificity testis-specific protein kinase 2	Homo sapiens (human)	Kd	30.0000	0.0020	0.0020	0.0020	AID1425195
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	Homo sapiens (human)	Kd	30.0000	0.0440	0.9285	2.9000	AID1425116
Mitogen-activated protein kinase kinase kinase 5	Homo sapiens (human)	Kd	30.0000	0.0700	6.5647	50.5360	AID1425049
Mitogen-activated protein kinase kinase kinase 3	Homo sapiens (human)	Kd	30.0000	0.0060	1.5331	9.9000	AID1425047
Eukaryotic translation initiation factor 2-alpha kinase 1	Homo sapiens (human)	Kd	30.0000	0.0580	1.9224	4.8360	AID1424984
Nucleolar GTP-binding protein 1	Homo sapiens (human)	Kd	30.0000	0.0090	4.1035	8.1980	AID1425016
Serine/threonine-protein kinase D2	Homo sapiens (human)	Kd	30.0000	0.0081	2.3723	25.0190	AID1425136
NUAK family SNF1-like kinase 2	Homo sapiens (human)	Kd	30.0000	0.0001	0.6774	4.6000	AID1425095
RNA cytidine acetyltransferase	Homo sapiens (human)	Kd	30.0000	1.2400	1.2400	1.2400	AID1425083
Serine/threonine-protein kinase SIK2	Homo sapiens (human)	Kd	30.0000	0.0011	1.8165	41.7950	AID1425166
STE20-like serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0000	3.8573	99.2320	AID1425171
Serine/threonine-protein kinase TAO3	Homo sapiens (human)	Kd	30.0000	0.0002	2.7131	14.1960	AID1425191
dCTP pyrophosphatase 1	Homo sapiens (human)	Kd	30.0000	0.5730	1.7403	3.0540	AID1424971
Dual specificity protein kinase CLK4	Homo sapiens (human)	Kd	30.0000	0.0020	1.4122	8.3000	AID1424958
Casein kinase I isoform gamma-1	Homo sapiens (human)	Kd	30.0000	0.0530	2.0622	5.7000	AID1424964
Serine/threonine-protein kinase PAK 6	Homo sapiens (human)	Kd	30.0000	0.0004	1.9194	9.7000	AID1425101
Phenylalanine--tRNA ligase beta subunit	Homo sapiens (human)	Kd	30.0000	0.0030	0.0045	0.0060	AID1425000
Isoleucine--tRNA ligase, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0110	0.0110	0.0110	AID1425020
BMP-2-inducible protein kinase	Homo sapiens (human)	Kd	30.0000	0.0022	2.4097	56.0320	AID1424920
Obg-like ATPase 1	Homo sapiens (human)	Kd	30.0000	0.0030	0.0050	0.0070	AID1425096
Interleukin-1 receptor-associated kinase 4	Homo sapiens (human)	Kd	30.0000	0.0017	3.4719	34.1450	AID1425029
Mitogen-activated protein kinase kinase kinase 20	Homo sapiens (human)	Kd	30.0000	0.0023	1.7034	13.6380	AID1425213
Cyclin-dependent kinase 12	Homo sapiens (human)	Kd	30.0000	0.0320	1.8032	5.6350	AID1424939
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13	Homo sapiens (human)	Kd	30.0000	3.9200	3.9200	3.9200	AID1425084
Serine/threonine-protein kinase pim-2	Homo sapiens (human)	Kd	30.0000	0.0019	0.8415	5.0000	AID1425112
Serine/threonine-protein kinase 26	Homo sapiens (human)	Kd	30.0000	0.0074	1.7380	8.3000	AID1425181
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial	Homo sapiens (human)	Kd	30.0000	0.0070	0.0070	0.0070	AID1425187
Serine/threonine-protein kinase NLK	Homo sapiens (human)	Kd	30.0000	0.0060	1.0226	4.4000	AID1425090
5'-AMP-activated protein kinase subunit gamma-2	Homo sapiens (human)	Kd	30.0000	0.0050	1.1581	9.1280	AID1425127
Serine/threonine-protein kinase TBK1	Homo sapiens (human)	Kd	30.0000	0.0009	1.7674	49.6010	AID1425192
Septin-9	Homo sapiens (human)	Kd	30.0000	0.0100	0.2430	0.6350	AID1425165
Ribosomal protein S6 kinase alpha-6	Homo sapiens (human)	Kd	30.0000	0.0040	2.4153	23.7620	AID1425163
TRAF2 and NCK-interacting protein kinase	Homo sapiens (human)	Kd	30.0000	0.0047	1.3935	10.0000	AID1425199
Serine/threonine-protein kinase TAO2	Homo sapiens (human)	Kd	30.0000	0.0100	2.0176	12.9420	AID1425190
Serine/threonine-protein kinase ICK	Homo sapiens (human)	Kd	30.0000	0.0007	1.4717	9.3000	AID1425021
RAC-gamma serine/threonine-protein kinase	Homo sapiens (human)	Kd	30.0000	0.0025	1.7646	6.2000	AID1424912
Serine/threonine-protein kinase SIK3	Homo sapiens (human)	Kd	30.0000	0.0005	1.5086	10.3180	AID1425167
Mitogen-activated protein kinase kinase kinase 2	Homo sapiens (human)	Kd	30.0000	0.0024	1.3298	6.9000	AID1425046
Thyroid hormone receptor-associated protein 3	Homo sapiens (human)	Kd	30.0000	2.7460	2.7460	2.7460	AID1425198
Dual specificity tyrosine-phosphorylation-regulated kinase 1B	Homo sapiens (human)	Kd	30.0000	0.0280	1.8129	9.5000	AID1424982
Mitogen-activated protein kinase kinase kinase kinase 5	Homo sapiens (human)	Kd	30.0000	0.0005	1.9494	50.2140	AID1425055
Receptor-interacting serine/threonine-protein kinase 3	Homo sapiens (human)	Kd	30.0000	0.0110	1.4797	6.7000	AID1425156
Serine/threonine-protein kinase MRCK beta	Homo sapiens (human)	Kd	30.0000	0.0340	3.6252	50.0050	AID1424934
Interleukin-1 receptor-associated kinase 3	Homo sapiens (human)	Kd	30.0000	0.0070	1.7137	25.5810	AID1425028
Serine/threonine-protein kinase 24	Homo sapiens (human)	Kd	30.0000	0.0065	0.8920	4.0840	AID1425180
Casein kinase I isoform gamma-3	Homo sapiens (human)	Kd	30.0000	0.0970	2.3978	8.7000	AID1424966
Mitogen-activated protein kinase kinase kinase 4	Homo sapiens (human)	Kd	30.0000	0.0390	2.3970	8.4000	AID1425048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of gene expression	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cartilage condensation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ovarian cumulus expansion	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
osteoblast differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
eye development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
chondrocyte development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
inflammatory response	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
central nervous system neuron differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
proteoglycan biosynthetic process	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of bone mineralization	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP signaling pathway	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
retinal ganglion cell axon guidance	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of chondrocyte differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ovulation cycle	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of osteoblast differentiation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
retina development in camera-type eye	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
endochondral bone morphogenesis	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of cartilage development	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cellular response to BMP stimulus	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptors	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
negative regulation of chondrocyte proliferation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
dorsal/ventral pattern formation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein phosphorylation	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
cellular response to growth factor stimulus	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
heme biosynthetic process	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
positive regulation of lipoprotein transport	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of cell population proliferation	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of nuclear cell cycle DNA replication	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cell cycle phase transition	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cell division	Cell division cycle 7-related protein kinase	Homo sapiens (human)
peptidyl-serine phosphorylation	Cell division cycle 7-related protein kinase	Homo sapiens (human)
double-strand break repair via break-induced replication	Cell division cycle 7-related protein kinase	Homo sapiens (human)
signal transduction	Cell division cycle 7-related protein kinase	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
trophoblast giant cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
translational initiation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
chromosome segregation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
response to virus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA secondary structure unwinding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of gene expression	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
Wnt signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of translation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of cell growth	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of cell growth	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of protein-containing complex assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein autophosphorylation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of type I interferon production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
DNA duplex unwinding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of interferon-alpha production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of interferon-beta production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
stress granule assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of toll-like receptor 7 signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of toll-like receptor 8 signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
intracellular signal transduction	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of translation in response to endoplasmic reticulum stress	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytosolic ribosome assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of viral genome replication	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
innate immune response	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of translation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of translational initiation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
lipid homeostasis	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cellular response to arsenic-containing substance	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cellular response to osmotic stress	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of chemokine (C-C motif) ligand 5 production	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
intrinsic apoptotic signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cellular response to virus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assembly	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein acetylation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
positive regulation of protein K63-linked ubiquitination	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
protein localization to cytoplasmic stress granule	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
negative regulation of gene expression	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
gamete generation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cell differentiation	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
pyridoxal 5'-phosphate salvage	Pyridoxal kinase	Homo sapiens (human)
pyridoxal metabolic process	Pyridoxal kinase	Homo sapiens (human)
pyridoxamine metabolic process	Pyridoxal kinase	Homo sapiens (human)
mitotic cell cycle	Citron Rho-interacting kinase	Homo sapiens (human)
mitotic cytokinesis	Citron Rho-interacting kinase	Homo sapiens (human)
positive regulation of cytokinesis	Citron Rho-interacting kinase	Homo sapiens (human)
negative regulation of hippo signaling	Citron Rho-interacting kinase	Homo sapiens (human)
generation of neurons	Citron Rho-interacting kinase	Homo sapiens (human)
neuron apoptotic process	Citron Rho-interacting kinase	Homo sapiens (human)
DNA damage checkpoint signaling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
inner cell mass cell proliferation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA replication	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA repair	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
chromatin remodeling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus organization	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of double-strand break repair via homologous recombination	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of cell population proliferation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
signal transduction in response to DNA damage	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
mitotic G2/M transition checkpoint	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
positive regulation of cell cycle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of mitotic nuclear division	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of mitotic centrosome separation	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of G0 to G1 transition	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cellular response to mechanical stimulus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cellular response to caffeine	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
replicative senescence	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
apoptotic process involved in development	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
negative regulation of DNA biosynthetic process	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein phosphorylation	Aurora kinase A	Homo sapiens (human)
response to wounding	Aurora kinase A	Homo sapiens (human)
liver regeneration	Aurora kinase A	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
chromatin remodeling	Aurora kinase A	Homo sapiens (human)
protein phosphorylation	Aurora kinase A	Homo sapiens (human)
apoptotic process	Aurora kinase A	Homo sapiens (human)
spindle organization	Aurora kinase A	Homo sapiens (human)
spindle assembly involved in female meiosis I	Aurora kinase A	Homo sapiens (human)
mitotic centrosome separation	Aurora kinase A	Homo sapiens (human)
anterior/posterior axis specification	Aurora kinase A	Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
negative regulation of gene expression	Aurora kinase A	Homo sapiens (human)
peptidyl-serine phosphorylation	Aurora kinase A	Homo sapiens (human)
regulation of protein stability	Aurora kinase A	Homo sapiens (human)
negative regulation of protein binding	Aurora kinase A	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Aurora kinase A	Homo sapiens (human)
negative regulation of apoptotic process	Aurora kinase A	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Aurora kinase A	Homo sapiens (human)
positive regulation of mitotic nuclear division	Aurora kinase A	Homo sapiens (human)
positive regulation of mitotic cell cycle	Aurora kinase A	Homo sapiens (human)
regulation of centrosome cycle	Aurora kinase A	Homo sapiens (human)
protein autophosphorylation	Aurora kinase A	Homo sapiens (human)
cell division	Aurora kinase A	Homo sapiens (human)
centrosome localization	Aurora kinase A	Homo sapiens (human)
cilium disassembly	Aurora kinase A	Homo sapiens (human)
protein localization to centrosome	Aurora kinase A	Homo sapiens (human)
positive regulation of mitochondrial fission	Aurora kinase A	Homo sapiens (human)
positive regulation of oocyte maturation	Aurora kinase A	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Aurora kinase A	Homo sapiens (human)
neuron projection extension	Aurora kinase A	Homo sapiens (human)
mitotic spindle organization	Aurora kinase A	Homo sapiens (human)
regulation of cytokinesis	Aurora kinase A	Homo sapiens (human)
receptor-mediated endocytosis	Cyclin-G-associated kinase	Homo sapiens (human)
endoplasmic reticulum organization	Cyclin-G-associated kinase	Homo sapiens (human)
Golgi organization	Cyclin-G-associated kinase	Homo sapiens (human)
negative regulation of neuron projection development	Cyclin-G-associated kinase	Homo sapiens (human)
synaptic vesicle uncoating	Cyclin-G-associated kinase	Homo sapiens (human)
protein localization to Golgi apparatus	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular transport	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin coat assembly	Cyclin-G-associated kinase	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin coat disassembly	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin-dependent endocytosis	Cyclin-G-associated kinase	Homo sapiens (human)
protein localization to plasma membrane	Cyclin-G-associated kinase	Homo sapiens (human)
Golgi to lysosome transport	Cyclin-G-associated kinase	Homo sapiens (human)
regulation of clathrin coat assembly	Cyclin-G-associated kinase	Homo sapiens (human)
protein phosphorylation	Ephrin type-B receptor 6	Homo sapiens (human)
ephrin receptor signaling pathway	Ephrin type-B receptor 6	Homo sapiens (human)
axon guidance	Ephrin type-B receptor 6	Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidase	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
lipid homeostasis	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
toll-like receptor 2 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
adaptive immune response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of T-helper 1 type immune response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
apoptotic process	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
inflammatory response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
JNK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytokine-mediated signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein ubiquitination	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
lipopolysaccharide-mediated signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of chemokine production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interferon-alpha production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interferon-beta production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of type II interferon production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-12 production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-2 production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of interleukin-6 production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
immature T cell proliferation in thymus	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of immature T cell proliferation in thymus	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
defense response to bacterium	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of apoptotic process	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to exogenous dsRNA	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
innate immune response	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of T-helper 1 cell differentiation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of JNK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
defense response to Gram-positive bacterium	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
T cell receptor signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein homooligomerization	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
stress-activated MAPK cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of macrophage cytokine production	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
ERK1 and ERK2 cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to interleukin-1	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to interleukin-12	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
response to interleukin-18	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to lipoteichoic acid	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to peptidoglycan	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to muramyl dipeptide	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
xenophagy	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein K63-linked ubiquitination	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of xenophagy	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferation	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
chromatin remodeling	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
apoptotic process	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
chromosome segregation	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
regulation of sister chromatid cohesion	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
mitotic spindle assembly checkpoint signaling	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
cell division	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
regulation of chromosome segregation	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
positive regulation of maintenance of mitotic sister chromatid cohesion, centromeric	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
meiotic sister chromatid cohesion, centromeric	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
mitochondrion organization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial genome maintenance	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial fission	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
neural tube closure	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
apoptotic process	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrion organization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
inner mitochondrial membrane organization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
visual perception	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial fusion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
axonal transport of mitochondrion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-17 production	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cristae formation	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTP metabolic process	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
protein complex oligomerization	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane fusion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cellular senescence	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane tubulation	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane fusion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitment	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
positive regulation of platelet aggregation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of platelet activation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to antibiotic	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of SMAD protein signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
microglial cell activation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
chromatin remodeling	Tyrosine-protein kinase JAK2	Homo sapiens (human)
transcription by RNA polymerase II	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK2	Homo sapiens (human)
mesoderm development	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cell population proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stress	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell-substrate adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to amine	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytokine-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of cell-cell adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
actin filament polymerization	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
erythrocyte differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell migration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
axon regeneration	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intracellular mineralocorticoid receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of insulin secretion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to lipopolysaccharide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of type II interferon production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of interleukin-17 production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of natural killer cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to hydroperoxide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
symbiont-induced defense-related programmed cell death	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to tumor necrosis factor	Tyrosine-protein kinase JAK2	Homo sapiens (human)
post-embryonic hemopoiesis	Tyrosine-protein kinase JAK2	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to interleukin-3	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-5-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
collagen-activated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-3-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte-macrophage colony-stimulating factor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of T cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of protein import into nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of Janus kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of DNA binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of MAPK cascade	Tyrosine-protein kinase JAK2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
post-translational protein modification	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of MHC class II biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of nitric oxide biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cell differentiation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein autophosphorylation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of inflammatory response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
modulation of chemical synaptic transmission	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of NK T cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type II interferon-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of growth hormone receptor signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
mammary gland epithelium development	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-6-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of leukocyte proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
response to interleukin-12	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-35-mediated signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to lipopolysaccharide	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to dexamethasone stimulus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cellular response to virus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of epithelial cell apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of signaling receptor activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of T-helper 17 type immune response	Tyrosine-protein kinase JAK2	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of apoptotic process	Tyrosine-protein kinase JAK2	Homo sapiens (human)
regulation of translational initiation	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
ribosome assembly	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
translational initiation	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
epithelial to mesenchymal transition	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
response to ischemia	Rho-associated protein kinase 2	Homo sapiens (human)
aortic valve morphogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
protein phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
smooth muscle contraction	Rho-associated protein kinase 2	Homo sapiens (human)
canonical NF-kappaB signal transduction	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of endothelial cell migration	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of gene expression	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of gene expression	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of centrosome duplication	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of angiogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell adhesion	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of cell migration	Rho-associated protein kinase 2	Homo sapiens (human)
cortical actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of nervous system process	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of connective tissue growth factor production	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of circadian rhythm	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of MAPK cascade	Rho-associated protein kinase 2	Homo sapiens (human)
modulation by host of viral process	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of nitric oxide biosynthetic process	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of keratinocyte differentiation	Rho-associated protein kinase 2	Homo sapiens (human)
rhythmic process	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome duplication	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of stress fiber assembly	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of stress fiber assembly	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of focal adhesion assembly	Rho-associated protein kinase 2	Homo sapiens (human)
mRNA destabilization	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of biomineral tissue development	Rho-associated protein kinase 2	Homo sapiens (human)
cellular response to testosterone stimulus	Rho-associated protein kinase 2	Homo sapiens (human)
response to transforming growth factor beta	Rho-associated protein kinase 2	Homo sapiens (human)
protein localization to plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Rho-associated protein kinase 2	Homo sapiens (human)
blood vessel diameter maintenance	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of angiotensin-activated signaling pathway	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of protein localization to lysosome	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cellular response to hypoxia	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of amyloid-beta formation	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of protein localization to early endosome	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic process	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of establishment of endothelial barrier	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Rho-associated protein kinase 2	Homo sapiens (human)
cellular response to acetylcholine	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of connective tissue replacement	Rho-associated protein kinase 2	Homo sapiens (human)
response to angiotensin	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of establishment of cell polarity	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell motility	Rho-associated protein kinase 2	Homo sapiens (human)
actomyosin structure organization	Rho-associated protein kinase 2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
mitotic cytokinesis	Rho-associated protein kinase 2	Homo sapiens (human)
embryonic morphogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell junction assembly	Rho-associated protein kinase 2	Homo sapiens (human)
Rho protein signal transduction	Rho-associated protein kinase 2	Homo sapiens (human)
autophagosome assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
signal transduction	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein localization	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of cell population proliferation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
macroautophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of macroautophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
neuron projection regeneration	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
neuron projection development	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cellular response to nutrient levels	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
response to starvation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
regulation of protein lipidation	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
positive regulation of autophagosome assembly	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon extension	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagy of mitochondrion	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
reticulophagy	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
piecemeal microautophagy of the nucleus	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
negative regulation of collateral sprouting	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
endothelial cell proliferation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mRNA catabolic process	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
regulation of macroautophagy	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of RNA splicing	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to unfolded protein	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
response to endoplasmic reticulum stress	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
peptidyl-serine autophosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-mediated unfolded protein response	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of JUN kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein autophosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to hydrogen peroxide	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cellular response to glucose stimulus	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein response	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
insulin metabolic process	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
peptidyl-serine trans-autophosphorylation	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
negative regulation of cytokine production	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
chromatin remodeling	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein phosphorylation	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
inflammatory response	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
axon guidance	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
intracellular signal transduction	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
post-translational protein modification	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
negative regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
regulation of postsynapse organization	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
peptidyl-serine phosphorylation	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cis assembly of pre-catalytic spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
spliceosome conformational change to release U4 (or U4atac) and U1 (or U11)	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
mRNA splicing, via spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
osteoblast differentiation	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
negative regulation of cytokine production	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
chromatin remodeling	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
regulation of DNA-templated transcription	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein phosphorylation	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transmembrane signaling receptor activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
protein binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
ATP binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
SMAD binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
metal ion binding	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
BMP receptor activity	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
transforming growth factor beta receptor activity, type I	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
amyloid-beta binding	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
steroid binding	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
protein binding	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
heme binding	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
protein homodimerization activity	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
metal ion binding	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
protein kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
ATP binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
metal ion binding	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Cell division cycle 7-related protein kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
DNA binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
DNA helicase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA helicase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
mRNA binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
GTPase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
protein binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ATP binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
transcription factor binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
poly(A) binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
eukaryotic initiation factor 4E binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ribonucleoside triphosphate phosphatase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
translation initiation factor binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA strand annealing activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
signaling adaptor activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
RNA stem-loop binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
gamma-tubulin binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ribosomal small subunit binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
CTPase activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
protein serine/threonine kinase activator activity	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cadherin binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
mRNA 5'-UTR binding	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
magnesium ion binding	Pyridoxal kinase	Homo sapiens (human)
ATP binding	Pyridoxal kinase	Homo sapiens (human)
zinc ion binding	Pyridoxal kinase	Homo sapiens (human)
pyridoxal kinase activity	Pyridoxal kinase	Homo sapiens (human)
pyridoxal phosphate binding	Pyridoxal kinase	Homo sapiens (human)
potassium ion binding	Pyridoxal kinase	Homo sapiens (human)
sodium ion binding	Pyridoxal kinase	Homo sapiens (human)
lithium ion binding	Pyridoxal kinase	Homo sapiens (human)
protein homodimerization activity	Pyridoxal kinase	Homo sapiens (human)
transcription coactivator binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase activity	Citron Rho-interacting kinase	Homo sapiens (human)
protein binding	Citron Rho-interacting kinase	Homo sapiens (human)
ATP binding	Citron Rho-interacting kinase	Homo sapiens (human)
SH3 domain binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein kinase binding	Citron Rho-interacting kinase	Homo sapiens (human)
PDZ domain binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine/threonine kinase inhibitor activity	Citron Rho-interacting kinase	Homo sapiens (human)
metal ion binding	Citron Rho-interacting kinase	Homo sapiens (human)
scaffold protein binding	Citron Rho-interacting kinase	Homo sapiens (human)
protein serine kinase activity	Citron Rho-interacting kinase	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein domain specific binding	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
histone H3T11 kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein kinase activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Aurora kinase A	Homo sapiens (human)
protein binding	Aurora kinase A	Homo sapiens (human)
ATP binding	Aurora kinase A	Homo sapiens (human)
protein kinase binding	Aurora kinase A	Homo sapiens (human)
ubiquitin protein ligase binding	Aurora kinase A	Homo sapiens (human)
histone H3S10 kinase activity	Aurora kinase A	Homo sapiens (human)
protein heterodimerization activity	Aurora kinase A	Homo sapiens (human)
protein serine kinase activity	Aurora kinase A	Homo sapiens (human)
molecular function activator activity	Aurora kinase A	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-G-associated kinase	Homo sapiens (human)
protein binding	Cyclin-G-associated kinase	Homo sapiens (human)
ATP binding	Cyclin-G-associated kinase	Homo sapiens (human)
cyclin binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein-folding chaperone binding	Cyclin-G-associated kinase	Homo sapiens (human)
protein serine kinase activity	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin binding	Cyclin-G-associated kinase	Homo sapiens (human)
ephrin receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
protein binding	Ephrin type-B receptor 6	Homo sapiens (human)
ATP binding	Ephrin type-B receptor 6	Homo sapiens (human)
signaling receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
transmembrane-ephrin receptor activity	Ephrin type-B receptor 6	Homo sapiens (human)
FAD binding	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
flavin adenine dinucleotide binding	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
pristanoyl-CoA oxidase activity	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
fatty acid binding	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
protein serine/threonine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signaling receptor binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
ATP binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
LIM domain binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
signaling adaptor activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
identical protein binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein homodimerization activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
CARD domain binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
caspase binding	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
JUN kinase kinase kinase activity	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
protein serine/threonine kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
protein binding	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
ATP binding	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
protein serine kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
histone H2A kinase activity	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
magnesium ion binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTPase activity	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
protein binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTP binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
phosphatidic acid binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
GTPase-dependent fusogenic activity	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane bending activity	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cardiolipin binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
microtubule binding	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
growth hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
heme binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
type 1 angiotensin receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
acetylcholine receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone H3Y41 kinase activity	Tyrosine-protein kinase JAK2	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
histone binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
insulin receptor substrate binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
peptide hormone receptor binding	Tyrosine-protein kinase JAK2	Homo sapiens (human)
tRNA binding	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
RNA binding	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
translation initiation factor activity	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
GTPase activity	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
protein binding	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
GTP binding	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
metal ion binding	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
protease binding	Rho-associated protein kinase 2	Homo sapiens (human)
RNA binding	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
structural molecule activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
ATP binding	Rho-associated protein kinase 2	Homo sapiens (human)
small GTPase binding	Rho-associated protein kinase 2	Homo sapiens (human)
metal ion binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau-protein kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
endopeptidase activator activity	Rho-associated protein kinase 2	Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
small GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
GTPase binding	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
RNA endonuclease activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
platelet-derived growth factor receptor binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
enzyme binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Hsp70 protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
ADP binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Hsp90 protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
unfolded protein binding	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein tyrosine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H3S10 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H3S28 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
histone H2AS1 kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
RNA binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
RNA helicase activity	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
helicase activity	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
protein binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
ATP binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
ATP hydrolysis activity	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
identical protein binding	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
magnesium ion binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein serine/threonine kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
ribosomal protein S6 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
ATP binding	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
histone H3S10 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
histone H3S28 kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
protein serine kinase activity	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 16	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein binding	Cyclin-dependent kinase-like 5	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase-like 5	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
small GTPase binding	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase-like 5	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein homodimerization activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase 10	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
metal ion binding	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase D3	Homo sapiens (human)
single-stranded DNA binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
protein binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
ATP binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
ATP hydrolysis activity	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
chromatin binding	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
magnesium ion binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
MAP kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase 6	Homo sapiens (human)
creatine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein serine/threonine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
ATP binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
microtubule binding	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
MAP kinase kinase kinase kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
protein serine kinase activity	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
nuclear estrogen receptor binding	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cadherin binding involved in cell-cell adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
supercoiled DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
magnesium ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
four-way junction DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
bubble DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
transcription coactivator activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin monomer binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein kinase C binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
syntaxin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
manganese ion binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuropilin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin filament binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitogen-activated protein kinase binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
proline-rich region binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
delta-catenin binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Tyrosine-protein kinase ABL1	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	High affinity nerve growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	High affinity nerve growth factor receptor	Homo sapiens (human)
GPI-linked ephrin receptor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin p75 receptor binding	High affinity nerve growth factor receptor	Homo sapiens (human)
protein binding	High affinity nerve growth factor receptor	Homo sapiens (human)
ATP binding	High affinity nerve growth factor receptor	Homo sapiens (human)
nerve growth factor receptor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
kinase binding	High affinity nerve growth factor receptor	Homo sapiens (human)
identical protein binding	High affinity nerve growth factor receptor	Homo sapiens (human)
protein homodimerization activity	High affinity nerve growth factor receptor	Homo sapiens (human)
nerve growth factor binding	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin binding	High affinity nerve growth factor receptor	Homo sapiens (human)
neurotrophin receptor activity	High affinity nerve growth factor receptor	Homo sapiens (human)
protein binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
GTP binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
metal ion binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G-protein beta/gamma-subunit complex binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
G protein-coupled receptor binding	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
GTPase activity	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
adenine nucleotide transmembrane transporter activity	ADP/ATP translocase 2	Homo sapiens (human)
RNA binding	ADP/ATP translocase 2	Homo sapiens (human)
ATP:ADP antiporter activity	ADP/ATP translocase 2	Homo sapiens (human)
protein binding	ADP/ATP translocase 2	Homo sapiens (human)
proton transmembrane transporter activity	ADP/ATP translocase 2	Homo sapiens (human)
adenine transmembrane transporter activity	ADP/ATP translocase 2	Homo sapiens (human)
oxidative phosphorylation uncoupler activity	ADP/ATP translocase 2	Homo sapiens (human)
ubiquitin protein ligase binding	ADP/ATP translocase 2	Homo sapiens (human)
chromatin binding	Protein kinase C beta type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C beta type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C beta type	Homo sapiens (human)
protein kinase C binding	Protein kinase C beta type	Homo sapiens (human)
calcium channel regulator activity	Protein kinase C beta type	Homo sapiens (human)
protein binding	Protein kinase C beta type	Homo sapiens (human)
ATP binding	Protein kinase C beta type	Homo sapiens (human)
zinc ion binding	Protein kinase C beta type	Homo sapiens (human)
nuclear receptor coactivator activity	Protein kinase C beta type	Homo sapiens (human)
histone H3T6 kinase activity	Protein kinase C beta type	Homo sapiens (human)
histone binding	Protein kinase C beta type	Homo sapiens (human)
nuclear androgen receptor binding	Protein kinase C beta type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C beta type	Homo sapiens (human)
amyloid-beta binding	Insulin receptor	Homo sapiens (human)
protein tyrosine kinase activity	Insulin receptor	Homo sapiens (human)
insulin receptor activity	Insulin receptor	Homo sapiens (human)
insulin-like growth factor receptor binding	Insulin receptor	Homo sapiens (human)
protein binding	Insulin receptor	Homo sapiens (human)
ATP binding	Insulin receptor	Homo sapiens (human)
GTP binding	Insulin receptor	Homo sapiens (human)
protein domain specific binding	Insulin receptor	Homo sapiens (human)
insulin-like growth factor I binding	Insulin receptor	Homo sapiens (human)
insulin-like growth factor II binding	Insulin receptor	Homo sapiens (human)
cargo receptor activity	Insulin receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Insulin receptor	Homo sapiens (human)
insulin binding	Insulin receptor	Homo sapiens (human)
insulin receptor substrate binding	Insulin receptor	Homo sapiens (human)
protein-containing complex binding	Insulin receptor	Homo sapiens (human)
PTB domain binding	Insulin receptor	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein serine/threonine phosphatase activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein phosphatase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
T cell receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
CD4 receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
CD8 receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
ATPase binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Lck	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
enzyme binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
alpha-tubulin binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau-protein kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
growth factor receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
disordered domain specific binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
virus receptor activity	Cyclin-dependent kinase 1	Homo sapiens (human)
chromatin binding	Cyclin-dependent kinase 1	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 1	Homo sapiens (human)
ATP binding	Cyclin-dependent kinase 1	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin binding	Cyclin-dependent kinase 1	Homo sapiens (human)
Hsp70 protein binding	Cyclin-dependent kinase 1	Homo sapiens (human)
histone kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent kinase 1	Homo sapiens (human)
purine nucleobase binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
protein binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
ATP binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
glucose binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
glycogen phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
AMP binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
vitamin binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
bile acid binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
identical protein binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
linear malto-oligosaccharide phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
SHG alpha-glucan phosphorylase activity	Glycogen phosphorylase, liver form	Homo sapiens (human)
pyridoxal phosphate binding	Glycogen phosphorylase, liver form	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
microtubule binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
immunoglobulin receptor binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
phosphatidylinositol binding	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
adenine phosphoribosyltransferase activity	Adenine phosphoribosyltransferase	Homo sapiens (human)
protein binding	Adenine phosphoribosyltransferase	Homo sapiens (human)
AMP binding	Adenine phosphoribosyltransferase	Homo sapiens (human)
adenine binding	Adenine phosphoribosyltransferase	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Yes	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
enzyme binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Yes	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
platelet-derived growth factor receptor binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
integrin binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
SH3 domain binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ubiquitin protein ligase binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
gamma-tubulin binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
glycosphingolipid binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
phosphoprotein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
phosphorylation-dependent protein binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Tyrosine-protein kinase Lyn	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Lyn	Homo sapiens (human)
protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
calcium ion binding	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
protein binding	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
ATP binding	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
signaling receptor activity	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
G-protein alpha-subunit binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein tyrosine kinase activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor receptor activity	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin receptor binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
protein binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
ATP binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
insulin-like growth factor I binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
identical protein binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Insulin-like growth factor 1 receptor	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
plasma membrane	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
dendrite	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
neuronal cell body	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
receptor complex	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
HFE-transferrin receptor complex	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
plasma membrane	Bone morphogenetic protein receptor type-1B	Homo sapiens (human)
plasma membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
extracellular region	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
mitochondrial outer membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
endoplasmic reticulum	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
plasma membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
smooth endoplasmic reticulum membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
specific granule membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
neuron projection	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
neuronal cell body	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
cell body	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
synapse	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
endoplasmic reticulum	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
endomembrane system	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
membrane	Membrane-associated progesterone receptor component 1	Homo sapiens (human)
nucleus	Cell division cycle 7-related protein kinase	Homo sapiens (human)
nucleoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
intercellular bridge	Cell division cycle 7-related protein kinase	Homo sapiens (human)
mitotic spindle	Cell division cycle 7-related protein kinase	Homo sapiens (human)
nucleus	Cell division cycle 7-related protein kinase	Homo sapiens (human)
cytoplasm	Cell division cycle 7-related protein kinase	Homo sapiens (human)
XY body	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
deuterosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole replication complex	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
eukaryotic translation initiation factor 3 complex	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytosolic small ribosomal subunit	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extracellular region	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
nucleoplasm	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytoplasm	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
centrosome	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytosol	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
plasma membrane	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cytoplasmic stress granule	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
lamellipodium	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
cell leading edge	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
secretory granule lumen	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extracellular exosome	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
ficolin-1-rich granule lumen	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
NLRP3 inflammasome complex	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
nucleus	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
P granule	ATP-dependent RNA helicase DDX3X	Homo sapiens (human)
extracellular region	Pyridoxal kinase	Homo sapiens (human)
nucleus	Pyridoxal kinase	Homo sapiens (human)
nucleoplasm	Pyridoxal kinase	Homo sapiens (human)
cytosol	Pyridoxal kinase	Homo sapiens (human)
secretory granule lumen	Pyridoxal kinase	Homo sapiens (human)
specific granule lumen	Pyridoxal kinase	Homo sapiens (human)
extracellular exosome	Pyridoxal kinase	Homo sapiens (human)
cytosol	Pyridoxal kinase	Homo sapiens (human)
cytosol	Citron Rho-interacting kinase	Homo sapiens (human)
membrane	Citron Rho-interacting kinase	Homo sapiens (human)
chromosome, telomeric region	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
condensed nuclear chromosome	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
extracellular space	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
replication fork	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
intracellular membrane-bounded organelle	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
protein-containing complex	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase Chk1	Homo sapiens (human)
spindle microtubule	Aurora kinase A	Homo sapiens (human)
nucleus	Aurora kinase A	Homo sapiens (human)
nucleoplasm	Aurora kinase A	Homo sapiens (human)
centrosome	Aurora kinase A	Homo sapiens (human)
centriole	Aurora kinase A	Homo sapiens (human)
spindle	Aurora kinase A	Homo sapiens (human)
cytosol	Aurora kinase A	Homo sapiens (human)
postsynaptic density	Aurora kinase A	Homo sapiens (human)
microtubule cytoskeleton	Aurora kinase A	Homo sapiens (human)
basolateral plasma membrane	Aurora kinase A	Homo sapiens (human)
midbody	Aurora kinase A	Homo sapiens (human)
spindle pole centrosome	Aurora kinase A	Homo sapiens (human)
ciliary basal body	Aurora kinase A	Homo sapiens (human)
germinal vesicle	Aurora kinase A	Homo sapiens (human)
axon hillock	Aurora kinase A	Homo sapiens (human)
pronucleus	Aurora kinase A	Homo sapiens (human)
perinuclear region of cytoplasm	Aurora kinase A	Homo sapiens (human)
mitotic spindle	Aurora kinase A	Homo sapiens (human)
meiotic spindle	Aurora kinase A	Homo sapiens (human)
mitotic spindle pole	Aurora kinase A	Homo sapiens (human)
glutamatergic synapse	Aurora kinase A	Homo sapiens (human)
spindle pole centrosome	Aurora kinase A	Homo sapiens (human)
chromosome passenger complex	Aurora kinase A	Homo sapiens (human)
spindle midzone	Aurora kinase A	Homo sapiens (human)
kinetochore	Aurora kinase A	Homo sapiens (human)
Golgi apparatus	Cyclin-G-associated kinase	Homo sapiens (human)
cytosol	Cyclin-G-associated kinase	Homo sapiens (human)
focal adhesion	Cyclin-G-associated kinase	Homo sapiens (human)
membrane	Cyclin-G-associated kinase	Homo sapiens (human)
clathrin-coated vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-G-associated kinase	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-G-associated kinase	Homo sapiens (human)
presynapse	Cyclin-G-associated kinase	Homo sapiens (human)
vesicle	Cyclin-G-associated kinase	Homo sapiens (human)
cytoplasm	Cyclin-G-associated kinase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-G-associated kinase	Homo sapiens (human)
extracellular region	Ephrin type-B receptor 6	Homo sapiens (human)
cytosol	Ephrin type-B receptor 6	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 6	Homo sapiens (human)
plasma membrane	Ephrin type-B receptor 6	Homo sapiens (human)
dendrite	Ephrin type-B receptor 6	Homo sapiens (human)
peroxisome	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
peroxisomal matrix	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
cytosol	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
membrane	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
peroxisome	Peroxisomal acyl-coenzyme A oxidase 3	Homo sapiens (human)
plasma membrane	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytoplasm	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytosol	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
cytoskeleton	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
vesicle	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
protein-containing complex	Receptor-interacting serine/threonine-protein kinase 2	Homo sapiens (human)
kinetochore	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
nucleoplasm	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
cytosol	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
membrane	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
intracellular membrane-bounded organelle	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
outer kinetochore	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
kinetochore	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
nucleus	Mitotic checkpoint serine/threonine-protein kinase BUB1	Homo sapiens (human)
nucleoplasm	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrion	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial outer membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial intermembrane space	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cytosol	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial crista	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
dendrite	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
axon cytoplasm	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial intermembrane space	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
cytoplasm	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
microtubule	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
mitochondrial membrane	Dynamin-like 120 kDa protein, mitochondrial	Homo sapiens (human)
extrinsic component of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytoskeleton	Tyrosine-protein kinase JAK2	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase JAK2	Homo sapiens (human)
caveola	Tyrosine-protein kinase JAK2	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase JAK2	Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
endosome lumen	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-12 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase JAK2	Homo sapiens (human)
interleukin-23 receptor complex	Tyrosine-protein kinase JAK2	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
glutamatergic synapse	Tyrosine-protein kinase JAK2	Homo sapiens (human)
euchromatin	Tyrosine-protein kinase JAK2	Homo sapiens (human)
cytosol	Tyrosine-protein kinase JAK2	Homo sapiens (human)
nucleus	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
cytoplasm	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
cytosol	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
synapse	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
cytoplasm	Eukaryotic translation initiation factor 5B	Homo sapiens (human)
nucleus	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytosol	Rho-associated protein kinase 2	Homo sapiens (human)
plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
mitochondrial outer membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
axon	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
recycling endosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
omegasome membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
Atg1/ULK1 kinase complex	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
autophagosome	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
phagophore assembly site membrane	Serine/threonine-protein kinase ULK1	Homo sapiens (human)
nuclear inner membrane	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
mitochondrion	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
endoplasmic reticulum	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
endoplasmic reticulum membrane	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
Ire1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
AIP1-IRE1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-TRAF2-ASK1 complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
IRE1-RACK1-PP2A complex	Serine/threonine-protein kinase/endoribonuclease IRE1	Homo sapiens (human)
nucleus	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-5	Homo sapiens (human)
nucleus	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
nucleoplasm	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
membrane	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U4/U6 x U5 tri-snRNP complex	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
spliceosomal complex	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U5 snRNP	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U2-type precatalytic spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
U2-type catalytic step 1 spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
catalytic step 2 spliceosome	U5 small nuclear ribonucleoprotein 200 kDa helicase	Homo sapiens (human)
nucleus	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
cytosol	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
synapse	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
cytoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Ribosomal protein S6 kinase alpha-4	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
Golgi-associated vesicle	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 16	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 16	Homo sapiens (human)
perinuclear region of cytoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase 16	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 16	Homo sapiens (human)
ruffle membrane	Cyclin-dependent kinase-like 5	Homo sapiens (human)
glutamatergic synapse	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleus	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
centrosome	Cyclin-dependent kinase-like 5	Homo sapiens (human)
dendrite cytoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
ciliary basal body	Cyclin-dependent kinase-like 5	Homo sapiens (human)
dendritic growth cone	Cyclin-dependent kinase-like 5	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
ciliary tip	Cyclin-dependent kinase-like 5	Homo sapiens (human)
postsynaptic density, intracellular component	Cyclin-dependent kinase-like 5	Homo sapiens (human)
nucleus	Cyclin-dependent kinase-like 5	Homo sapiens (human)
dendrite cytoplasm	Cyclin-dependent kinase-like 5	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase 10	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase 10	Homo sapiens (human)
specific granule membrane	Serine/threonine-protein kinase 10	Homo sapiens (human)
extracellular exosome	Serine/threonine-protein kinase 10	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase 10	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase D3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D3	Homo sapiens (human)
plasma membrane	Serine/threonine-protein kinase D3	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase D3	Homo sapiens (human)
nuclear chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensed chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensed nuclear chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensin complex	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
nucleus	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
nucleoplasm	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
nucleolus	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cytoplasm	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cytosol	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
extracellular exosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
condensed chromosome	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
chromatin	Structural maintenance of chromosomes protein 2	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
cytoplasm	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
focal adhesion	Mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase LATS1	Homo sapiens (human)
Golgi apparatus	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
adherens junction	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
focal adhesion	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PAK 4	Homo sapiens (human)
ruffle	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nucleolus	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase ABL1	Homo sapiens (human)
cytosol	Tyrosine-protein kinase ABL1	Homo sapiens (human)
actin cytoskeleton	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
dendrite	Tyrosine-protein kinase ABL1	Homo sapiens (human)
growth cone	Tyrosine-protein kinase ABL1	Homo sapiens (human)
nuclear membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
neuronal cell body	Tyrosine-protein kinase ABL1	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase ABL1	Homo sapiens (human)
postsynapse	Tyrosine-protein kinase ABL1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase ABL1	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase ABL1	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome	High affinity nerve growth factor receptor	Homo sapiens (human)
late endosome	High affinity nerve growth factor receptor	Homo sapiens (human)
plasma membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
cell surface	High affinity nerve growth factor receptor	Homo sapiens (human)
endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
dendrite	High affinity nerve growth factor receptor	Homo sapiens (human)
early endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
late endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
neuronal cell body	High affinity nerve growth factor receptor	Homo sapiens (human)
recycling endosome membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
protein-containing complex	High affinity nerve growth factor receptor	Homo sapiens (human)
receptor complex	High affinity nerve growth factor receptor	Homo sapiens (human)
axon	High affinity nerve growth factor receptor	Homo sapiens (human)
plasma membrane	High affinity nerve growth factor receptor	Homo sapiens (human)
nucleoplasm	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cytoplasm	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
centrosome	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cytosol	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
plasma membrane	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
membrane	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
dendrite	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
midbody	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cell body	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
synapse	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
extracellular exosome	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
neuronal dense core vesicle	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
extracellular vesicle	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
heterotrimeric G-protein complex	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
cytoplasm	Guanine nucleotide-binding protein G(i) subunit alpha-2	Homo sapiens (human)
nucleus	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrion	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial inner membrane	ADP/ATP translocase 2	Homo sapiens (human)
plasma membrane	ADP/ATP translocase 2	Homo sapiens (human)
membrane	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial nucleoid	ADP/ATP translocase 2	Homo sapiens (human)
mitochondrial permeability transition pore complex	ADP/ATP translocase 2	Homo sapiens (human)
MMXD complex	ADP/ATP translocase 2	Homo sapiens (human)
nucleus	Protein kinase C beta type	Homo sapiens (human)
nucleoplasm	Protein kinase C beta type	Homo sapiens (human)
cytoplasm	Protein kinase C beta type	Homo sapiens (human)
centrosome	Protein kinase C beta type	Homo sapiens (human)
cytosol	Protein kinase C beta type	Homo sapiens (human)
plasma membrane	Protein kinase C beta type	Homo sapiens (human)
brush border membrane	Protein kinase C beta type	Homo sapiens (human)
calyx of Held	Protein kinase C beta type	Homo sapiens (human)
extracellular exosome	Protein kinase C beta type	Homo sapiens (human)
presynaptic cytosol	Protein kinase C beta type	Homo sapiens (human)
spectrin	Protein kinase C beta type	Homo sapiens (human)
nuclear envelope	Insulin receptor	Homo sapiens (human)
nuclear lumen	Insulin receptor	Homo sapiens (human)
lysosome	Insulin receptor	Homo sapiens (human)
late endosome	Insulin receptor	Homo sapiens (human)
plasma membrane	Insulin receptor	Homo sapiens (human)
caveola	Insulin receptor	Homo sapiens (human)
external side of plasma membrane	Insulin receptor	Homo sapiens (human)
endosome membrane	Insulin receptor	Homo sapiens (human)
membrane	Insulin receptor	Homo sapiens (human)
dendrite membrane	Insulin receptor	Homo sapiens (human)
neuronal cell body membrane	Insulin receptor	Homo sapiens (human)
extracellular exosome	Insulin receptor	Homo sapiens (human)
insulin receptor complex	Insulin receptor	Homo sapiens (human)
receptor complex	Insulin receptor	Homo sapiens (human)
plasma membrane	Insulin receptor	Homo sapiens (human)
axon	Insulin receptor	Homo sapiens (human)
pericentriolar material	Tyrosine-protein kinase Lck	Homo sapiens (human)
immunological synapse	Tyrosine-protein kinase Lck	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Lck	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lck	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Lck	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Lck	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lck	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase Fyn	Homo sapiens (human)
endosome	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
actin filament	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
postsynaptic density	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perikaryon	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell body	Tyrosine-protein kinase Fyn	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear endoplasmic reticulum	Tyrosine-protein kinase Fyn	Homo sapiens (human)
glial cell projection	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
mitochondrial matrix	Cyclin-dependent kinase 1	Homo sapiens (human)
chromosome, telomeric region	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 1	Homo sapiens (human)
mitochondrion	Cyclin-dependent kinase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Cyclin-dependent kinase 1	Homo sapiens (human)
centrosome	Cyclin-dependent kinase 1	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 1	Homo sapiens (human)
spindle microtubule	Cyclin-dependent kinase 1	Homo sapiens (human)
membrane	Cyclin-dependent kinase 1	Homo sapiens (human)
midbody	Cyclin-dependent kinase 1	Homo sapiens (human)
extracellular exosome	Cyclin-dependent kinase 1	Homo sapiens (human)
mitotic spindle	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin A1-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin A2-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin B1-CDK1 complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 1	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 1	Homo sapiens (human)
extracellular region	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytosol	Glycogen phosphorylase, liver form	Homo sapiens (human)
secretory granule lumen	Glycogen phosphorylase, liver form	Homo sapiens (human)
extracellular exosome	Glycogen phosphorylase, liver form	Homo sapiens (human)
ficolin-1-rich granule lumen	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytoplasm	Glycogen phosphorylase, liver form	Homo sapiens (human)
cytoplasmic vesicle	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
microtubule cytoskeleton	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fes/Fps	Homo sapiens (human)
extracellular region	Adenine phosphoribosyltransferase	Homo sapiens (human)
nucleoplasm	Adenine phosphoribosyltransferase	Homo sapiens (human)
cytoplasm	Adenine phosphoribosyltransferase	Homo sapiens (human)
cytosol	Adenine phosphoribosyltransferase	Homo sapiens (human)
secretory granule lumen	Adenine phosphoribosyltransferase	Homo sapiens (human)
extracellular exosome	Adenine phosphoribosyltransferase	Homo sapiens (human)
cytoplasm	Adenine phosphoribosyltransferase	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase Yes	Homo sapiens (human)
centrosome	Tyrosine-protein kinase Yes	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Yes	Homo sapiens (human)
actin filament	Tyrosine-protein kinase Yes	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Yes	Homo sapiens (human)
focal adhesion	Tyrosine-protein kinase Yes	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Yes	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Yes	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cytoplasmic side of plasma membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase Lyn	Homo sapiens (human)
lysosomal membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
Golgi apparatus	Tyrosine-protein kinase Lyn	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Lyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
adherens junction	Tyrosine-protein kinase Lyn	Homo sapiens (human)
mitochondrial crista	Tyrosine-protein kinase Lyn	Homo sapiens (human)
endocytic vesicle membrane	Tyrosine-protein kinase Lyn	Homo sapiens (human)
intracellular membrane-bounded organelle	Tyrosine-protein kinase Lyn	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Lyn	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase Lyn	Homo sapiens (human)
extracellular exosome	Tyrosine-protein kinase Lyn	Homo sapiens (human)
glutamatergic synapse	Tyrosine-protein kinase Lyn	Homo sapiens (human)
postsynaptic specialization, intracellular component	Tyrosine-protein kinase Lyn	Homo sapiens (human)
integrin alpha2-beta1 complex	Tyrosine-protein kinase Lyn	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
early endosome	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
endosome membrane	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
dendrite	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
neuronal cell body	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
receptor complex	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
plasma membrane protein complex	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
axon	Proto-oncogene tyrosine-protein kinase receptor Ret	Homo sapiens (human)
plasma membrane	Insulin-like growth factor 1 receptor	Homo sapiens (human)

Assay ID	Title	Year	Journal	Article
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1424932	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425206	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425055	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424980	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425164	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424935	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425094	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424972	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424994	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424899	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425137	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424975	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425101	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425013	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425011	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424921	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424905	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876095	Cytotoxicity against human A549 cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425159	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424986	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1826397	Displacement of [32]P from human MEK1 (K97R) assessed as half time in presence of [gamma-33P]-ATP measured after 120 mins by microbeta scintillation counter
AID1425061	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425197	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425110	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425033	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424946	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425168	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425044	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425198	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1247135	Effective half life in patient	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Recent progress on MAP kinase pathway inhibitors.
AID1425057	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424934	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425045	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424900	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425156	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425174	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425022	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424955	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424909	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424991	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425136	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425036	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425007	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876112	Cytotoxicity against MDCK-II cells	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425060	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425099	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424984	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424919	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424893	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425199	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424931	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876026	Inhibition of MEK1 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1424990	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424920	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425026	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876027	Inhibition of MEK2 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425038	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425079	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425024	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425196	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425102	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424906	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424979	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424947	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425015	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1691968	Antiproliferative activity against human A375 cells harboring BRAF V600E mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	2020	European journal of medicinal chemistry, Jun-15, Volume: 196	Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425150	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425069	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425132	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425031	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425153	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425154	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425149	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425180	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425056	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425037	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425051	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424889	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425021	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424948	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425179	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424983	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425047	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425209	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424960	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425125	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425050	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424957	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425049	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425144	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425157	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425151	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425023	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424963	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425128	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424941	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1581576	Antiproliferative activity against human A375 cells assessed as reduction in cell viability	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Design, Synthesis, and Biological Evaluation of MEK PROTACs.
AID1425058	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425203	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424995	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424954	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425104	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425189	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424949	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1697066	Antiproliferative activity against human KYSE-520 cells
AID1425030	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425067	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1247134	Plasma half life in po dosed Sprague-Dawley rat	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	Recent progress on MAP kinase pathway inhibitors.
AID1425200	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424930	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1691970	Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	2020	European journal of medicinal chemistry, Jun-15, Volume: 196	Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424985	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425138	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424933	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424938	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425161	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424992	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424981	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425167	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425005	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424969	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425108	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425082	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425119	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425095	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425006	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1691969	Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	2020	European journal of medicinal chemistry, Jun-15, Volume: 196	Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425147	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424940	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425158	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424958	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876235	Antiviral activity against MERS-CoV infected in human HUh-7 cells at 0.1 to 10 uM	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Kinase Inhibitors as Underexplored Antiviral Agents.
AID1424939	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425211	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425096	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425186	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425129	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425085	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424915	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425090	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1875924	Non competitive inhibition of MEK2 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1425070	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424901	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425080	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424908	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424910	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425172	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425097	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425135	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424998	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425048	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424904	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425195	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425018	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425000	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425127	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425124	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424890	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425107	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425072	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425071	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425042	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425002	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425035	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425192	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425093	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425207	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424999	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425213	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425063	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425142	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425004	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425073	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425190	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425126	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424977	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425103	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424922	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425062	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424918	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425008	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425162	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425118	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425134	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424925	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424944	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1697076	Inhibition of MEK in human KYSE-520 cells assessed as reduction in p-ERK levels
AID1424945	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425148	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425034	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425041	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424923	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424892	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425146	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425202	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1691971	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	2020	European journal of medicinal chemistry, Jun-15, Volume: 196	Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424982	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425027	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424978	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424894	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425019	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424987	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425212	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424912	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425116	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425043	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425169	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424903	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424937	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425053	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425204	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425112	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425086	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424974	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425171	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425177	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424959	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424993	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425173	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425074	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425178	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424971	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1623456	Inhibition of ABCB1 in human A2780/ADR cells assessed as potentiation of daunorubicin-induced cytotoxicity measured after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
AID1425111	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424965	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425028	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425052	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425014	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425130	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425077	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425106	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424967	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425185	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425140	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425181	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425025	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425001	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424970	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1866981	Binding affinity to MEK1/2 (unknown origin) assessed as dissociation constant	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Principles of Kinase Allosteric Inhibition and Pocket Validation.
AID1424961	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425109	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424976	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425188	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424973	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425016	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425145	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425059	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1866982	Inhibition of MEK1/2 (unknown origin)	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Principles of Kinase Allosteric Inhibition and Pocket Validation.
AID1424962	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424902	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425141	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425012	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1633264	Inhibition of MEK2 (unknown origin)	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
AID1425160	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425068	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424898	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424942	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424896	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425193	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425098	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425191	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424966	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425009	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425201	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424964	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425175	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424928	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425155	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424907	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425084	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425194	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425010	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1691972	Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	2020	European journal of medicinal chemistry, Jun-15, Volume: 196	Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425165	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425120	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425076	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1633263	Inhibition of MEK1 (unknown origin)	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
AID1425123	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425083	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425122	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425046	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425100	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425064	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425182	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425040	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425017	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876276	Inhibition of MEK 1/2 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Kinase Inhibitors as Underexplored Antiviral Agents.
AID1424989	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424956	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425133	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1875925	Antiviral activity against influenza A RB1/H1N1pdm09 virus	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1424936	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424988	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425020	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425208	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424996	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425039	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425054	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425087	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425163	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424924	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424951	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424929	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424953	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425176	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425187	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424943	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425029	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424917	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425166	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425143	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1875923	Non competitive inhibition of MEK1 (unknown origin)	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1424926	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425170	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425078	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425205	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424968	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425115	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425089	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425065	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425210	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424911	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425131	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425117	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425003	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424997	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425105	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424952	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424891	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425081	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424950	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425121	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1813988	Induction of apoptosis in human DLD-1 cells harboring KRAS G13D mutant assessed as cleaved-PRAP at 0.1 nM measured after 24 to 48 hrs	2021	Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10	One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
AID1425113	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1424895	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1425066	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry	2017	Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367	The target landscape of clinical kinase drugs.
AID1876113	In vivo antiviral activity against influenza A virus infected in mouse assessed as reduction of vRNPs at 3 mg/kg, po	2022	Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2	Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345759	Human mitogen-activated protein kinase kinase 1 (STE7 family)	2011	Clinical cancer research : an official journal of the American Association for Cancer Research, Mar-01, Volume: 17, Issue:5	GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
AID1345759	Human mitogen-activated protein kinase kinase 1 (STE7 family)	2011	International journal of oncology, Jul, Volume: 39, Issue:1	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
AID1345779	Human mitogen-activated protein kinase kinase 2 (STE7 family)	2011	International journal of oncology, Jul, Volume: 39, Issue:1	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	571 (61.46)	24.3611
2020's	358 (38.54)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	134 (14.26%)	5.53%
Reviews	74 (7.87%)	6.00%
Case Studies	220 (23.40%)	4.05%
Observational	9 (0.96%)	0.25%
Other	503 (53.51%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (243)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer [NCT03825289]	Phase 1	39 participants (Anticipated)	Interventional	2019-01-18	Recruiting
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 Mutations [NCT04439357]	Phase 2	4 participants (Actual)	Interventional	2016-02-25	Active, not recruiting
A Phase I/II Study of Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) [NCT03087448]	Phase 1	9 participants (Actual)	Interventional	2017-09-09	Terminated(stopped due to Low Accrual)
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy [NCT04557956]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2021-08-19	Recruiting
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies [NCT02642042]	Phase 2	60 participants (Actual)	Interventional	2016-07-18	Active, not recruiting
Molecular Analysis for Therapy Choice (MATCH) [NCT02465060]	Phase 2	6,452 participants (Anticipated)	Interventional	2015-08-17	Active, not recruiting
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma [NCT02196181]	Phase 2	280 participants (Anticipated)	Interventional	2014-09-19	Active, not recruiting
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only) [NCT01989585]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2014-03-24	Active, not recruiting
A Single-Arm, Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in Subjects With Metastatic Uveal Melanoma or With Mutation-Positive GNAQ or GNA11 Metastatic Melanoma [NCT01328106]	Phase 2	0 participants (Actual)	Interventional	2010-11-30	Withdrawn(stopped due to The study was cancelled by the sponsor prior to initiation of study enrollment. No subjects were accrued.)
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer [NCT01912625]	Phase 1	16 participants (Actual)	Interventional	2013-10-28	Terminated(stopped due to Inadequate accrual rate)
A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) [NCT05275374]	Phase 1/Phase 2	221 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer [NCT01287546]	Phase 1	117 participants (Anticipated)	Interventional	2010-04-13	Completed
An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma [NCT02083354]	Phase 2	77 participants (Actual)	Interventional	2014-03-18	Completed
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma [NCT03580382]	Phase 1/Phase 2	3 participants (Actual)	Interventional	2018-07-06	Terminated(stopped due to Per regulatory coordinator, the sponsor is no longer supporting the study.)
A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations [NCT04892017]	Phase 1/Phase 2	323 participants (Anticipated)	Interventional	2021-06-15	Recruiting
A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors. [NCT01155453]	Phase 1	113 participants (Actual)	Interventional	2010-04-30	Completed
A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer [NCT01336634]	Phase 2	177 participants (Actual)	Interventional	2011-08-05	Completed
A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With Trametinib in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours [NCT04111458]	Phase 1	71 participants (Actual)	Interventional	2019-10-28	Active, not recruiting
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program) [NCT03225664]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2018-02-03	Active, not recruiting
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma [NCT03149029]	Phase 2	16 participants (Actual)	Interventional	2017-11-27	Active, not recruiting
Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer [NCT04675710]	Phase 2	30 participants (Anticipated)	Interventional	2021-06-24	Recruiting
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer) [NCT04439292]	Phase 2	35 participants (Anticipated)	Interventional	2015-08-12	Active, not recruiting
A Real-life Study to Evaluate the Use of Adjuvant Treatment With Dabrafenib and Trametinib in Routine Practice in Patients With Completely Resected High-risk Stage III Melanoma [NCT04961619]		84 participants (Anticipated)	Observational	2021-12-01	Recruiting
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study [NCT03631953]	Phase 1	25 participants (Anticipated)	Interventional	2019-09-30	Recruiting
A lead-in Phase I Followed by a Phase II Clinical Trial on the Combination of Dabrafenib, Trametinib and the Autophagy Inhibitor Hydroxychloroquine in BRAF/MEK Inhibitor-pretreated Patients With Advanced BRAF V600 Mutant Melanoma [NCT03754179]	Phase 1/Phase 2	63 participants (Anticipated)	Interventional	2018-01-23	Recruiting
A Phase 1 Trial of Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma [NCT05440942]	Phase 1	35 participants (Anticipated)	Interventional	2023-01-19	Recruiting
An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors [NCT01371487]	Phase 1	40 participants (Actual)	Interventional	2011-05-02	Completed
A Phase I Clinical Study to Evaluate the Safety and Efficacy of MEK Inhibitor Combined With Anlotinib in the Treatment of Patients With Advanced KRAS Mutant Non-small Cell Lung Cancer [NCT04967079]	Phase 1	30 participants (Anticipated)	Interventional	2021-08-01	Recruiting
Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma [NCT05525273]	Phase 2	25 participants (Anticipated)	Interventional	2023-05-31	Recruiting
COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Py [NCT03551626]	Phase 3	556 participants (Actual)	Interventional	2018-08-29	Completed
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer [NCT03317119]	Phase 1	26 participants (Anticipated)	Interventional	2018-04-11	Active, not recruiting
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer [NCT02428270]	Phase 2	16 participants (Actual)	Interventional	2016-04-30	Completed
A Phase 1b With Expansion Study Evaluating the Efficacy and Safety of Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding L [NCT02258607]	Phase 1	21 participants (Actual)	Interventional	2015-03-11	Terminated
An Open Label Non Randomized Access Study of Trametinib for Patients With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma [NCT02416232]		0 participants	Expanded Access		No longer available
A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors [NCT04965220]	Phase 1	220 participants (Anticipated)	Interventional	2022-01-05	Recruiting
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors [NCT02097225]	Phase 1	22 participants (Actual)	Interventional	2014-05-29	Active, not recruiting
A Phase I Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma [NCT02357732]	Phase 1	0 participants (Actual)	Interventional	2015-08-31	Withdrawn(stopped due to PI decided not to proceed)
SARC029: Phase II Pilot Study of Trametinib in Combination With Pazopanib in Patients With Metastatic or Local-regionally Recurrent GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib [NCT02342600]	Phase 2	0 participants (Actual)	Interventional	2017-01-31	Withdrawn(stopped due to Supporting company withdrew interest)
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United States [NCT05260684]		1 participants (Actual)	Observational	2022-01-17	Active, not recruiting
A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers [NCT01740648]	Phase 1	19 participants (Actual)	Interventional	2012-11-26	Completed
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058) [NCT05849662]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer [NCT04452877]	Phase 2	40 participants (Actual)	Interventional	2020-08-19	Active, not recruiting
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA) [NCT02910700]	Phase 2	52 participants (Actual)	Interventional	2016-12-09	Active, not recruiting
A Multi-center, Open-Label，Dose Escalation and Dose Expansion Phase I Study of HRS2300 Monotherapy or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies [NCT05048134]	Phase 1	345 participants (Anticipated)	Interventional	2021-10-25	Recruiting
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma [NCT02138292]	Phase 1	27 participants (Actual)	Interventional	2014-07-31	Completed
An Open-label, Multicenter, Phase II Study of Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation [NCT03543306]	Phase 2	27 participants (Anticipated)	Interventional	2018-06-30	Recruiting
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial [NCT02224781]	Phase 3	300 participants (Anticipated)	Interventional	2015-09-08	Active, not recruiting
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) [NCT05182931]	Phase 2	80 participants (Anticipated)	Interventional	2022-07-14	Recruiting
A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC) [NCT02580708]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Discontinued development of rociletinib in NSCLC. Stopped enrollment of new patients into all studies involving rociletinib.)
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME [NCT03878524]	Phase 1	2 participants (Actual)	Interventional	2020-04-01	Active, not recruiting
An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of th [NCT03516214]	Phase 1	24 participants (Anticipated)	Interventional	2018-04-25	Recruiting
A Single-center, Phase 1 Dose Escalation Study of Trametinib Combined With HDM201 in Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer. [NCT03714958]	Phase 1	12 participants (Actual)	Interventional	2018-12-20	Completed
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK [NCT03553329]		20 participants (Actual)	Observational	2018-06-02	Completed
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients With Tumors With NF1 Mutations [NCT04439318]	Phase 2	50 participants (Actual)	Interventional	2016-02-25	Active, not recruiting
A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway. [NCT03363217]	Phase 2	114 participants (Actual)	Interventional	2018-08-16	Active, not recruiting
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile [NCT02925234]	Phase 2	1,550 participants (Anticipated)	Interventional	2016-08-31	Recruiting
A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics and Safety of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) and to Characterize the Pharmacokinetics of Trametinib's Metaboli [NCT02292732]	Phase 1	0 participants (Actual)	Interventional	2016-02-29	Withdrawn
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors [NCT01231594]	Phase 1	214 participants (Actual)	Interventional	2010-11-05	Completed
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma [NCT04417621]	Phase 2	134 participants (Actual)	Interventional	2020-10-30	Active, not recruiting
A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients [NCT03087071]	Phase 2	59 participants (Actual)	Interventional	2017-12-29	Active, not recruiting
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid T [NCT01192165]	Phase 1	169 participants (Actual)	Interventional	2010-09-14	Completed
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 [NCT01138085]	Phase 1	240 participants (Actual)	Interventional	2010-05-04	Completed
Prospective Evaluation of Clinical Outcomes in Patients With Resectable or Metastatic BRAF+ Melanoma Treated With Dabrafenib and Trametinib in Real Practice [NCT05171374]		500 participants (Anticipated)	Observational	2021-09-30	Recruiting
BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/II Open-Label Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma [NCT02257424]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2014-10-31	Completed
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2) [NCT05071183]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2021-09-23	Terminated(stopped due to Inability to achieve and optimize a dose that could provide a positive benefit risk profile)
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease [NCT03794297]	Phase 2	0 participants (Actual)	Interventional	2019-01-04	Withdrawn(stopped due to Inadequate accrual rate)
TraMel-WT: A Stratified Dual-stratum Open-label Two-stage Phase 2 Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma [NCT04059224]	Phase 2	45 participants (Actual)	Interventional	2019-01-28	Completed
A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer [NCT01231581]	Phase 2	160 participants (Actual)	Interventional	2010-08-31	Completed
An Open-Label, Phase Ib Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer [NCT01938456]	Phase 1	0 participants (Actual)	Interventional	2013-10-31	Withdrawn(stopped due to This study was Cancelled Before Active)
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma [NCT00687622]	Phase 1	206 participants (Actual)	Interventional	2008-07-28	Completed
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer [NCT04294160]	Phase 1	122 participants (Actual)	Interventional	2020-07-22	Active, not recruiting
A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral Sclerosis [NCT04326283]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2020-04-02	Terminated(stopped due to Terminated as it is considered that necessary data have been collected)
INTERIM: a Randomised Phase II Feasibility Study of INTERmittent Versus Continuous Dosing or Oral Targeted Combination Therapy in Patients With BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma [NCT03352947]	Phase 2	79 participants (Actual)	Interventional	2017-11-03	Completed
A Phase II Clinical Trial on the Combination of Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients With Advanced BRAF V600 Mutant Melanoma [NCT02296996]	Phase 2	25 participants (Actual)	Interventional	2014-10-31	Completed
A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared With Docetaxel in 2nd Line Subjects With Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cance [NCT01362296]	Phase 2	134 participants (Actual)	Interventional	2011-09-30	Completed
A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, Trametinib, Combined With the CDK4/6 Inhibitor, Palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects With Solid T [NCT02065063]	Phase 1	28 participants (Actual)	Interventional	2014-04-22	Completed
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma [NCT03434262]	Phase 1	68 participants (Actual)	Interventional	2018-03-05	Active, not recruiting
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma [NCT02974725]	Phase 1	241 participants (Actual)	Interventional	2017-02-24	Active, not recruiting
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation [NCT03065387]	Phase 1	93 participants (Actual)	Interventional	2017-10-31	Active, not recruiting
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain [NCT02439411]		135 participants (Actual)	Observational	2015-03-03	Completed
A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma [NCT02110355]	Phase 1	31 participants (Actual)	Interventional	2014-12-19	Completed
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer [NCT02101788]	Phase 2/Phase 3	260 participants (Actual)	Interventional	2014-02-27	Active, not recruiting
Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma [NCT02410863]	Phase 2	10 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to lack of recruitment due to changed therapy options)
Managed Access Program (MAP) Cohort Treatment Plan CDRB436F2001CM to Provide Access to Trametinib and Dabrafenib Combination Therapy in the Adjuvant Treatment of High-risk BRAF 600 Mutation-positive Melanoma After Surgical Resection [NCT04544202]		0 participants	Expanded Access		Available
Managed Access Program (MAP) Cohort Treatment Plan CDRB436B2005CM to Provide Access to Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma [NCT04489433]		0 participants	Expanded Access		Available
An Observational Phase II Study to Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib in Advanced Non-small Cell Lung Cancer Patients With BRAF V600E Mutation [NCT05988697]		36 participants (Anticipated)	Observational	2023-11-01	Not yet recruiting
A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors [NCT01324258]	Phase 1	19 participants (Actual)	Interventional	2011-01-24	Completed
Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma [NCT05874414]	Phase 1/Phase 2	74 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma [NCT01245062]	Phase 3	322 participants (Actual)	Interventional	2010-11-22	Completed
A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer [NCT02672358]	Phase 2	0 participants (Actual)	Interventional	2018-09-03	Withdrawn(stopped due to Company Decision)
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea [NCT05616923]	Phase 1	12 participants (Actual)	Interventional	2021-11-01	Completed
Impact of Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) on Patients Quality of Life (QoL) and Clinical Outcomes in Portuguese Real World Setting [NCT04547946]		3 participants (Actual)	Observational	2021-10-15	Completed
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile [NCT05159245]	Phase 2	250 participants (Anticipated)	Interventional	2021-12-10	Recruiting
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment [NCT04454476]	Phase 1	15 participants (Anticipated)	Interventional	2022-11-09	Active, not recruiting
A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer [NCT03299088]	Phase 1	15 participants (Actual)	Interventional	2018-06-26	Active, not recruiting
Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. [NCT03272464]	Phase 1	1 participants (Actual)	Interventional	2019-05-29	Terminated(stopped due to Slow accrual)
Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief [NCT03741101]	Phase 2	15 participants (Anticipated)	Interventional	2019-06-10	Active, not recruiting
A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma [NCT02140840]	Phase 2	0 participants (Actual)	Interventional	2015-03-31	Withdrawn(stopped due to PI left institution)
A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanom [NCT02872259]	Phase 1/Phase 2	74 participants (Actual)	Interventional	2017-02-13	Active, not recruiting
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive [NCT04940052]	Phase 3	150 participants (Anticipated)	Interventional	2021-11-15	Recruiting
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults [NCT04201457]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2020-01-17	Recruiting
A Phase II Study of Azacitidine, Venetoclax and Trametinib for Patients With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome [NCT04487106]	Phase 2	21 participants (Actual)	Interventional	2020-07-21	Completed
A Multicenter Phase I/Ib Study of Capmatinib Plus Trametinib in Patients With Metastatic MET Exon 14 Skipping Mutation Positive NSCLC [NCT05435846]	Phase 1	33 participants (Anticipated)	Interventional	2022-08-10	Recruiting
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias [NCT00920140]	Phase 2	97 participants (Actual)	Interventional	2011-05-31	Completed
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed o [NCT05372354]	Phase 1/Phase 2	220 participants (Anticipated)	Interventional	2022-10-18	Recruiting
Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation [NCT02625337]	Phase 2	32 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. [NCT01248858]	Phase 1	69 participants (Actual)	Interventional	2010-12-03	Terminated(stopped due to The reason for termination was lack of tolerability and efficacy of the combination treatment)
A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma [NCT01989598]	Phase 2	25 participants (Actual)	Interventional	2013-10-30	Completed
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment [NCT04943224]	Phase 2	12 participants (Anticipated)	Interventional	2021-04-01	Recruiting
A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma [NCT01940809]	Phase 1	15 participants (Actual)	Interventional	2013-08-28	Terminated(stopped due to Inadequate accrual rate)
A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 With Seribantumab (MM-121), Istiratumab (MM-141), or Trametinib in Biomarker-selected Cancer Patients [NCT02538627]	Phase 1	5 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Sponsor decision)
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma: A Phase Ib/II Trial of Trametinib Plus Hydroxychloroquine in Patients With NRAS Melanoma [NCT03979651]		29 participants (Anticipated)	Interventional	2019-10-15	Recruiting
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) [NCT03919071]	Phase 2	58 participants (Anticipated)	Interventional	2020-02-20	Recruiting
An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors [NCT00955773]	Phase 1	64 participants (Actual)	Interventional	2009-08-17	Completed
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia [NCT02016729]	Phase 1	36 participants (Actual)	Interventional	2014-04-01	Completed
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) [NCT02900664]	Phase 1	283 participants (Actual)	Interventional	2016-08-23	Completed
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma: A Pilot Study [NCT03972046]	Phase 2	0 participants (Actual)	Interventional	2019-06-24	Withdrawn(stopped due to Principal investigator leaving study site; no replacement PI will be sought)
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) [NCT02684058]	Phase 2	151 participants (Actual)	Interventional	2017-12-28	Completed
A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973 [NCT01935973]	Phase 1	26 participants (Actual)	Interventional	2013-09-30	Completed
A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors [NCT01938443]	Phase 1	34 participants (Actual)	Interventional	2013-11-18	Completed
An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS [NCT02079740]	Phase 1/Phase 2	130 participants (Anticipated)	Interventional	2014-03-26	Active, not recruiting
A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib [NCT02034110]	Phase 2	206 participants (Actual)	Interventional	2014-03-12	Completed
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers [NCT03377361]	Phase 1/Phase 2	232 participants (Anticipated)	Interventional	2018-02-01	Active, not recruiting
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib [NCT04238624]	Phase 2	15 participants (Anticipated)	Interventional	2020-01-20	Recruiting
A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer [NCT03085056]	Early Phase 1	13 participants (Actual)	Interventional	2017-03-15	Active, not recruiting
A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone [NCT02027961]	Phase 1	68 participants (Actual)	Interventional	2013-12-20	Completed
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours [NCT02939846]	Phase 1	0 participants (Actual)	Interventional	2017-05-31	Withdrawn(stopped due to Change in strategy)
Phase II Clinical Trial in Radioactive Iodine-Refractory Advanced Thyroid Carcinoma Evaluating BRAF & MEK Blockade Therapy for Re-differentiation- Applying a Novel Time-Dependent Concept [NCT04554680]	Phase 2	5 participants (Anticipated)	Interventional	2020-12-30	Recruiting
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation [NCT05358249]	Phase 1/Phase 2	346 participants (Anticipated)	Interventional	2022-10-24	Recruiting
PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas [NCT04485559]	Phase 1	50 participants (Anticipated)	Interventional	2020-12-09	Recruiting
A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer [NCT03704688]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2018-10-09	Completed
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) [NCT06079333]	Phase 2	20 participants (Anticipated)	Interventional	2023-01-01	Recruiting
An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors [NCT01647659]	Phase 1	18 participants (Actual)	Interventional	2012-07-30	Completed
Stereotactic Body Radiation Therapy Plus Pembrolizumab and Trametinib vs. Stereotactic Body Radiation Therapy Plus Gemcitabine for Locally Recurrent Pancreatic Cancer After Surgical Resection: an Open-label, Randomized, Controlled, Phase 2 Trial [NCT02704156]	Phase 2	170 participants (Actual)	Interventional	2016-10-31	Completed
A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors [NCT02703571]	Phase 1	95 participants (Actual)	Interventional	2016-06-29	Terminated(stopped due to Company decision)
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With [NCT05658640]	Phase 1/Phase 2	26 participants (Anticipated)	Interventional	2023-04-01	Not yet recruiting
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma [NCT03026517]	Phase 1	18 participants (Actual)	Interventional	2017-01-31	Active, not recruiting
An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor [NCT01037127]	Phase 2	97 participants (Actual)	Interventional	2009-11-30	Completed
An Open-label Mass Balance Study to Investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK Inhibitor [14C]GSK1120212 in Male Subjects With Solid Tumors [NCT01387204]	Phase 1	6 participants (Actual)	Interventional	2011-02-15	Completed
Determination of the Absolute Bioavailability of GSK1120212 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microdose of GSK1120212 in Subjects With Solid Tumors [NCT01416337]	Phase 1	6 participants (Actual)	Interventional	2011-06-20	Completed
A Phase IB Combination Study of MEK Inhibitor GSK1120212 With Gemcitabine in Subjects With Solid Tumors [NCT01428427]	Phase 1	31 participants (Actual)	Interventional	2009-08-12	Completed
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations [NCT05907304]	Phase 1	115 participants (Anticipated)	Interventional	2023-08-17	Recruiting
A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition [NCT04903119]	Phase 1	15 participants (Anticipated)	Interventional	2022-06-01	Recruiting
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic [NCT01072175]	Phase 2	430 participants (Actual)	Interventional	2010-03-26	Completed
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) [NCT03975829]	Phase 4	250 participants (Anticipated)	Interventional	2019-11-04	Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Mela [NCT02967692]	Phase 3	569 participants (Actual)	Interventional	2017-02-17	Active, not recruiting
A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate Cancer [NCT02881242]	Phase 2	14 participants (Actual)	Interventional	2018-01-30	Active, not recruiting
An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myel [NCT01476137]	Phase 1	335 participants (Actual)	Interventional	2011-10-26	Completed
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Ti [NCT01438554]	Phase 1	89 participants (Actual)	Interventional	2011-10-31	Completed
A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition [NCT03455764]	Phase 1/Phase 2	43 participants (Anticipated)	Interventional	2018-06-22	Active, not recruiting
A Phase 1B Clinical Trial of Dabrafenib, Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma [NCT02915666]	Phase 1	0 participants (Actual)	Interventional	2016-10-31	Withdrawn(stopped due to No subjects consented for enrollment on this study.)
Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT) [NCT04310397]	Phase 2	4 participants (Actual)	Interventional	2020-01-29	Completed
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma [NCT04303403]	Phase 1	48 participants (Anticipated)	Interventional	2018-07-31	Recruiting
A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors [NCT02705963]	Phase 1	19 participants (Actual)	Interventional	2016-10-20	Completed
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor [NCT01619774]	Phase 2	28 participants (Actual)	Interventional	2012-09-30	Completed
Phase I/II Study of BET and MEK Inhibition in Advanced Uveal Melanoma [NCT05677373]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2023-01-13	Withdrawn(stopped due to The drug company supporting this trial has withdrawn support, including the ability to provide study agent.)
Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). [NCT04566133]	Phase 2	2 participants (Actual)	Interventional	2022-02-15	Terminated(stopped due to Slow accrual)
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer [NCT01902173]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2013-07-19	Active, not recruiting
Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo) [NCT02231775]	Phase 2	66 participants (Actual)	Interventional	2014-10-22	Active, not recruiting
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 [NCT01467310]	Early Phase 1	15 participants (Actual)	Interventional	2012-01-31	Completed
A Phase IIa Study of the MEK Inhibitor GSK1120212 Monotherapy in the Treatment of Gemcitabine Refractory Locally Advanced, Recurrent or Metastatic Biliary Tract Cancers [NCT01943864]	Phase 2	20 participants (Actual)	Interventional	2013-09-19	Completed
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer [NCT04544111]	Phase 2	19 participants (Actual)	Interventional	2020-09-02	Active, not recruiting
An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain [NCT01978236]	Phase 2	6 participants (Actual)	Interventional	2014-04-08	Terminated(stopped due to This study was terminated due to the limited enrollment.)
A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer [NCT03668431]	Phase 2	25 participants (Anticipated)	Interventional	2018-10-15	Recruiting
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain [NCT02039947]	Phase 2	127 participants (Actual)	Interventional	2014-02-21	Completed
Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer [NCT03428126]	Phase 2	29 participants (Actual)	Interventional	2018-03-21	Completed
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study [NCT03784014]	Phase 3	960 participants (Anticipated)	Interventional	2019-10-19	Recruiting
A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) [NCT01584648]	Phase 3	423 participants (Actual)	Interventional	2012-05-04	Completed
Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma [NCT01941927]	Phase 2	20 participants (Actual)	Interventional	2013-09-10	Completed
A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer [NCT01958112]	Phase 2	14 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to Drug supply)
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma [NCT03148275]	Phase 2	44 participants (Actual)	Interventional	2017-06-20	Completed
A Phase 2 Prospective Trial of Dabrafenib and Trametinib With Stereotactic Radiosurgery in BRAF Mutant Melanoma Brain Metastases [NCT01721603]	Phase 2	2 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to Low accrual)
An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer [NCT01990196]	Phase 2	45 participants (Actual)	Interventional	2014-09-23	Active, not recruiting
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors. [NCT04116541]	Phase 2	425 participants (Anticipated)	Interventional	2020-01-28	Recruiting
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study [NCT03340506]	Phase 4	100 participants (Anticipated)	Interventional	2017-12-28	Recruiting
A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients [NCT02143050]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2014-09-30	Withdrawn(stopped due to No participant enrollment)
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection [NCT04666272]		80 participants (Anticipated)	Observational	2020-12-31	Recruiting
A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors [NCT01658553]	Phase 1	60 participants (Actual)	Interventional	2012-09-19	Completed
Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden: An Observational Study [NCT05611229]		1,975 participants (Actual)	Observational	2020-06-16	Completed
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma [NCT01767454]	Phase 1	38 participants (Actual)	Interventional	2013-02-12	Completed
Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With Steroids [NCT03563729]	Phase 2	80 participants (Anticipated)	Interventional	2018-06-06	Recruiting
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma [NCT02858921]	Phase 2	60 participants (Actual)	Interventional	2017-11-08	Active, not recruiting
An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients With Unresectable (Stage IIIc) and Metastatic (Stage IV) BRAF V600E/K Mutatio [NCT02392871]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2015-05-31	Completed
A Phase II Study of Concurrent Dabrafenib and Trametinib With Stereotactic Radiation in the Management of Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases [NCT02974803]	Phase 2	6 participants (Actual)	Interventional	2018-02-09	Terminated(stopped due to Very slow accrual)
A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) [NCT04185883]	Phase 1/Phase 2	1,143 participants (Anticipated)	Interventional	2019-12-17	Recruiting
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer [NCT01964924]	Phase 2	37 participants (Actual)	Interventional	2013-10-02	Completed
Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma [NCT01701037]	Phase 2	13 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to PI leaving VICC, low future accrual predicted, continued funding improbable,)
Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma [NCT02300935]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Study concept was terminated.)
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study [NCT04801966]		3 participants (Actual)	Interventional	2021-09-23	Terminated(stopped due to low recruitment)
Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma [NCT03501368]	Phase 1	27 participants (Actual)	Interventional	2018-06-27	Active, not recruiting
Trametinib Combined With Everolimus and Lenvatinib in the Treatment of Recurrent/Refractory Advanced Solid Tumors: a Phase II Clinical Trial [NCT04803318]	Phase 2	100 participants (Anticipated)	Interventional	2021-01-01	Recruiting
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO) [NCT04739566]	Phase 2	18 participants (Anticipated)	Interventional	2021-01-22	Recruiting
A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer [NCT03975231]	Phase 1	6 participants (Anticipated)	Interventional	2020-09-14	Recruiting
Phase II Biomarker Study Evaluating The Upfront Combination Of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus The Combination After Eight Weeks Of Monotherapy With Dabrafenib Or Trametinib In Patients With Metastatic And Unresectable Stage [NCT02314143]	Phase 2	48 participants (Actual)	Interventional	2013-11-13	Terminated(stopped due to The study was terminated early due to slow enrollment and limited numbers of viable tissue samples.)
A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K [NCT01928940]	Phase 2	12 participants (Actual)	Interventional	2013-08-15	Completed
A Randomized and Controlled Phase II National Protocol in Non NF1 Pediatric and AYA (Adolescent and Young Adults) Patients Bearing a Wild Type BRAF Gene Newly Diagnosed Comparing a Daily Oral MEK Inhibitor (Trametinib) Versus Weekly Vinblastine During 18 [NCT05180825]	Phase 2	134 participants (Anticipated)	Interventional	2022-05-05	Recruiting
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma [NCT02367859]	Phase 2	1 participants (Actual)	Interventional	2017-07-17	Completed
Phase II Trial to Evaluate Trametinib in Patients With Advanced NF1-mutant Non-small Cell Lung Cancer [NCT03232892]	Phase 2	1 participants (Actual)	Interventional	2018-02-13	Terminated(stopped due to Low Accrual)
A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC [NCT03333343]	Phase 1	105 participants (Actual)	Interventional	2018-01-29	Active, not recruiting
A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer [NCT01553851]	Phase 2	20 participants (Actual)	Interventional	2013-02-28	Completed
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma [NCT03091257]	Phase 1	60 participants (Anticipated)	Interventional	2017-06-21	Recruiting
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Small Cell Lung Cancer and Ras-Mutated Solid Tumors [NCT03266159]	Phase 2	0 participants (Actual)	Interventional	2017-11-27	Withdrawn(stopped due to Study withdrawn before active to fully evaluate impact of changing practice in target population.)
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib [NCT02124772]	Phase 1/Phase 2	139 participants (Actual)	Interventional	2015-01-15	Completed
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib With Trametinib in Chinese Subjects With Melanoma [NCT02447939]	Phase 1	0 participants (Actual)	Interventional	2017-05-31	Withdrawn(stopped due to Change in strategy)
Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM) [NCT04258046]	Phase 2	30 participants (Anticipated)	Interventional	2020-12-01	Recruiting
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study [NCT04619316]	Phase 2	70 participants (Anticipated)	Interventional	2018-02-05	Recruiting
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma [NCT04527549]	Phase 2	84 participants (Anticipated)	Interventional	2021-06-01	Active, not recruiting
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma [NCT01723202]	Phase 2	53 participants (Actual)	Interventional	2012-11-07	Active, not recruiting
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: a Non-interventional Observatory Study [NCT03944356]		232 participants (Actual)	Observational	2019-07-01	Active, not recruiting
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations [NCT01907815]	Phase 2	24 participants (Actual)	Interventional	2013-10-31	Terminated(stopped due to Lack of efficacy.)
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma [NCT02645149]	Phase 2	1,000 participants (Anticipated)	Interventional	2021-11-22	Recruiting
An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive Melanoma [NCT01972347]	Phase 2	35 participants (Actual)	Interventional	2014-10-31	Active, not recruiting
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection [NCT01682083]	Phase 3	870 participants (Actual)	Interventional	2013-01-08	Completed
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia [NCT03190915]	Phase 2	10 participants (Actual)	Interventional	2018-09-09	Active, not recruiting
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors [NCT01827384]	Phase 2	208 participants (Actual)	Interventional	2014-01-07	Completed
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [NCT01725100]	Phase 1	80 participants (Actual)	Interventional	2013-02-05	Completed
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies [NCT02399943]	Phase 2	14 participants (Actual)	Interventional	2015-06-30	Completed
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors [NCT05668585]	Phase 1/Phase 2	102 participants (Anticipated)	Interventional	2022-12-08	Recruiting
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations [NCT04439279]	Phase 2	35 participants (Actual)	Interventional	2015-08-12	Active, not recruiting
A Phase 1b Trial of Talimogene Laherparepvec in Combination With Dabrafenib and Trametinib in Advanced Melanoma With an Activating BRAF Mutation [NCT03088176]	Phase 1	4 participants (Actual)	Interventional	2017-06-25	Active, not recruiting
A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Muta [NCT01597908]	Phase 3	704 participants (Actual)	Interventional	2012-06-04	Completed
MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors or Leukemia [NCT01376310]	Phase 2	159 participants (Actual)	Interventional	2010-11-02	Terminated(stopped due to Company Decision)
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" [NCT05299580]	Phase 2	0 participants (Actual)	Interventional	2021-02-18	Withdrawn(stopped due to lack of enrollment)
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [NCT01726738]	Phase 2	17 participants (Actual)	Interventional	2013-04-04	Completed
Efficacy of a Selective MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors Associated With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer With RAS or BRAFV600E Mutation [NCT03244956]	Phase 2	40 participants (Actual)	Interventional	2017-12-27	Active, not recruiting
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib [NCT03076164]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2017-03-01	Completed
Phase I/II Study With Lapatinib Plus Trametinib in Patients With Metastatic KRAS Mutant Non-small Cell Lung Cancer [NCT02230553]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2014-10-31	Recruiting
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer [NCT02292173]	Phase 1	17 participants (Actual)	Interventional	2015-02-18	Completed
Individual Patient Program for Patient With Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib [NCT03386071]		0 participants	Expanded Access		No longer available
Pilot Study on the Efficacy of MEK1/MEK2 Inhibitor Trametinib in Patients With Surgical Unruptured Arteriovenous Malformations [NCT06098872]	Phase 2	10 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction [NCT02070549]	Phase 1	46 participants (Actual)	Interventional	2014-03-10	Active, not recruiting
A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases [NCT02015117]	Phase 1	10 participants (Actual)	Interventional	2014-04-28	Active, not recruiting
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer [NCT02042443]	Phase 2	53 participants (Actual)	Interventional	2014-02-28	Completed
PaTcH Trial: A Phase 2 Study to Explore Primary and Emerging Resistance Mechanisms in Patients With Metastatic Refractory Pancreatic Cancer Treated With Trametinib and Hydroxychloroquine [NCT05518110]	Phase 2	22 participants (Anticipated)	Interventional	2023-05-31	Recruiting
A Phase II, Open-label Study of Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations [NCT05876806]	Phase 2	30 participants (Anticipated)	Interventional	2023-06-20	Recruiting
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers [NCT02152995]	Phase 2	34 participants (Actual)	Interventional	2014-08-14	Active, not recruiting
A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma [NCT02130466]	Phase 1/Phase 2	184 participants (Actual)	Interventional	2014-05-29	Completed
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma [NCT05714371]		618 participants (Actual)	Observational	2021-10-02	Completed
A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease [NCT02281760]	Phase 2	9 participants (Actual)	Interventional	2014-11-01	Completed
A Phase II, Two Parallel Group Study of Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations [NCT06054191]	Phase 2	40 participants (Anticipated)	Interventional	2024-02-01	Not yet recruiting
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma [NCT01979523]	Phase 2	42 participants (Actual)	Interventional	2013-10-23	Completed
An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects Wi [NCT01750918]	Phase 1/Phase 2	166 participants (Actual)	Interventional	2012-12-19	Completed
A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations [NCT02296112]	Phase 2	9 participants (Actual)	Interventional	2015-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00920140 (14) [back to overview]	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose
NCT00920140 (14) [back to overview]	Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Clinical Chemistry Parameters by Dose
NCT00920140 (14) [back to overview]	Ctau of GSK1120212 in Part 2
NCT00920140 (14) [back to overview]	Tmax of GSK1120212 in Part 1
NCT00920140 (14) [back to overview]	t1/2 at C1D1 and t1/2 Effective (Eff.) at C1D15 of GSK1120212 in Part 1
NCT00920140 (14) [back to overview]	Number of Participants With an Investigator-assessed Best Response (Achieving Complete Response [CR], Marrow CR, Partial Response [PR], Complete Response Without Platelet Recovery [CRp] or Morphologic Leukaemia-free State[MLFS]) by Cohort
NCT00920140 (14) [back to overview]	Number of Participants With a Change From Baseline in Temperature by Dose
NCT00920140 (14) [back to overview]	Number of Participants With a Change From Baseline in Systolic and Diastolic Blood Pressure by Dose
NCT00920140 (14) [back to overview]	Cmin and Cmax of GSK1120212 in Part 1
NCT00920140 (14) [back to overview]	Number of Participants With a Change From Baseline in Heart Rate by Dose
NCT00920140 (14) [back to overview]	Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose
NCT00920140 (14) [back to overview]	AUC(0-24), AUC(0-t), and AUC(0-tau) of GSK1120212 in Part 1
NCT00920140 (14) [back to overview]	Overall Survival by Cohort
NCT00920140 (14) [back to overview]	Accumulation Ratio (AR) of GSK1120212 in Part 1
NCT01037127 (11) [back to overview]	Overall Survival
NCT01037127 (11) [back to overview]	Number of Participants With Any Adverse Event (AE)
NCT01037127 (11) [back to overview]	Duration of Tumor Response
NCT01037127 (11) [back to overview]	Number of Participants With Tumor Progression
NCT01037127 (11) [back to overview]	Number of Participants With Best Confirmed Response
NCT01037127 (11) [back to overview]	Number of Participants With Best Confirmed Response in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors
NCT01037127 (11) [back to overview]	Number of Participants Who Survived Until 6 Months, 12 Months and 24 Months From Baseline
NCT01037127 (11) [back to overview]	Number of Participants With Best Unconfirmed Response at the Time of the Interim Analysis (Week 8)
NCT01037127 (11) [back to overview]	Mean Plasma Concentrations
NCT01037127 (11) [back to overview]	Progression-free Survival (PFS)
NCT01037127 (11) [back to overview]	PFS in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors
NCT01072175 (64) [back to overview]	Part C: Plasma Concentrations of Trametinib
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range
NCT01072175 (64) [back to overview]	Part B: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline
NCT01072175 (64) [back to overview]	Part B: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range
NCT01072175 (64) [back to overview]	Part B: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline
NCT01072175 (64) [back to overview]	Part B: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range
NCT01072175 (64) [back to overview]	Part D: Tmax of Dabrafenib Metabolites
NCT01072175 (64) [back to overview]	Part D: Tmax Assessment of Trametinib
NCT01072175 (64) [back to overview]	Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure
NCT01072175 (64) [back to overview]	Part D: Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants
NCT01072175 (64) [back to overview]	Part D: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT01072175 (64) [back to overview]	Part D: Cmax of Dabrafenib Metabolites
NCT01072175 (64) [back to overview]	Part D: Cmax Assessment of Trametinib
NCT01072175 (64) [back to overview]	Part D: Area Under the Concentration-time Curve Assessment of Trametinib
NCT01072175 (64) [back to overview]	Part D: Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites
NCT01072175 (64) [back to overview]	Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part D (Analyte=GSK2118436): AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part B: Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part C: Plasma Concentrations of Dabrafenib and Its Metabolites
NCT01072175 (64) [back to overview]	Part D (Analyte=GSK2118436): Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib
NCT01072175 (64) [back to overview]	Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR)
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT01072175 (64) [back to overview]	Part C (Randomized): Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR)
NCT01072175 (64) [back to overview]	Part C (Crossover): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline
NCT01072175 (64) [back to overview]	Part B: Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part B: Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part B: Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part B: Pre- and Post-dose H-scores for Individual Participants
NCT01072175 (64) [back to overview]	Part B: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure
NCT01072175 (64) [back to overview]	Part B: Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator
NCT01072175 (64) [back to overview]	Part B: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT01072175 (64) [back to overview]	Part B: AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part B: AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib
NCT01072175 (64) [back to overview]	Part B (Analyte=GSK1120212): Tmax Assessment of Trametinib in Combination With Dabrafenib
NCT01072175 (64) [back to overview]	Part B (Analyte=GSK1120212): Tmax Assessment of Trametinib in Combination With Dabrafenib
NCT01072175 (64) [back to overview]	Part B (Analyte=GSK1120212): Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib
NCT01072175 (64) [back to overview]	Part B (Analyte=GSK1120212): Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib
NCT01072175 (64) [back to overview]	Part D: Duration of Response as Assessed by the Investigator
NCT01072175 (64) [back to overview]	Part B (Analyte=GSK1120212): AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib
NCT01072175 (64) [back to overview]	Part B (Analyte=GSK1120212): AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib
NCT01072175 (64) [back to overview]	Part A: Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib
NCT01072175 (64) [back to overview]	Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib
NCT01072175 (64) [back to overview]	Part A: AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites
NCT01072175 (64) [back to overview]	Part D: Progression-free Survival (PFS) as Assessed by the Investigator
NCT01072175 (64) [back to overview]	Part C (Randomized): Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range
NCT01072175 (64) [back to overview]	Part D: Overall Survival (OS)
NCT01072175 (64) [back to overview]	Part C: Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib
NCT01072175 (64) [back to overview]	Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Investigator
NCT01072175 (64) [back to overview]	Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR)
NCT01072175 (64) [back to overview]	Part C (Randomized): Overall Survival (OS)
NCT01072175 (64) [back to overview]	Part C (Crossover): Progression-free Survival (PFS) as Assessed by the Investigator
NCT01072175 (64) [back to overview]	Part B: Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma
NCT01072175 (64) [back to overview]	Part B: Overall Survival (OS) in BRAFi Naïve Melanoma Participants
NCT01072175 (64) [back to overview]	Part B: Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma
NCT01072175 (64) [back to overview]	Part D: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline
NCT01072175 (64) [back to overview]	Part D: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range
NCT01072175 (64) [back to overview]	Part D: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline
NCT01072175 (64) [back to overview]	Part D: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range
NCT01231581 (7) [back to overview]	Investigator-Assessed Duration of Response
NCT01231581 (7) [back to overview]	Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)
NCT01231581 (7) [back to overview]	Number of Participants (Par.) With a Worst-case Change to Grade 3 or Grade 4 From Baseline Grade in Chemistry Parameters
NCT01231581 (7) [back to overview]	Overall Survival
NCT01231581 (7) [back to overview]	Number of Participants With Change From Baseline Increase to Grade 3/Grade 4 in Lab Hematology Test Measurements
NCT01231581 (7) [back to overview]	Progression-free Survival (PFS) as Assessed by the Investigator
NCT01231581 (7) [back to overview]	Number of Participants With an Investigator-assessed Best Response, With or Without Confirmation, of Complete Response (CR) or Partial Response (PR)
NCT01245062 (17) [back to overview]	Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
NCT01245062 (17) [back to overview]	PFS Following Cross-over to Trametinib as Assessed by the Investigator
NCT01245062 (17) [back to overview]	PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator
NCT01245062 (17) [back to overview]	PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator
NCT01245062 (17) [back to overview]	Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
NCT01245062 (17) [back to overview]	Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review
NCT01245062 (17) [back to overview]	Progression-free Survival in All Participants
NCT01245062 (17) [back to overview]	DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator
NCT01245062 (17) [back to overview]	Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review
NCT01245062 (17) [back to overview]	Number of Participants With OR as Assessed by the Investigator and Independent Review
NCT01245062 (17) [back to overview]	Number of Participants With OR Following Cross-over to Trametinib
NCT01245062 (17) [back to overview]	DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review
NCT01245062 (17) [back to overview]	DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review
NCT01245062 (17) [back to overview]	DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review
NCT01245062 (17) [back to overview]	Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review
NCT01245062 (17) [back to overview]	Overall Survival in All Participants
NCT01245062 (17) [back to overview]	Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases
NCT01336634 (10) [back to overview]	Progression Free Survival (PFS) Based on Local Investigator Assessment
NCT01336634 (10) [back to overview]	Overall Survival (OS)
NCT01336634 (10) [back to overview]	Overall Response Rate (ORR)
NCT01336634 (10) [back to overview]	Oral Volume of Distribution (V/F) of Trametinib
NCT01336634 (10) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT01336634 (10) [back to overview]	All Collected Deaths
NCT01336634 (10) [back to overview]	Oral Volume of Distribution (V/F) of Dabrafenib
NCT01336634 (10) [back to overview]	Duration of Response (DoR) Based on Local Investigator Assessment
NCT01336634 (10) [back to overview]	Apparent Clearance (CL/F) of Trametinib
NCT01336634 (10) [back to overview]	Apparent Clearance (CL/F) of Dabrafenib
NCT01362296 (20) [back to overview]	Change From Baseline in SBP and DBP: Crossover Phase
NCT01362296 (20) [back to overview]	GSK1120212 Plasma Pharmacokinetic (PK) Concentration
NCT01362296 (20) [back to overview]	Overall Survival (OS)
NCT01362296 (20) [back to overview]	Number of Participants With a Best Response of Either a CR or PR as Assessed by the Investigator: Crossover Phase
NCT01362296 (20) [back to overview]	Number of Participants With Any Serious Adverse Event (SAE) or Non-serious Adverse Event (AE): Randomized Phase
NCT01362296 (20) [back to overview]	Number of Participants With Any SAE or Non-serious AE: Crossover Phase
NCT01362296 (20) [back to overview]	Change From Baseline in Heart Rate: Randomized Phase
NCT01362296 (20) [back to overview]	Number of Participants With a Best Response of Either a Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator: Randomized Phase
NCT01362296 (20) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Randomized Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Clinical Chemistry Parameters: Randomized Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Hematology Parameters: Crossover Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Hematology Parameters: Randomized Phase
NCT01362296 (20) [back to overview]	Duration of Response (DOR) as Assessed by the Investigator: Randomized Phase
NCT01362296 (20) [back to overview]	Change From Baseline in Heart Rate: Crossover Phase
NCT01362296 (20) [back to overview]	Progression-Free Survival (PFS) as Assessed by the Investigator (INV)
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Clinical Chemistry Parameters: Crossover Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Clinical Chemistry Parameters: Randomized Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Hematology Parameters: Crossover Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Hematology Parameters: Randomized Phase
NCT01362296 (20) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Clinical Chemistry Parameters: Crossover Phase
NCT01376310 (1) [back to overview]	Number of Participants With Adverse Events
NCT01553851 (7) [back to overview]	Number of Participants With Changes in TumorCell Surface CD44 Expression After Treatment With GSK1120212.
NCT01553851 (7) [back to overview]	Safety of GSK1120212
NCT01553851 (7) [back to overview]	Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After Treatment With GSK1120212.
NCT01553851 (7) [back to overview]	Percentage of Participants With Clinical Response Induced by GSK1120212, as Determined by Change in Tumor Size.
NCT01553851 (7) [back to overview]	Percent of Participants With Metabolic Changes in OCSCC Using FDG-PET/CT Imaging.
NCT01553851 (7) [back to overview]	Percent Change in Tumor Size Area
NCT01553851 (7) [back to overview]	Percent Change in Maximum Standard Uptake Value in Oral Cavity Saqumous Cell Carcinoma (OCSCC) Using F18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT).
NCT01584648 (8) [back to overview]	Progression-Free Survival (PFS) as Assessed by the Investigator
NCT01584648 (8) [back to overview]	Overall Survival (OS)
NCT01584648 (8) [back to overview]	Objective Response Rate (ORR) as Assessed by the Investigator
NCT01584648 (8) [back to overview]	Duration of Response (DoR)
NCT01584648 (8) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT01584648 (8) [back to overview]	Trametinib Pharmacokinetic Concentrations
NCT01584648 (8) [back to overview]	Dabrafenib and Dabrafenib Metabolites (Hydroxy-, Carboxy- and Desmethyl-Dabrafenib) Concentrations
NCT01584648 (8) [back to overview]	All Collected Deaths
NCT01597908 (5) [back to overview]	All Collected Deaths
NCT01597908 (5) [back to overview]	Progression-Free Survival (PFS), as Assessed by the Investigator
NCT01597908 (5) [back to overview]	Overall Survival (OS)
NCT01597908 (5) [back to overview]	Overall Response Rate (ORR) During Randomized Phase, as Assessed by the Investigator
NCT01597908 (5) [back to overview]	Duration of Response (DOR), as Assessed by the Investigator
NCT01619774 (3) [back to overview]	Overall Response Rate (ORR)
NCT01619774 (3) [back to overview]	Progression-Free Survival (PFS)
NCT01619774 (3) [back to overview]	Number of Participants by Response
NCT01682083 (4) [back to overview]	Freedom From Relapse
NCT01682083 (4) [back to overview]	Relapse-free Survival (RFS)
NCT01682083 (4) [back to overview]	Overall Survival
NCT01682083 (4) [back to overview]	Distant Metastasis-free Survival
NCT01701037 (6) [back to overview]	Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0
NCT01701037 (6) [back to overview]	Change in Tumor Volume Reduction in Participants With Intrinsic Resistance to B-RAF Targeted Therapy From Day 14 to Day 28.
NCT01701037 (6) [back to overview]	Clinical Tumor Response Rate (Response is Based on Greater Than 30% Reduction From Baseline in Tumor Volume by RECIST Criteria) at Day 14.
NCT01701037 (6) [back to overview]	Percent of Patients Completing Second and Third (Surgical) Biopsies
NCT01701037 (6) [back to overview]	Investigational Agent Taken
NCT01701037 (6) [back to overview]	Percentage of Biopsies With Adequate Tissue for Biomarker Analysis
NCT01721603 (4) [back to overview]	Patients Reaching 6 Month Distant Brain Metastasis-free Survival (DBMFS)
NCT01721603 (4) [back to overview]	Systemic Overall Response Rate
NCT01721603 (4) [back to overview]	Patients Displaying 6-month Local Control Rate
NCT01721603 (4) [back to overview]	Best Overall Response Rate (by RECIST v1.1 )
NCT01726738 (7) [back to overview]	BRAF and MEK Inhibition Associated With New Functional Mutations in the Approximately 150 Oncogenes
NCT01726738 (7) [back to overview]	Change in Kinase Expression
NCT01726738 (7) [back to overview]	Rate of Overall Survival (OS) at 12 Months
NCT01726738 (7) [back to overview]	Progression Free Survival (PFS)
NCT01726738 (7) [back to overview]	Overall Response Rate (ORR)
NCT01726738 (7) [back to overview]	Kinome Signature Predictive of Resistance
NCT01726738 (7) [back to overview]	Duration of Overall Response
NCT01750918 (55) [back to overview]	Ctau of Panitumumab in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Ctau of Panitumumab in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Ctau of Panitumumab in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	AUC[0-8] of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Ctau of Panitumumab in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Ctau of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Cmax of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	AUC[0-8] of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Cmax of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Cmax of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Cmax of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Cmax of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Cmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Cmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Cmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	All Collected Deaths
NCT01750918 (55) [back to overview]	Apparent Base Clearance (CL0/F) and Apparent Maximum Inducible Clearance at Steady State (CLIND,SS/F) of Dabrafenib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Ctau of Panitumumab in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Cmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Time When Ka1 Transitions to Ka2 of Trametinib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Change in Levels of Proteins/Ribonucleic Acid (RNA)
NCT01750918 (55) [back to overview]	Progression Free Survival (PFS)
NCT01750918 (55) [back to overview]	Overall Survival (OS)
NCT01750918 (55) [back to overview]	Overall Response Rate (ORR)
NCT01750918 (55) [back to overview]	Oral Volume of Distribution (V/F) of Dabrafenib in the Triple Combination (D+T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Oral Volume of Distribution (V/F) of Dabrafenib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Effect of Combination With Trametinib on Apparent Maximum Inducible Clearance at Steady State of Dabrafenib in the Triple Combination (D+T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Duration of Response (DoR)
NCT01750918 (55) [back to overview]	Apparent Central Volume (V/F) of Trametinib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Absorption Rate Constant (Ka) of Dabrafenib in the Triple Combination (D+T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Absorption Rate Constant (Ka) of Dabrafenib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Tmax of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	AUC[0-t] of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	AUC[0-t] of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	AUC[0-8] of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	AUC[0-8] of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Apparent Clearance (CL/F) of Trametinib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	AUC[0-8] of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	AUC[0-8] of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Apparent Base Clearance (CL0/F) and Apparent Maximum Inducible Clearance at Steady State (CLIND,SS/F) of Dabrafenib in the Triple Combination (D+T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	AUC[0-8] of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	AUC[0-8] of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Tmax of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Tmax of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Tmax of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Tmax of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Tmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Absorption Rate Constant 1 (Ka1) and Absorption Rate Constant 2 (Ka2) of Trametinib in the Double Combination (T+P) Estimated With a PopPK Model
NCT01750918 (55) [back to overview]	Tmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Tmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Tmax of Dabrafenib and Derived Metabolites in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Number of Participants With Adverse Events
NCT01750918 (55) [back to overview]	Ctau of Trametinib in the Triple Combination (D+T+P)
NCT01750918 (55) [back to overview]	Ctau of Trametinib in the Double Combination (T+P)
NCT01750918 (55) [back to overview]	Ctau of Panitumumab in the Triple Combination (D+T+P)
NCT01827384 (3) [back to overview]	Proportion of Participants With 4 Month Progression-free Survival (PFS)
NCT01827384 (3) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT01827384 (3) [back to overview]	Number of Participants With an Objective Response
NCT01902173 (2) [back to overview]	Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib.
NCT01902173 (2) [back to overview]	Maximum-tolerated Dose (MTD) of Akt Inhibitor GSK2141795 in Combination With Dabrafenib.
NCT01907815 (2) [back to overview]	Most Frequently Reported Adverse Events (AE)
NCT01907815 (2) [back to overview]	Complete Response Rate (CRR, Defined as CR+CRp) Assessed by AML 2003 Response Criteria
NCT01928940 (37) [back to overview]	Phase II: Number of Participant With Confirmed Overall Response
NCT01928940 (37) [back to overview]	Phase II: Duration of Response
NCT01928940 (37) [back to overview]	Phase II: Change From Baseline in Weight at the Indicated Time Points
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With Any Adverse Event and Any Serious Adverse Event
NCT01928940 (37) [back to overview]	Phase II: Change From Baseline in Oxygen Saturation Measured Via Pulse Oxymetry at the Indicated Time Points
NCT01928940 (37) [back to overview]	Phase I: Time of Occurrence of Cmax (Tmax) and Terminal Phase Half Life (t1/2) of GSK2118436 and Metabolites, and GSK1120212 After a Single and Repeat Dose
NCT01928940 (37) [back to overview]	Phase I: Progression Free Survival (PFS)
NCT01928940 (37) [back to overview]	Phase I: Plasma Trough Concentration (Ctau) of GSK2118436 and Metabolites, and GSK1120212 After a Single and Repeat Dose
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Worst-case On-therapy Increase From Baseline in Systolic and Diastolic Blood Pressure to Grade 2 or Grade 3
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Temperature
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Assessed by Echocardiogram (ECHO)
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Worst-case On-therapy Change From Baseline in Heart Rate
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Unconfirmed Overall Response Rate
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Clinical Chemistry Parameters
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With the Indicated Urinalysis Results
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With the Indicated Electrocardiogram Findings at the Indicated Time Points
NCT01928940 (37) [back to overview]	Phase I: Change From Baseline in Weight at the Indicated Time Points
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance (Pef) Status
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With the Indicated Worst-case Change From Baseline (BL) in the Indicated Clinical Chemistry Parameters (CCPs)
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With the Indicated Urinalysis Parameters
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With the Indicated Electrocardiogram (ECG) Findings at the Indicated Time Points
NCT01928940 (37) [back to overview]	Phase I: Change From Baseline in Oxygen Saturation (SpO2) Measured Via Pulse Oxymetry at the Indicated Time Points
NCT01928940 (37) [back to overview]	Phase I: Area Under the Plasma Concentration Versus Time Curve (AUC) of GSK2118436 and Metabolites, and GSK1120212 After Single and Repeat Dose
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With a Dose-limiting Toxicity (DLT)
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Hematology Parameters
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Confirmed Overall Response Rate
NCT01928940 (37) [back to overview]	Phase II: Progression Free Survival (PFS)
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With Worst-case On-therapy Increase From Baseline in Systolic and Diastolic Blood Pressure to Grade 2 or Grade 3
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With Worst-case On-therapy Change From Baseline in Temperature
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With Worst-case On-therapy Change From Baseline in Left Ventricular Ejection Fraction as Assessed by Echocardiogram
NCT01928940 (37) [back to overview]	Phase I: Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With Worst-case On-therapy Change From Baseline in Heart Rate
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With Unconfirmed Overall Response
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in ECOG Perormance Status
NCT01928940 (37) [back to overview]	Phase II: Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Hematology Parameters
NCT01928940 (37) [back to overview]	Phase I: Maximum Plasma Concentration (Cmax) of GSK2118436 and Metabolites, and GSK1120212 After a Single and Repeat Dose
NCT01928940 (37) [back to overview]	Phase I: Duration of Response
NCT01941927 (4) [back to overview]	Number of Severe Adverse Events (Grade 3 and 4) Reported by Patients Related With the Treatment of Trametinib and GSK2141795.
NCT01941927 (4) [back to overview]	Progression-Free Survival of Patients Treated With the Combination of Trametinib and GSK 2141795
NCT01941927 (4) [back to overview]	Objective Response Rate (ORR)
NCT01941927 (4) [back to overview]	Overall Survival of Patients Treated With the Combination of Trametinib and GSK 2141795
NCT01943864 (24) [back to overview]	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
NCT01943864 (24) [back to overview]	Expression of Interstitial Lung Disease Marker Surfactant Protein D
NCT01943864 (24) [back to overview]	Expression of Interstitial Lung Disease Marker KL-6
NCT01943864 (24) [back to overview]	Change From Baseline in Oxygen Saturation (SpO2)
NCT01943864 (24) [back to overview]	Number of Weeks Until Time to Response Assessed With Independent Radiologist
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Carcinoembryonic Antigen Measurements With Respect to the Normal Range
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Body Temperature
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Blood Pressure
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Prothrombin Time Measurements With Respect to the Normal Range
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Pulse Rate
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Clinical Chemistry Grade Shifts From Baseline
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Coagulation Grade Shifts From Baseline
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Hematology Grade Shifts From Baseline
NCT01943864 (24) [back to overview]	Number of Participants With Progression-Free Survival as Assessed by Investigator
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Clinical Chemistry Measurements With Respect to the Normal Range
NCT01943864 (24) [back to overview]	Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in Hematology Measurements With Respect to the Normal Range
NCT01943864 (24) [back to overview]	Number of Participants With Progression-Free Survival as Assessed by Independent Radiologist
NCT01943864 (24) [back to overview]	Number of Participants With Overall Survival
NCT01943864 (24) [back to overview]	Number of Participants With Overall Response Rate as Assessed by Investigator Per RECIST 1.1 Criteria
NCT01943864 (24) [back to overview]	Number of Participants With Overall Response Rate as Assessed by Independent Radiologist Per RECIST 1.1 Criteria
NCT01943864 (24) [back to overview]	Number of Participants With Investigator-Assessed Duration of Response
NCT01943864 (24) [back to overview]	Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12
NCT01943864 (24) [back to overview]	Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12
NCT01943864 (24) [back to overview]	Number of Participants With Independent Radiologist Assessed Duration of Response
NCT01958112 (4) [back to overview]	Duration of Progression-free (PFS)
NCT01958112 (4) [back to overview]	Overall Survival
NCT01958112 (4) [back to overview]	Mutation and Co-mutation Rates of Genes in the PI3K and RAS ERK Signaling Pathways in Recurrent Cervical Cancer Using High Throughput Targeted Mutational Analysis on Participant Tumor Samples.
NCT01958112 (4) [back to overview]	Toxicity of GSK1120212 (Trametinib) and GSK2141795 as Measured by the Number of Participants With Adverse Events
NCT01964924 (10) [back to overview]	Tolerability of the Regimen Defined as the Number of Patients Who Required Dose Modifications and/or Dose Delays
NCT01964924 (10) [back to overview]	Proportion of Patients Who Refuse Further Treatment for Lesser Toxicities That Inhibit Their Willingness to Continue Participation on the Trial
NCT01964924 (10) [back to overview]	Proportion of Patients Who go Off Treatment Due to Adverse Reactions
NCT01964924 (10) [back to overview]	Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6 Months After Initiation of Therapy With Trametinib
NCT01964924 (10) [back to overview]	Incidence of Severe (Grade 3+) Adverse Events or Toxicities Graded Per NCI CTCAE Version 4.0
NCT01964924 (10) [back to overview]	Incidence of Adverse Events That Are Classified as Either Possibly, Probably, or Definitely Related to Study Treatment
NCT01964924 (10) [back to overview]	Duration of Objective Response
NCT01964924 (10) [back to overview]	Clinical Benefit Rate (CBR = CR+PR+Stable Disease [SD])
NCT01964924 (10) [back to overview]	Overall Survival
NCT01964924 (10) [back to overview]	Progression-free Survival
NCT01978236 (4) [back to overview]	Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT01978236 (4) [back to overview]	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Parenchymal Brain Metastases
NCT01978236 (4) [back to overview]	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib in Peripheral Blood (Plasma)
NCT01978236 (4) [back to overview]	Concentrations of Dabrafenib, Its Metabolites Hydroxy-, Carboxy- and Desmethyl-dabrafenib) in Cerebrospinal Fluid (CSF) Samples
NCT01979523 (4) [back to overview]	Response Rate (Complete Response+ Partial Response) Using the RECIST Criteria
NCT01979523 (4) [back to overview]	Number of Participants With Toxicity, Graded According to the National Cancer Institute CTCAE v4.0, Who Were Treated and Did Not Withdraw Consent
NCT01979523 (4) [back to overview]	Overall Survival (OS) Per RECIST Criteria
NCT01979523 (4) [back to overview]	Time to Progression (Progression-free Survival [PFS]), Defined From the Date of Randomization to the Date of Documented Progression or Death Per RECIST
NCT01989598 (5) [back to overview]	PFS
NCT01989598 (5) [back to overview]	ORR After the Addition of AKT Inhibitor GSK2141795 to Trametinib in Patients Who Have Developed Progressive Disease or Have Achieved Less Than a PR
NCT01989598 (5) [back to overview]	ORR Evidenced by Confirmed Response Rate, Defined as Number of Patients With Partial Response or Better by International Myeloma Working Group (IMWG) Criteria Divided by the Number of Patients in the Applicable Group (Biomarker Positive or Negative)
NCT01989598 (5) [back to overview]	Detection of RAS and RAF Mutations Using cfDNA
NCT01989598 (5) [back to overview]	Incidence of Adverse Event Reactions Reported According to CTCAE v4.0
NCT02034110 (31) [back to overview]	All Collected Deaths
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Hairy Cell Leukemia (HCL) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the Low Grade (WHO G1/G2) Glioma (LGG) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the High Grade (WHO G3/G4) Glioma (HGG) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the Biliary Tract Cancer (BTC) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the Anaplastic Thyroid Cancer (ATC) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the Adenocarcinoma of the Small Intestine (ASI) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Low Grade (WHO G1/G2) Glioma (LGG) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the High Grade (WHO G3/G4) Glioma (HGG) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Gastrointestinal Stromal Tumor (GIST) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Biliary Tract Cancer (BTC) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort
NCT02034110 (31) [back to overview]	Overall Response Rate (ORR) in the Adenocarcinoma of the Small Intestine (ASI) Cohort
NCT02034110 (31) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the Low Grade (WHO G1/G2) Glioma (LGG) Cohort
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the High Grade (WHO G3/G4) Glioma (HGG) Cohort
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the Biliary Tract Cancer (BTC) Cohort
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the Adenocarcinoma of the Small Intestine (ASI) Cohort
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the Hairy Cell Leukemia (HCL) Cohort
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the Multiple Myeloma (MM) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the Adenocarcinoma of the Small Intestine (ASI) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the Anaplastic Thyroid Cancer (ATC) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the Biliary Tract Cancer (BTC) Cohort
NCT02034110 (31) [back to overview]	Duration of Response (DoR) in the Anaplastic Thyroid Cancer (ATC) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the High Grade (WHO G3/G4) Glioma (HGG) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the Low Grade (WHO G1/G2) Glioma (LGG) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the Multiple Myeloma (MM) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the Hairy Cell Leukemia (HCL) Cohort
NCT02034110 (31) [back to overview]	Progression Free Survival (PFS) in the Multiple Myeloma (MM) Cohort
NCT02034110 (31) [back to overview]	Overall Survival (OS) in the Hairy Cell Leukemia (HCL) Cohort
NCT02039947 (8) [back to overview]	Intracranial Response (IR) Rate in Cohort A
NCT02039947 (8) [back to overview]	Intracranial Response Rate of Cohorts B, C and D
NCT02039947 (8) [back to overview]	Overall Response (OR) for Each Cohort
NCT02039947 (8) [back to overview]	Overall Survival (OS) for Each Cohort
NCT02039947 (8) [back to overview]	Disease Control for Intracranial, Extracranial and Overall Response for Each Cohort
NCT02039947 (8) [back to overview]	Duration of Intracranial, Extracranial and Overall Response for Each Cohort
NCT02039947 (8) [back to overview]	Progression-free Survival (PFS) for Each Cohort Based on Investigator Assessment
NCT02039947 (8) [back to overview]	Extracranial Response Rate (ER) for Each Cohort
NCT02042443 (4) [back to overview]	Objective Response Rate
NCT02042443 (4) [back to overview]	Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug
NCT02042443 (4) [back to overview]	Progression-free Survival
NCT02042443 (4) [back to overview]	Overall Survival
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Dabrafenib - Cmax
NCT02083354 (37) [back to overview]	Objective Response Rate (ORR)
NCT02083354 (37) [back to overview]	Overall Survival (OS) - Median
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Carboxydabrafenib - Ctrough
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Carboxydabrafenib - Racc
NCT02083354 (37) [back to overview]	Duration of Response (DOR) - Estimate for Duration of Response - Median
NCT02083354 (37) [back to overview]	Progression-free Survival (PFS)
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Trametinib - Tmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Trametinib - Cmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Trametinib - AUC(0-t)
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Trametinib - AUC(0-24)
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Hydroxydabrafenib - Tmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Hydroxydabrafenib - Rm/p
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Hydroxydabrafenib - Cmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Hydroxydabrafenib - AUC(0-12)
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Desmethyl-dabrafenib - Tmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Desmethyl-dabrafenib - Cmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Dabrafenib - Tmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Dabrafenib - AUC(0-12)
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Carboxydabrafenib - Tmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Carboxydabrafenib - Rm/p
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Carboxydabrafenib - Cmax
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Carboxydabrafenib - AUC(0-12)
NCT02083354 (37) [back to overview]	Overall Survival (OS)
NCT02083354 (37) [back to overview]	Number of Participants With Adverse Events
NCT02083354 (37) [back to overview]	Duration of Response (DOR)
NCT02083354 (37) [back to overview]	All Collected Deaths
NCT02083354 (37) [back to overview]	Progression-free Survival (PFS) - Median
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Trametinib - Racc
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Trametinib - Ctrough
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Hydroxydabrafenib - Racc
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Hydroxydabrafenib - Ctrough
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Desmethyl-dabrafenib - Rm/p
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Desmethyl-dabrafenib - Ctrough
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Desmethyl-dabrafenib - AUC(0-12)
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Dabrafenib - Racc
NCT02083354 (37) [back to overview]	Population Pharmacokinetics of Dabrafenib - Ctrough
NCT02101788 (7) [back to overview]	Patients Reported Acute Quality of Life
NCT02101788 (7) [back to overview]	Patient Reported Acute Peripheral Neuropathy Symptoms
NCT02101788 (7) [back to overview]	Incidence of Adverse Events (AEs)
NCT02101788 (7) [back to overview]	Progression-free Survival (PFS)
NCT02101788 (7) [back to overview]	Progression Free Survival
NCT02101788 (7) [back to overview]	Objective Tumor Response Rate (Complete Response and Partial Response)
NCT02101788 (7) [back to overview]	Overall Survival
NCT02124772 (25) [back to overview]	Trough Concentration (Ctrough) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Trametinib When Administered Alone and in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Objective Response Rate (ORR) Based on RECIST v1.1, RANO and Dombi Criteria and as Per Investigator Assessment
NCT02124772 (25) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Trametinib When Administered Alone and in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Clinical Benefit Rate (CBR) Based on RECIST v1.1, RANO and Dombi Criteria and as Per Investigator Assessment
NCT02124772 (25) [back to overview]	Average Steady State Plasma Concentration (Cavg) of Trametinib When Administered in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Average Steady State Plasma Concentration (Cavg) of Trametinib When Administered Alone (Monotherapy)
NCT02124772 (25) [back to overview]	Average Steady State Plasma Concentration (Cavg) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Palatability of Dabrafenib Oral Suspension in Pediatric Subjects Assessed by Palatability Questionnaire
NCT02124772 (25) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Trametinib When Administered Alone and in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau at Steady-state (AUCtau) of Trametinib When Administered Alone and in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau at Steady-state (AUCtau) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Apparent Plasma Clearance (CL/F) of Trametinib When Administered Alone and in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Apparent Plasma Clearance (CL/F) of Dabrafenib When Administered in Combination With Trametinib
NCT02124772 (25) [back to overview]	Apparent Clearance (CL/F) of Trametinib Estimated With a PopPK Model
NCT02124772 (25) [back to overview]	Apparent Central Volume (Vc/F) of Trametinib Estimated With a PopPK Model
NCT02124772 (25) [back to overview]	Palatability of Trametinib Oral Solution in Pediatric Subjects Assessed by Palatability Questionnaire
NCT02124772 (25) [back to overview]	Significant Covariates Estimated With a PopPK Model
NCT02124772 (25) [back to overview]	Incidence of Treatment Emergent Adverse Events in Subjects Treated With Trametinib Monotherapy
NCT02124772 (25) [back to overview]	Incidence of Treatment Emergent Adverse Events in Subjects Treated With Trametinib in Combination With Dabrafenib
NCT02124772 (25) [back to overview]	Absorption Rate Constants (Ka1 and Ka2) of Trametinib Estimated With a PopPK Model
NCT02124772 (25) [back to overview]	Trough Concentration (Ctrough) of Trametinib When Administered Alone and in Combination With Dabrafenib
NCT02130466 (39) [back to overview]	Part 3: Overall Survival (OS) in Participants With BRAF V600 E or K Mutations
NCT02130466 (39) [back to overview]	Part 3: Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator in Participants With BRAF V600 E or K Mutations
NCT02130466 (39) [back to overview]	Part 5: ORR Per RECIST 1.1 as Assessed by Investigator in Participants Without BRAF V600 E or K Mutations or With Solid Tumors Irrespective of BRAF Status
NCT02130466 (39) [back to overview]	Parts 1, 2, 4, and 5: Number of Participants Who Discontinued Study Treatment Due to an AE
NCT02130466 (39) [back to overview]	Parts 1, 2, 4, and 5: Number of Participants Who Experienced an Adverse Event (AE)
NCT02130466 (39) [back to overview]	Parts 1, 2, 4, and 5: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs)
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Dabrafenib Following Administration of 150 mg Dabrafenib in Combination With 2 mg/kg Pembrolizumab and 2 mg Trametinib in Participants From Part 3
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Dabrafenib Following Administration of 150 mg Dabrafenib in Combination With 2 mg/kg Pembrolizumab and 2 mg Trametinib in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Dabrafenib Following Administration of 150 mg Dabrafenib in Combination With Placebo and 2 mg Trametinib in Participants From Part 3
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab Following Administration of 2 mg/kg Pembrolizumab in Combination With Dabrafenib and Trametinib in Participants From Part 3
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab Following Administration of 2 mg/kg Pembrolizumab in Combination With Dabrafenib and/or Trametinib in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab Following Administration of 200 mg Pembrolizumab in Combination With Trametinib in Participants From Part 4
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 1.5 mg Trametinib in Combination With 2 mg/kg Pembrolizumab in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 1.5 mg Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 4
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 2 mg of Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 5
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 2 mg Trametinib in Combination With 2 mg/kg Pembrolizumab and 150 mg Dabrafenib in Participants From Part 3
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 2 mg Trametinib in Combination With 2 mg/kg Pembrolizumab and 150 mg Dabrafenib in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 2 mg Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 4
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 2 mg Trametinib in Combination With Placebo and 150 mg Dabrafenib in Participants From Part 3
NCT02130466 (39) [back to overview]	Trough Concentration (Ctrough) of Trametinib Following Administration of 1.5 mg of Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 5
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Dabrafenib Following Administration of 150 mg Dabrafenib in Combination With 2 mg/kg Pembrolizumab and 2 mg Trametinib in Participants From Part 3
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Dabrafenib Following Administration of 150 mg Dabrafenib in Combination With 2 mg/kg Pembrolizumab and 2 mg Trametinib in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Dabrafenib Following Administration of 150 mg Dabrafenib in Combination With Placebo and 2 mg Trametinib in Participants From Part 3
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab Following Administration of 2 mg/kg Pembrolizumab in Combination With Dabrafenib and Trametinib in Participants From Part 3
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab Following Administration of 2 mg/kg Pembrolizumab in Combination With Dabrafenib and/or Trametinib in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab Following Administration of 200 mg Pembrolizumab in Combination With Trametinib in Participants From Part 4
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 1.5 mg of Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 5
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 1.5 mg Trametinib in Combination With 2 mg/kg Pembrolizumab in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 1.5 mg Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 4
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 2 mg of Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 5
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 2 mg Trametinib in Combination With 2 mg/kg Pembrolizumab and 150 mg Dabrafenib in Participants From Part 3
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 2 mg Trametinib in Combination With 2 mg/kg Pembrolizumab and 150 mg Dabrafenib in Participants Pooled From Parts 1 and 2
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 2 mg Trametinib in Combination With 200 mg Pembrolizumab in Participants From Part 4
NCT02130466 (39) [back to overview]	Maximum Concentration (Cmax) of Trametinib Following Administration of 2 mg Trametinib in Combination With Placebo and 150 mg Dabrafenib in Participants From Part 3
NCT02130466 (39) [back to overview]	Part 1: ORR Per RECIST 1.1 as Assessed by Investigator in Participants With BRAF V600 E or K Mutations
NCT02130466 (39) [back to overview]	Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator in Participants Without BRAF V600 E or K Mutations
NCT02130466 (39) [back to overview]	Part 2: ORR Per RECIST 1.1 as Assessed by Investigator in Participants With BRAF V600 E or K Mutations
NCT02130466 (39) [back to overview]	Part 3: Duration of Response (DOR) Per RECIST 1.1 as Assessed by Investigator in Participants With BRAF V600 E or K Mutations
NCT02130466 (39) [back to overview]	Part 3: ORR Per RECIST 1.1 as Assessed by Investigator in Participants With BRAF V600 E or K Mutations
NCT02152995 (6) [back to overview]	Number of Participants With Toxicity (Cohort A)
NCT02152995 (6) [back to overview]	Percentage of Patients Alive Without Disease Progression (Cohort B)
NCT02152995 (6) [back to overview]	Percentage With Objective Response (Complete Response or Partial Response) (Cohort A)
NCT02152995 (6) [back to overview]	Number of Participants With Toxicity (Cohort B)
NCT02152995 (6) [back to overview]	Percentage of Patients Progression Free at 6 Months Following Treatment With Trametinib and I-124 (Cohort A)
NCT02152995 (6) [back to overview]	Percentage With an Objective Response (Complete Response or Partial Response) (Cohort B)
NCT02281760 (7) [back to overview]	Progression-free Survival in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease
NCT02281760 (7) [back to overview]	Number of Participants With Partial Response to Dabrafenib and Trametinib
NCT02281760 (7) [back to overview]	Number of Participants With Adverse Events to Dabrafenib and/or Trametinib
NCT02281760 (7) [back to overview]	Overall Survival in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease
NCT02281760 (7) [back to overview]	Disease Resistance to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease
NCT02281760 (7) [back to overview]	Clinical Response Rate to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease.
NCT02281760 (7) [back to overview]	Time Response to Dabrafenib/Trametinib Combination Therapy in a Cohort of Patients With BRAFV600E Positive Erdheim Chester Disease.
NCT02296112 (8) [back to overview]	"Overall Response Rate in Low Affinity Group"
NCT02296112 (8) [back to overview]	Number of Patients With Each Worst-Grade Toxicity
NCT02296112 (8) [back to overview]	Overall Survival
NCT02296112 (8) [back to overview]	"Duration of Response in High Affinity Group"
NCT02296112 (8) [back to overview]	Progression-Free Survival All Patients
NCT02296112 (8) [back to overview]	"Clinical Benefit (Complete Response [CR] + Partial Response [PR] + Stable Disease [SD]) Per RECIST v. 1.1 in High Affinity Group"
NCT02296112 (8) [back to overview]	"Duration of Response in Low Affinity Group"
NCT02296112 (8) [back to overview]	"Overall Response Rate in High Affinity Group"
NCT02314143 (15) [back to overview]	Number of Participants With Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Scores From Baseline
NCT02314143 (15) [back to overview]	Number of Participants With Change in Hematology Parameters From Baseline
NCT02314143 (15) [back to overview]	Number of Participants With Change in Vital Signs From Baseline
NCT02314143 (15) [back to overview]	Number of Participants With Change in Vital Signs From Baseline
NCT02314143 (15) [back to overview]	Plasma Pharmacokinetic Concentration of Dabrafenib
NCT02314143 (15) [back to overview]	Number of Participants With Change in Vital Signs From Baseline
NCT02314143 (15) [back to overview]	Number of Participants With On-treatment Serious Adverse Events (SAEs) and Non-SAEs
NCT02314143 (15) [back to overview]	Number of Participants With Percentage Change From Baseline in Extracellular Signal-regulated Kinase (ERK) Phosphorylation (p-ERK) H Score From Week 0 to Week 2
NCT02314143 (15) [back to overview]	Number of Participants With Incidence of Squamous Cell Carcinoma and Keratoacanthoma
NCT02314143 (15) [back to overview]	Number of Participants With Overall Response Rate (ORR)
NCT02314143 (15) [back to overview]	Number of Participants With Percentage Change in p-ERK H Score From Week 8 to Week 10
NCT02314143 (15) [back to overview]	Number of Participants With Abnormal Electrocardiograms (ECG) Findings
NCT02314143 (15) [back to overview]	Number of Participants With Absolute Change in Left Ventricular Ejection Fraction From Baseline
NCT02314143 (15) [back to overview]	Number of Participants With Change in Clinical Chemistry Parameters From Baseline
NCT02314143 (15) [back to overview]	Plasma Pharmacokinetic Concentration of Trametinib
NCT02642042 (10) [back to overview]	Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With G12C KRAS Mutation
NCT02642042 (10) [back to overview]	Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With Non-G12C KRAS Mutation
NCT02642042 (10) [back to overview]	Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT02642042 (10) [back to overview]	Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants
NCT02642042 (10) [back to overview]	Progression Free Survival in Participants With Non-G12C KRAS Mutation
NCT02642042 (10) [back to overview]	Progression Free Survival in Participants With G12C KRAS Mutation
NCT02642042 (10) [back to overview]	Progression Free Survival in All KRAS Mutant Participants
NCT02642042 (10) [back to overview]	Overall Survival in Participants With G12C KRAS Mutation
NCT02642042 (10) [back to overview]	Overall Survival in All KRAS Mutants
NCT02642042 (10) [back to overview]	Overall Survival in Participants With Non-G12C KRAS Mutation
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Progression-Free Survival (PFS) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: ORR by Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	Ctrough for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]	Cmax for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]	AUCtau for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]	AUClast for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]	All-collected Deaths
NCT02684058 (53) [back to overview]	All-collected Deaths
NCT02684058 (53) [back to overview]	T1/2 for Trametinib
NCT02684058 (53) [back to overview]	LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Estimates of Time to Response (TTR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Estimates of Time to Response (TTR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)
NCT02684058 (53) [back to overview]	LGG Cohort: Clinical Benefit Rate (CBR) by Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: Clinical Benefit Rate (CBR) by Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	LGG Cohort: 2-year OS Estimate
NCT02684058 (53) [back to overview]	HGG Cohort: Time to Response (TTR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Time to Response (TTR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria (Longer Follow-up Time)
NCT02684058 (53) [back to overview]	HGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Investigatort Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Kaplan-Meier Estimates of Overall Survival (OS)
NCT02684058 (53) [back to overview]	HGG Cohort: Clinical Benefit Rate (CBR) as Per Investigator Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	HGG Cohort: Clinical Benefit Rate (CBR) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	Ctrough for Trametinib
NCT02684058 (53) [back to overview]	Tmax for Trametinib
NCT02684058 (53) [back to overview]	HGG Cohort: Kaplan-Meier Estimates of Progression Free Survival (PFS) as Per Central Independent Assessment Using RANO Criteria
NCT02684058 (53) [back to overview]	Cmax for Trametinib
NCT02684058 (53) [back to overview]	AUCtau for Trametinib
NCT02684058 (53) [back to overview]	AUClast for Trametinib
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: After- Taste Once the Medication Was Swallowed
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Taste of the Medication Before Rinsing the Mouth
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Remaining After-taste Once Rinsing the Mouth With Water
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Questionnaire Item: Immediate Reaction Once the Medication Was Placed Into the Mouth
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Dabrafenib Oral Suspension Based on the Palatability Assessment: After- Taste Once the Medication Was Swallowed
NCT02684058 (53) [back to overview]	Tmax for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]	T1/2 for Dabrafenib and Its Metabolites (Carboxy-dabrafenib, Desmethyl-dabrafenib Amd Hydroxy-dabrafenib)
NCT02684058 (53) [back to overview]	LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Pain Score
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Questionnaire Item: Taste of the Medication Before Rinsing the Mouth
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: Remaining After-taste Once Rinsing the Mouth With Water
NCT02684058 (53) [back to overview]	LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Pain Score
NCT02684058 (53) [back to overview]	LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Global Health Score
NCT02684058 (53) [back to overview]	LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Global Health Score
NCT02684058 (53) [back to overview]	LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Fatigue Score
NCT02684058 (53) [back to overview]	HGG and LGG Cohort: Palatability of Trametinib Oral Solution Based on the Palatability Assessment: Immediate Reaction Once the Medication Was Placed Into the Mouth
NCT02684058 (53) [back to overview]	LGG Cohort: PROMIS Parent Proxy Global Health 7+2 Scores- Fatigue Score
NCT02684058 (53) [back to overview]	LGG Cohort: ORR by Investigator Assessment Using RANO Criteria
NCT02704156 (6) [back to overview]	The Median Survival Time Will be Determined.
NCT02704156 (6) [back to overview]	One- and Two-year Overall Survival Rate Will be Determined.
NCT02704156 (6) [back to overview]	One- and Two-year Progression Survival Rate Will be Determined. Will be Determined.
NCT02704156 (6) [back to overview]	The Quality of Life Will be Analyzed.
NCT02704156 (6) [back to overview]	Treatment-related Adverse Effects Will be Determined.
NCT02704156 (6) [back to overview]	The Median Progression Free Survival Time Will be Determined.
NCT02967692 (23) [back to overview]	Randomized (Part 3): PFS as Per Investigator's Assessment by RECIST 1.1 by PD-L1 Expression
NCT02967692 (23) [back to overview]	Randomized (Part 3): Change From Baseline in EuroQoL 5-level Instrument (EQ-5D-5L)- Visual Analog Scale (VAS) Score
NCT02967692 (23) [back to overview]	Randomized (Part 3): Time to 10 Point Definitive Deterioration in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status
NCT02967692 (23) [back to overview]	Pre-dose Plasma Concentration for Dabrafenib
NCT02967692 (23) [back to overview]	Disease Control Rate (DCR) as Per Investigator's Assessment by RECIST 1.1
NCT02967692 (23) [back to overview]	Duration of Response (DOR) as Per Investigator's Assessment by RECIST 1.1
NCT02967692 (23) [back to overview]	Overall Response Rate (ORR) as Per Investigator's Assessment by RECIST 1.1
NCT02967692 (23) [back to overview]	Randomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1
NCT02967692 (23) [back to overview]	Randomized (Part 3): Change From Baseline in Function Assessment Cancer Therapy-melanoma (FACT-M) Melanoma Subscale Score
NCT02967692 (23) [back to overview]	Safety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)
NCT02967692 (23) [back to overview]	Trough Concentration (Ctrough) for Spartalizumab
NCT02967692 (23) [back to overview]	Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Physical Functioning Scale Scores
NCT02967692 (23) [back to overview]	Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Pain Symptom Scale Scores
NCT02967692 (23) [back to overview]	Randomized (Part 3): Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30- Global Health Status Scores
NCT02967692 (23) [back to overview]	Spartalizumab ADA Incidence
NCT02967692 (23) [back to overview]	Spartalizumab Anti-drug Antibody (ADA) Prevalence at Baseline
NCT02967692 (23) [back to overview]	Biomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
NCT02967692 (23) [back to overview]	Pre-dose Plasma Concentration for Dabrafenib
NCT02967692 (23) [back to overview]	Biomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
NCT02967692 (23) [back to overview]	Pre-dose Plasma Concentration for Dabrafenib
NCT02967692 (23) [back to overview]	Pre-dose Plasma Concentration for Trametinib
NCT02967692 (23) [back to overview]	Pre-dose Plasma Concentration for Trametinib
NCT02967692 (23) [back to overview]	Pre-dose Plasma Concentration for Trametinib
NCT03076164 (2) [back to overview]	Participants Response Rate
NCT03076164 (2) [back to overview]	Number of Participants Evaluated for Toxicities
NCT03149029 (3) [back to overview]	Overall Survival at 1 Year
NCT03149029 (3) [back to overview]	The Rate of Clinical Benefit
NCT03149029 (3) [back to overview]	Progression Free Survival (PFS)
NCT03272464 (4) [back to overview]	Overall Survival
NCT03272464 (4) [back to overview]	Objective Response Rate
NCT03272464 (4) [back to overview]	Number of Participants With Progression-Free Survival at 6 Months
NCT03272464 (4) [back to overview]	Maximum Tolerated Dose
NCT03428126 (4) [back to overview]	Disease Control Rate
NCT03428126 (4) [back to overview]	Immune-related Best Overall Response Rate.
NCT03428126 (4) [back to overview]	Overall Survival
NCT03428126 (4) [back to overview]	Progression Free Survival as Determined by irRC
NCT03704688 (1) [back to overview]	Maximum Tolerated Dose of Ponatinib, Phase I
NCT04439279 (3) [back to overview]	6-month Progression-free Survival (PFS) Rate
NCT04439279 (3) [back to overview]	Overall Response Rate (ORR)
NCT04439279 (3) [back to overview]	Progression-free Survival
NCT04439318 (3) [back to overview]	Progression Free Survival (PFS)
NCT04439318 (3) [back to overview]	Objective Response Rate (ORR)
NCT04439318 (3) [back to overview]	6-month Progression-free Survival (PFS) Rate
NCT04439357 (3) [back to overview]	Objective Response Rate (ORR)
NCT04439357 (3) [back to overview]	Progression Free Survival (PFS)
NCT04439357 (3) [back to overview]	6-month Progression-free Survival (PFS) Rate
NCT04566133 (6) [back to overview]	Proportion of Participants With a Response (Complete Response (CR) + Partial Response (PR) Reported With an 80% Confidence Interval
NCT04566133 (6) [back to overview]	Overall Survival
NCT04566133 (6) [back to overview]	Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT04566133 (6) [back to overview]	Serious Adverse Events Possibly, Probably, and/or Definitely Related to Treatment
NCT04566133 (6) [back to overview]	Proportion of Participants With a Response (Complete Response (CR) + Partial Response (PR) Reported With an 95% Confidence Interval
NCT04566133 (6) [back to overview]	Median Progression Free Survival (PFS)

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose

An AE is any untoward medical occurrence in a participant (par.) or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs. (NCT00920140)
Timeframe: From the start of the study drug until the final study visit (up to approximately 407 days)

Intervention	Participants (Number)
	Any AE	Any SAE
GSK1120212 <2 mg OD	6	2
GSK1120212 2 mg OD	91	64

Intervention	Participants (Number)
	Albumin (Low), Grade 3, n=6, 90	Albumin (Low), Grade 4, n=6, 90	Alkaline Phosphatase (High), Grade 3, n=6, 89	Alkaline Phosphatase (High), Grade 4, n=6, 89	Alanine Amino Transferase (High), Grade 3, n=6, 89	Alanine Amino Transferase (High), Grade 4, n=6, 89	AST (High), Grade 3, n=6, 86	AST (High), Grade 4, n=6, 86	Total Bilirubin (High), Grade 3, n=6, 89	Total Bilirubin (High), Grade 4, n=6, 89	Calcium (hypercalcemia), Grade 3, n=6, 91	Calcium (hypercalcemia), Grade 4, n=6, 91	Calcium (hypocalcemia), Grade 3, n=6, 91	Calcium (hypocalcemia), Grade 4, n=6, 91	Creatinine (High), Grade 3, n=6, 91	Creatinine (High), Grade 4, n=6, 91	Glucose (hyperglycemia), Grade 3, n=6, 91	Glucose (hyperglycemia), Grade 4, n=6, 91	Glucose (hypoglycemia), Grade 3, n=6, 91	Glucose (hypoglycemia), Grade 4, n=6, 91	Bicarbonate (Low), Grade 3, n=5, 82	Bicarbonate (Low), Grade 4, n=5, 82	Potassium (hyperkalemia), Grade 3, n=6, 91	Potassium (hyperkalemia), Grade 4, n=6, 91	Potassium (hypokalemia), Grade 3, n=6, 91	Potassium (hypokalemia), Grade 4, n=6, 91	Magnesium (hypermagnesemia), Grade 3, n=6, 88	Magnesium (hypermagnesemia), Grade 4, n=6, 88	Magnesium (hypomagnesemia), Grade 3, n=6, 88	Magnesium (hypomagnesemia), Grade 4, n=6, 88	Sodium (hypernatremia), Grade 3, n=6, 91	Sodium (hypernatremia), Grade 4, n=6, 91	Sodium (hyponatremia), Grade 3, n=6, 91	Sodium (hyponatremia), Grade 4, n=6, 91	Phosphorus, Grade 3, n=6, 88	Phosphorus, Grade 4, n=6, 88
GSK1120212 <2 mg OD	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
GSK1120212 2 mg OD	9	0	2	0	6	1	5	2	3	0	0	0	8	2	0	0	7	0	0	0	0	0	1	0	7	0	3	0	0	0	0	0	9	0	5	1

Intervention	nanograms per milliliter (ng/mL) (Geometric Mean)
	C1D15, n=72	C2D1, n=57	C3D1, n=38	C4D1, n=21	C5D1, n=10	C6D1, n=6	C7D1, n=6	C8D1, n=5	C9D1, n=3	C10D1, n=2	C11D1, n=1	C12D1, n=1
GSK1120212 2 mg OD	10.8	9.34	10.0	9.17	12.05	9.73	8.94	6.01	11.3	5.01	2.01	0.644

Intervention	Hours (Median)
	C1D1, tmax, n=3, 2, 9	C1D15, tmax, n=2, 2, 8
GSK1120212 0.5 mg OD/ 3/1 mg LD/OD	2.0	1.75
GSK1120212 1 mg OD	1.25	2.25
GSK1120212 2 mg OD	3.0	3.0

Intervention	Hours (Geometric Mean)
	C1D1, t1/2, n=3, 1, 8	C1D15, t1/2 eff., n=2, 2, 8
GSK1120212 0.5 mg OD/ 3/1 mg LD/OD	33.5	96.41
GSK1120212 1 mg OD	25.0	128
GSK1120212 2 mg OD	37.0	174

Intervention	Participants (Number)
	CR	CRp	Marrow CR	MLFS	PR	ORR
Cohort 1: AML/MDS With RAS Mutation	4	1	1	3	1	10
Cohort 2: AML/MDS/CMML With RAS wt/Unknown	0	0	0	0	1	1
Cohort 3: CMML With RAS Mutation	1	1	1	0	0	3

Intervention	Participants (Number)
	Decrease to <=35, n=6, 90	No Change, n=6, 90	Increase to >=38, n=6, 90
GSK1120212 <2 mg OD	0	4	2
GSK1120212 2 mg OD	4	76	12

Intervention	Participants (Number)
	DBP, Increase to Grade 1, n=6, 90	DBP, Increase to Grade 2, n=6, 90	DBP, Increase to Grade 3/4, n=6, 90	SBP, Increase to Grade 1, n=6, 90	SBP, Increase to Grade 2, n=6, 90	SBP, Increase to Grade 3/4, n=6, 90
GSK1120212 <2 mg OD	1	1	0	0	2	1
GSK1120212 2 mg OD	23	13	4	16	19	13

Intervention	nanograms per milliliter (ng/mL) (Geometric Mean)
	C1D1, Cmax, n=3, 2, 9	C1D15, Cmax , n=2, 2, 8	C1D15, Cmin, n=2, 2, 8
GSK1120212 0.5 mg OD/ 3/1 mg LD/OD	7.67	12.3	4.79
GSK1120212 1 mg OD	3.69	15.1	8.50
GSK1120212 2 mg OD	3.27	18.7	10.8

Intervention	Participants (Number)
	Decrease to <60, n=6, 90	No Change, n=6, 90	Increase to >100, n=6, 90
GSK1120212 <2 mg OD	0	4	2
GSK1120212 2 mg OD	10	67	19

Intervention	Participants (Number)
	Hemoglobin (Low), Grade 3, n=6, 91	Hemoglobin (Low), Grade 4, n=6, 91	INR (High), Grade 3, n=6, 75	INR (High), Grade 4, n=6, 75	Lymphocytes (Low), Grade 3, n=6, 90	Lymphocytes (Low), Grade 4, n=6, 90	Total Neutrophils (Low), Grade 3, n=6, 89	Total Neutrophils (Low), Grade 4, n=6, 89	Platelet count (Low), Grade 3, n=6, 91	Platelet count (Low), Grade 4, n=6, 91	PTT (High), Grade 3, n=5, 75	PTT (High), Grade 4, n=5, 75	White Blood Cell count (Low), Grade 3, n=6, 91	White Blood Cell count (Low), Grade 4, n=6, 91
GSK1120212 <2 mg OD	3	0	0	0	0	0	1	1	0	1	0	0	1	0
GSK1120212 2 mg OD	28	7	0	0	12	7	4	21	5	28	1	0	13	15

Intervention	nanograms*hour/milliliter (Geometric Mean)
	C1D1, AUC(0-24), n=3, 2, 9	C1D1, AUC(0-t), n=3, 2, 9	C1D15, AUC(0-t), n=2, 2, 8	C1D15, AUC(0-tau), n=2, 2, 8
GSK1120212 0.5 mg OD/ 3/1 mg LD/OD	77.6	77.6	172	170
GSK1120212 1 mg OD	29.4	29.4	155	241
GSK1120212 2 mg OD	28.0	28.0	298	330

Intervention	Ratio (Geometric Mean)
GSK1120212 0.5 mg OD/ 3/1 mg LD/OD	6.32
GSK1120212 1 mg OD	8.19
GSK1120212 2 mg OD	11.1

Intervention	Months (Median)
Trametinib 2 mg: Prior BRAF Inhibitors	5.5
Trametinib 2 mg: Prior Standard Therapy	14.3

Intervention	Participants (Number)
	Number of participants (par.) with DP	Number of par. with DP in target lesions	Number of par. with DP in non-target lesions	Number of par. with a new lesion	Number of par. with clinical progression
Trametinib 2 mg: Prior BRAF Inhibitors	35	21	8	22	3
Trametinib 2 mg: Prior Standard Therapy	43	22	11	23	0

Intervention	Participants (Number)
	CR	PR
Participants With BRAF Mutation V600E	1	11
Participants With BRAF Mutation V600E and no Prior Brain Mets	1	9
Participants With BRAF Mutation V600K	0	0
Participants With Prior Brain Mets	0	2
Participants Without Prior Brain Mets	1	11

Intervention	Participants (Number)
	Died at or prior to 6 months	Died after 6 months	Censored, less than 6 months follow-up	Censored, more than 6 months follow-up	Died at or prior to 12 months	Died after 12 months	Censored, less than 12 months follow-up	Censored, more than 12 months follow-up	Died at or prior to 24 months	Died after 24 months	Censored, less than 24 months follow-up	Censored, more than 24 months follow-up
Trametinib 2 mg: Prior BRAF Inhibitors	20	15	3	2	30	5	3	2	35	0	3	2
Trametinib 2 mg: Prior Standard Therapy	12	24	1	20	23	13	1	20	34	2	2	19

Intervention	Nanograms (ng)/milliliter (mL) (Mean)
	Day 15, pre-dose, n= 27, 44	Day 15, 0.5 to 2 hrs post-dose, n=23, 49	Day 15, 2 to 4 hrs post-dose, n=23, 48	Day 15, 4 to 8 hrs post-dose, n=22, 49	Week 4, pre-dose, n=23, 42	Week 8, pre-dose, n=19, 31	Week 12, pre-dose, n=7, 30
Trametinib 2 mg: Prior BRAF Inhibitors	12.3	18.6	23.6	21.3	11.7	11.6	13.2
Trametinib 2 mg: Prior Standard Therapy	11.6	15.2	20.8	19.0	11.6	11.8	12.5

Intervention	ng/mL (Median)
	Day 15	Week 8	Week 16	Week 24	Week 32	Week 40	Week 48	Week 56
Part C: Dabrafenib 150 mg	0	0	0	0	0	0	0	0
Part C: Dabrafenib 150 mg + Trametinib 1 mg	5.86	6.70	6.99	5.99	5.77	7.11	5.62	9.90
Part C: Dabrafenib 150 mg + Trametinib 2 mg	9.35	10.3	9.87	9.54	9.74	10.1	10.3	8.60

Intervention	Participants (Count of Participants)
	Albumin72360123		Albumin72360124	Albumin72360125	Alkaline Phosphatase72360123	Alkaline Phosphatase72360124	Alkaline Phosphatase72360125	Alanine Amino Transferase72360123	Alanine Amino Transferase72360124	Alanine Amino Transferase72360125	Aspartate Amino Transferase72360123	Aspartate Amino Transferase72360124	Aspartate Amino Transferase72360125	Total Bilirubin72360123	Total Bilirubin72360124	Total Bilirubin72360125	Calcium (Hypercalcemia)72360123	Calcium (Hypercalcemia)72360124	Calcium (Hypercalcemia)72360125	Calcium (Hypocalcemia)72360123	Calcium (Hypocalcemia)72360124	Calcium (Hypocalcemia)72360125	Cholesterol72360123	Cholesterol72360124	Cholesterol72360125	Creatine Kinase72360123	Creatine Kinase72360124	Creatine Kinase72360125	Creatinine72360123	Creatinine72360124	Creatinine72360125	Gamma Glutamyl Transferase72360123	Gamma Glutamyl Transferase72360124	Gamma Glutamyl Transferase72360125	Glucose (Hyperglycemia)72360123	Glucose (Hyperglycemia)72360124	Glucose (Hyperglycemia)72360125	Glucose (Hypoglycemia)72360123	Glucose (Hypoglycemia)72360124	Glucose (Hypoglycemia)72360125	Potassium (Hyperkalemia)72360123	Potassium (Hyperkalemia)72360124	Potassium (Hyperkalemia)72360125	Potassium (Hypokalemia)72360123	Potassium (Hypokalemia)72360124	Potassium (Hypokalemia)72360125	Magnesium (Hypermagnesemia)72360123	Magnesium (Hypermagnesemia)72360124	Magnesium (Hypermagnesemia)72360125	Magnesium (Hypomagnesemia)72360123	Magnesium (Hypomagnesemia)72360124	Magnesium (Hypomagnesemia)72360125	Sodium (Hypernatremia)72360123	Sodium (Hypernatremia)72360124	Sodium (Hypernatremia)72360125	Sodium (Hyponatremia)72360123	Sodium (Hyponatremia)72360124	Sodium (Hyponatremia)72360125	Phosphorus inorganic72360123	Phosphorus inorganic72360124	Phosphorus inorganic72360125	Triglycerides72360123	Triglycerides72360124	Triglycerides72360125
	Increase to Grade 3	Increase to Grade 4
Part C: Dabrafenib 150 mg + Trametinib 1 mg	1
Part C: Dabrafenib 150 mg + Trametinib 2 mg	1
Part C: Dabrafenib 150 mg + Trametinib 1 mg	3
Part C: Dabrafenib 150 mg + Trametinib 2 mg	2
Part C: Dabrafenib 150 mg + Trametinib 2 mg	0
Part C: Dabrafenib 150 mg	0
Part C: Dabrafenib 150 mg + Trametinib 1 mg	2
Part C: Dabrafenib 150 mg + Trametinib 1 mg	0
Part C: Dabrafenib 150 mg + Trametinib 2 mg	3
Part C: Dabrafenib 150 mg	1
Part C: Dabrafenib 150 mg + Trametinib 1 mg	11
Part C: Dabrafenib 150 mg + Trametinib 2 mg	7
Part C: Dabrafenib 150 mg + Trametinib 1 mg	4
Part C: Dabrafenib 150 mg + Trametinib 2 mg	6
Part C: Dabrafenib 150 mg	2
Part C: Dabrafenib 150 mg	3
Part C: Dabrafenib 150 mg + Trametinib 1 mg	10
Part C: Dabrafenib 150 mg + Trametinib 1 mg	6
Part C: Dabrafenib 150 mg + Trametinib 2 mg	4

Intervention	Participants (Count of Participants)
	Direct Bilirubin72360124		Direct Bilirubin72360125	Direct Bilirubin72360123	Creatine Kinase MB mass72360123	Creatine Kinase MB mass72360124	Creatine Kinase MB mass72360125	Chloride72360123	Chloride72360124	Chloride72360125	Carbon dioxide content/Bicarbonate72360123	Carbon dioxide content/Bicarbonate72360124	Carbon dioxide content/Bicarbonate72360125	C-Reactive protein72360123	C-Reactive protein72360124	C-Reactive protein72360125	Creatinine Clearance72360123	Creatinine Clearance72360124	Creatinine Clearance72360125	High Density Lipids, Cholesterol72360123	High Density Lipids, Cholesterol72360124	High Density Lipids, Cholesterol72360125	Lactate Dehydrogenase72360123	Lactate Dehydrogenase72360124	Lactate Dehydrogenase72360125	Low Density Lipids, Cholesterol72360123	Low Density Lipids, Cholesterol72360124	Low Density Lipids, Cholesterol72360125	Total Protein72360123	Total Protein72360124	Total Protein72360125	Troponin I72360123	Troponin I72360124	Troponin I72360125	Urea/BUN72360123	Urea/BUN72360124	Urea/BUN72360125
	Decrease to Low	Increase to High
Part C: Dabrafenib 150 mg + Trametinib 1 mg	1
Part C: Dabrafenib 150 mg	7
Part C: Dabrafenib 150 mg + Trametinib 2 mg	24
Part C: Dabrafenib 150 mg	11
Part C: Dabrafenib 150 mg + Trametinib 2 mg	12
Part C: Dabrafenib 150 mg + Trametinib 1 mg	14
Part C: Dabrafenib 150 mg + Trametinib 2 mg	16
Part C: Dabrafenib 150 mg + Trametinib 2 mg	3
Part C: Dabrafenib 150 mg + Trametinib 1 mg	16
Part C: Dabrafenib 150 mg + Trametinib 1 mg	11
Part C: Dabrafenib 150 mg + Trametinib 2 mg	10
Part C: Dabrafenib 150 mg	0
Part C: Dabrafenib 150 mg	2
Part C: Dabrafenib 150 mg + Trametinib 1 mg	3
Part C: Dabrafenib 150 mg + Trametinib 2 mg	2
Part C: Dabrafenib 150 mg	3
Part C: Dabrafenib 150 mg + Trametinib 1 mg	24
Part C: Dabrafenib 150 mg + Trametinib 2 mg	32
Part C: Dabrafenib 150 mg + Trametinib 2 mg	0
Part C: Dabrafenib 150 mg	4
Part C: Dabrafenib 150 mg + Trametinib 1 mg	10
Part C: Dabrafenib 150 mg + Trametinib 2 mg	19
Part C: Dabrafenib 150 mg	1
Part C: Dabrafenib 150 mg + Trametinib 1 mg	8
Part C: Dabrafenib 150 mg + Trametinib 1 mg	0
Part C: Dabrafenib 150 mg	5
Part C: Dabrafenib 150 mg + Trametinib 1 mg	4
Part C: Dabrafenib 150 mg + Trametinib 2 mg	9
Part C: Dabrafenib 150 mg	8
Part C: Dabrafenib 150 mg + Trametinib 1 mg	23
Part C: Dabrafenib 150 mg + Trametinib 2 mg	20

trametinib

Cross-References

Synonyms (86)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (7)

Protein Targets (311)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (2482)

Molecular Functions (489)

Ceullar Components (401)

Bioassays (376)

Research

Studies (929)

Market Indicators

Research Demand Index: 68.36

Study Types

Clinical Trials (243)

Trial Overview

Trial Outcomes

Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose

Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Clinical Chemistry Parameters by Dose

Ctau of GSK1120212 in Part 2

Tmax of GSK1120212 in Part 1

t1/2 at C1D1 and t1/2 Effective (Eff.) at C1D15 of GSK1120212 in Part 1

Number of Participants With an Investigator-assessed Best Response (Achieving Complete Response [CR], Marrow CR, Partial Response [PR], Complete Response Without Platelet Recovery [CRp] or Morphologic Leukaemia-free State[MLFS]) by Cohort

Number of Participants With a Change From Baseline in Temperature by Dose

Number of Participants With a Change From Baseline in Systolic and Diastolic Blood Pressure by Dose

Cmin and Cmax of GSK1120212 in Part 1

Number of Participants With a Change From Baseline in Heart Rate by Dose

Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Hematology Parameters by Dose

AUC(0-24), AUC(0-t), and AUC(0-tau) of GSK1120212 in Part 1

Overall Survival by Cohort

Accumulation Ratio (AR) of GSK1120212 in Part 1

Overall Survival

Number of Participants With Any Adverse Event (AE)

Duration of Tumor Response

Number of Participants With Tumor Progression

Number of Participants With Best Confirmed Response

Number of Participants With Best Confirmed Response in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors

Number of Participants Who Survived Until 6 Months, 12 Months and 24 Months From Baseline

Number of Participants With Best Unconfirmed Response at the Time of the Interim Analysis (Week 8)

Mean Plasma Concentrations

Progression-free Survival (PFS)

PFS in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors

Part C: Plasma Concentrations of Trametinib

Part C (Randomized): Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline

Part C (Randomized): Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range

Part B: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline

Part B: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range

Part B: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline

Part B: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range

Part D: Tmax of Dabrafenib Metabolites

Part D: Tmax Assessment of Trametinib

Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure

Part D: Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants

Part D: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

Part D: Cmax of Dabrafenib Metabolites

Part D: Cmax Assessment of Trametinib

Part D: Area Under the Concentration-time Curve Assessment of Trametinib

Part D: Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites

Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib

Part D (Analyte=GSK2118436): AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib

Part B: Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib

Part C: Plasma Concentrations of Dabrafenib and Its Metabolites

Part D (Analyte=GSK2118436): Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib

Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib

Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib

Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure

Intervention	Participants (Count of Participants)
	Hemoglobin (Increased)72360119		Hemoglobin (Increased)72360120	Hemoglobin (Increased)72360121	Hemoglobin (Increased)72360122	Hemoglobin (Anemia)72360119	Hemoglobin (Anemia)72360120	Hemoglobin (Anemia)72360121	Hemoglobin (Anemia)72360122	Lymphocytes (Increased)72360119	Lymphocytes (Increased)72360121	Lymphocytes (Increased)72360120	Lymphocytes (Increased)72360122	Lymphocytes (Decreased)72360119	Lymphocytes (Decreased)72360120	Lymphocytes (Decreased)72360121	Lymphocytes (Decreased)72360122	Total Neutrophils72360119	Total Neutrophils72360120	Total Neutrophils72360121	Total Neutrophils72360122	Platelet Count72360119	Platelet Count72360120	Platelet Count72360121	Platelet Count72360122	White Blood Cell Count72360119	White Blood Cell Count72360120	White Blood Cell Count72360121	White Blood Cell Count72360122
	Increase to Grade 3	Increase to Grade 4
Part B: Dabrafenib 150 mg + Trametinib 1 mg	0
Part B: Dabrafenib 75 mg + Trametinib 1 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	3
Part B: Dabrafenib 150 mg + Trametinib 2 mg	10
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	0
Part B: Dabrafenib 150 mg + Trametinib 2 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1 mg	7
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	4
Part B: Dabrafenib 150 mg + Trametinib 2 mg	19
Part B: Dabrafenib 150 mg + Trametinib 1 mg	1
Part B: Dabrafenib 150 mg + Trametinib 2 mg	5
Part B: Dabrafenib 75 mg + Trametinib 1 mg	1
Part B: Dabrafenib 150 mg + Trametinib 1 mg	3
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	2
Part B: Dabrafenib 150 mg + Trametinib 2 mg	1
Part B: Dabrafenib 150 mg + Trametinib 1 mg	2
Part B: Dabrafenib 150 mg + Trametinib 2 mg	8

Intervention	Participants (Count of Participants)
	Basophils72360119		Basophils72360120	Basophils72360121	Basophils72360122	Eosinophils72360119	Eosinophils72360120	Eosinophils72360121	Eosinophils72360122	Hematocrit72360119	Hematocrit72360120	Hematocrit72360121	Hematocrit72360122	Mean Corpuscle Hemoglobin concentration72360119	Mean Corpuscle Hemoglobin concentration72360120	Mean Corpuscle Hemoglobin concentration72360121	Mean Corpuscle Hemoglobin concentration72360122	Mean Corpuscle Hemoglobin72360119	Mean Corpuscle Hemoglobin72360120	Mean Corpuscle Hemoglobin72360121	Mean Corpuscle Hemoglobin72360122	Mean Corpuscle Volume72360119	Mean Corpuscle Volume72360120	Mean Corpuscle Volume72360121	Mean Corpuscle Volume72360122	Monocytes72360119	Monocytes72360120	Monocytes72360122	Monocytes72360121	Red Blood Cell count72360119	Red Blood Cell count72360120	Red Blood Cell count72360121	Red Blood Cell count72360122	Reticulocytes72360119	Reticulocytes72360120	Reticulocytes72360121	Reticulocytes72360122
	Increase to High	Decrease to Low
Part B: Dabrafenib 75 mg + Trametinib 1 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1 mg	2
Part B: Dabrafenib 150 mg + Trametinib 2 mg	7
Part B: Dabrafenib 75 mg + Trametinib 1 mg	1
Part B: Dabrafenib 150 mg + Trametinib 2 mg	28
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	7
Part B: Dabrafenib 150 mg + Trametinib 2 mg	24
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	2
Part B: Dabrafenib 150 mg + Trametinib 2 mg	2
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	11
Part B: Dabrafenib 75 mg + Trametinib 1 mg	2
Part B: Dabrafenib 150 mg + Trametinib 1 mg	6
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	8
Part B: Dabrafenib 150 mg + Trametinib 2 mg	12
Part B: Dabrafenib 150 mg + Trametinib 1 mg	3
Part B: Dabrafenib 150 mg + Trametinib 2 mg	11
Part B: Dabrafenib 150 mg + Trametinib 1 mg	5
Part B: Dabrafenib 150 mg + Trametinib 2 mg	13
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	4
Part B: Dabrafenib 150 mg + Trametinib 2 mg	5
Part B: Dabrafenib 150 mg + Trametinib 1 mg	8
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	10
Part B: Dabrafenib 150 mg + Trametinib 2 mg	21
Part B: Dabrafenib 150 mg + Trametinib 1 mg	4
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	9
Part B: Dabrafenib 150 mg + Trametinib 2 mg	30
Part B: Dabrafenib 150 mg + Trametinib 1 mg	9
Part B: Dabrafenib 150 mg + Trametinib 2 mg	25
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	1
Part B: Dabrafenib 150 mg + Trametinib 1 mg	1
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	5
Part B: Dabrafenib 150 mg + Trametinib 2 mg	3
Part B: Dabrafenib 150 mg + Trametinib 1 mg	7
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	6
Part B: Dabrafenib 150 mg + Trametinib 2 mg	6

Intervention	Participants (Count of Participants)
	Albumin72360119		Albumin72360120	Albumin72360121	Albumin72360122	Alkaline Phosphatase72360119	Alkaline Phosphatase72360120	Alkaline Phosphatase72360121	Alkaline Phosphatase72360122	Alanine Amino Transferase72360119	Alanine Amino Transferase72360120	Alanine Amino Transferase72360121	Alanine Amino Transferase72360122	Amylase72360119	Amylase72360120	Amylase72360121	Amylase72360122	Aspartate Amino Transferase72360119	Aspartate Amino Transferase72360120	Aspartate Amino Transferase72360121	Aspartate Amino Transferase72360122	Total Bilirubin72360119	Total Bilirubin72360120	Total Bilirubin72360121	Total Bilirubin72360122	Calcium (Hypercalcemia)72360119	Calcium (Hypercalcemia)72360120	Calcium (Hypercalcemia)72360121	Calcium (Hypercalcemia)72360122	Calcium (Hypocalcemia)72360119	Calcium (Hypocalcemia)72360120	Calcium (Hypocalcemia)72360121	Calcium (Hypocalcemia)72360122	Creatine Kinase72360119	Creatine Kinase72360120	Creatine Kinase72360121	Creatine Kinase72360122	Creatinine72360119	Creatinine72360120	Creatinine72360121	Creatinine72360122	Gamma Glutamyl Transferase72360122	Gamma Glutamyl Transferase72360119	Gamma Glutamyl Transferase72360120	Gamma Glutamyl Transferase72360121	Glucose (Hyperglycemia)72360119	Glucose (Hyperglycemia)72360120	Glucose (Hyperglycemia)72360121	Glucose (Hyperglycemia)72360122	Glucose (Hypoglycemia)72360119	Glucose (Hypoglycemia)72360120	Glucose (Hypoglycemia)72360121	Glucose (Hypoglycemia)72360122	Potassium (Hyperkalemia)72360119	Potassium (Hyperkalemia)72360120	Potassium (Hyperkalemia)72360121	Potassium (Hyperkalemia)72360122	Potassium (Hypokalemia)72360119	Potassium (Hypokalemia)72360120	Potassium (Hypokalemia)72360121	Potassium (Hypokalemia)72360122	Lipase72360119	Lipase72360120	Lipase72360121	Lipase72360122	Magnesium (Hypermagnesemia)72360119	Magnesium (Hypermagnesemia)72360120	Magnesium (Hypermagnesemia)72360121	Magnesium (Hypermagnesemia)72360122	Magnesium (Hypomagnesemia)72360119	Magnesium (Hypomagnesemia)72360120	Magnesium (Hypomagnesemia)72360121	Magnesium (Hypomagnesemia)72360122	Sodium (Hypernatremia)72360119	Sodium (Hypernatremia)72360120	Sodium (Hypernatremia)72360121	Sodium (Hypernatremia)72360122	Sodium (Hyponatremia)72360119	Sodium (Hyponatremia)72360120	Sodium (Hyponatremia)72360121	Sodium (Hyponatremia)72360122	Blood pH72360119	Blood pH72360120	Blood pH72360121	Blood pH72360122	Phosphorus inorganic72360119	Phosphorus inorganic72360120	Phosphorus inorganic72360121	Phosphorus inorganic72360122	Uric acid72360119	Uric acid72360120	Uric acid72360121	Uric acid72360122
	Increase to Grade 3	Increase to Grade 4
Part B: Dabrafenib 150 mg + Trametinib 2 mg	3
Part B: Dabrafenib 150 mg + Trametinib 2 mg	10
Part B: Dabrafenib 150 mg + Trametinib 2 mg	2
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	3
Part B: Dabrafenib 150 mg + Trametinib 2 mg	13
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	2
Part B: Dabrafenib 150 mg + Trametinib 2 mg	5
Part B: Dabrafenib 150 mg + Trametinib 2 mg	1
Part B: Dabrafenib 150 mg + Trametinib 2 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	1
Part B: Dabrafenib 150 mg + Trametinib 2 mg	4
Part B: Dabrafenib 150 mg + Trametinib 1 mg	2
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	7
Part B: Dabrafenib 150 mg + Trametinib 2 mg	12
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	6
Part B: Dabrafenib 75 mg + Trametinib 1 mg	0
Part B: Dabrafenib 75 mg + Trametinib 1 mg	1
Part B: Dabrafenib 150 mg + Trametinib 1 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	0

Intervention	Participants (Count of Participants)
	Direct Bilirubin72360120		Direct Bilirubin72360121	Direct Bilirubin72360119	Direct Bilirubin72360122	Indirect Bilirubin72360119	Indirect Bilirubin72360120	Indirect Bilirubin72360121	Indirect Bilirubin72360122	Creatine Kinase MB mass72360122	Creatine Kinase MB mass72360119	Creatine Kinase MB mass72360120	Creatine Kinase MB mass72360121	Chloride72360120	Chloride72360119	Chloride72360121	Chloride72360122	Carbon dioxide content/Bicarbonate72360119	Carbon dioxide content/Bicarbonate72360120	Carbon dioxide content/Bicarbonate72360121	Carbon dioxide content/Bicarbonate72360122	Creatinine clearance72360119	Creatinine clearance72360120	Creatinine clearance72360121	Creatinine clearance72360122	Lactate dehydrogenase72360119	Lactate dehydrogenase72360120	Lactate dehydrogenase72360121	Lactate dehydrogenase72360122	Total protein72360120	Total protein72360119	Total protein72360121	Total protein72360122	Troponin I72360119	Troponin I72360122	Troponin I72360120	Troponin I72360121	Trponin T72360122	Trponin T72360119	Trponin T72360120	Trponin T72360121	Urea/BUN72360122	Urea/BUN72360119	Urea/BUN72360120	Urea/BUN72360121
	Increase to High	Decrease to Low
Part B: Dabrafenib 150 mg + Trametinib 1 mg	0
Part B: Dabrafenib 150 mg + Trametinib 2 mg	39
Part B: Dabrafenib 150 mg + Trametinib 1 mg	11
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	8
Part B: Dabrafenib 150 mg + Trametinib 2 mg	16
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	6
Part B: Dabrafenib 150 mg + Trametinib 1 mg	7
Part B: Dabrafenib 150 mg + Trametinib 2 mg	25
Part B: Dabrafenib 150 mg + Trametinib 1 mg	4
Part B: Dabrafenib 150 mg + Trametinib 2 mg	19
Part B: Dabrafenib 150 mg + Trametinib 1 mg	5
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	5
Part B: Dabrafenib 150 mg + Trametinib 2 mg	8
Part B: Dabrafenib 150 mg + Trametinib 1 mg	2
Part B: Dabrafenib 150 mg + Trametinib 2 mg	4
Part B: Dabrafenib 75 mg + Trametinib 1 mg	4
Part B: Dabrafenib 150 mg + Trametinib 1 mg	9
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	11
Part B: Dabrafenib 150 mg + Trametinib 2 mg	35
Part B: Dabrafenib 150 mg + Trametinib 1 mg	10
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	10
Part B: Dabrafenib 150 mg + Trametinib 2 mg	30
Part B: Dabrafenib 75 mg + Trametinib 1 mg	3
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	1
Part B: Dabrafenib 150 mg + Trametinib 2 mg	7
Part B: Dabrafenib 150 mg + Trametinib 2 mg	0
Part B: Dabrafenib 75 mg + Trametinib 1 mg	0
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	0
Part B: Dabrafenib 75 mg + Trametinib 1 mg	2
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	3
Part B: Dabrafenib 150 mg + Trametinib 2 mg	17
Part B: Dabrafenib 75 mg + Trametinib 1 mg	1
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	16

Intervention	Hours (Median)
	GSK2285403, Day 1	GSK2285403, Day 21	GSK2298683, Day 1	GSK2298683, Day 21	GSK2167542, Day 1	GSK2167542, Day 21
Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg	3.00	2.00	10.0	5.00	24.0	0.75
Part D: Dabrafenib 150 mg + Trametinib 2 mg	2.07	2.00	8.00	4.00	24.0	1.75
Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg	3.51	2.00	8.93	4.00	24.0	2.00
Part D: Dabrafenib 75 mg + Trametinib 2 mg	3.00	2.00	10.0	5.98	24.0	2.00

Intervention	Hours (Median)
	Day 1	Day 21
Part D: Dabrafenib 150 mg + Trametinib 2 mg	1.50	2.00
Part D: Dabrafenib 75 mg + Trametinib 2 mg	2.00	2.00

Intervention	Participants (Number)
	Heart rate, Decrease to <60 bpm	Heart rate, Change to normal or no change	Heart rate, Increase to >100 bpm	Systolic BP (mmHg) , increase to G3 or G4	Diastolic BP (mmHg), increase to G3 or G4
Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg	2	9	5	3	4
Part D: Dabrafenib 150 mg + Trametinib 2 mg	14	17	12	6	3
Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg	3	8	5	1	0
Part D: Dabrafenib 75 mg + Trametinib 2 mg	12	18	12	5	2

Intervention	ng*hr/mL (Geometric Mean)
	GSK2285403, AUC(0-tau), Day 1	GSK2285403, AUC(0-inf), Day 1	GSK2285403, AUC (0-tau), Day 21	GSK2298683, AUC, (0-tau), Day 1	GSK2298683, AUC (0-t), Day 1	GSK2298683, AUC (0-tau), Day 21	GSK2167542, AUC(0-tau), Day 1	GSK2167542, AUC(0-t) Day 1	GSK2167542, AUC(0-tau), Day 21
Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg	3134	3963	2568	10396	20047	34283	132	500	1775
Part D: Dabrafenib 150 mg + Trametinib 2 mg	6524	7907	4216	20935	31666	52712	354	1316	3632
Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg	5950	7415	4262	15952	35206	59340	190	737	2707
Part D: Dabrafenib 75 mg + Trametinib 2 mg	3694	5026	2919	9575	22692	39672	88.8	614	2508

Intervention	ng*hr/mL (Geometric Mean)
	AUC (0-tau), Day 1	AUC (0-tau), Day 21	AUC (0-inf), Day 1
Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg	3593	3020	3982
Part D: Dabrafenib 150 mg + Trametinib 2 mg	7331	5886	8152
Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg	6507	4663	7291
Part D: Dabrafenib 75 mg + Trametinib 2 mg	4618	3434	5321

Intervention	Hours (Median)
	DAB Day 15	DAB Day 21	GSK2285403 Day 15	GSK2285403 Day 21	GSK2298683 Day 15	GSK2298683 Day 21	GSK2167542 Day 15	GSK2167542 Day 21
Part B: Dabrafenib 150 mg + Trametinib 1 mg	2.00	1.54	2.00	1.97	4.96	4.00	2.94	2.00
Part B: Dabrafenib 150 mg + Trametinib 1.5 mg	2.00	1.53	2.00	2.00	4.17	4.00	4.17	1.01
Part B: Dabrafenib 150 mg + Trametinib 2 mg	1.50	2.04	2.00	2.07	4.10	4.02	1.52	1.50